Hale o n  
Cli nical Pr ot oc ol  
Pr ot oc ol N u m ber : 3 0 0 1 0 4 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 of 1 1 3  C LI NI C A L P R O T O C O L  
AN 8-W E E K, R A N D O MI ZE D, C O N T R O L L E D, E X A MI N E R -B LI N D, 
C LI NI C A L S T U D Y T O E V A L U A T E T H E E F FI C A C Y O F A S T A N N O U S 
F L U O RI D E  T O O T H P A S T E F O R T H E R E LI E F O F D E N TI N 
H Y P E R S E N SI TI VI T Y I N A P O P U L A TI O N  O F D E N TI N 
H Y P E R S E N SI TI VI T Y  S U F F E R E R S  
Pr ot o c ol N u m b er:  [ADDRESS_116368] N a m e:  0. 4 5 4 p er c e nt ( %) w ei g ht/ w ei g ht ( w/ w ) 
st a n n o u s fl u ori d e  (S n F 2) t o ot h p a st e  
U nit e d St at e s ( U S) I n v e sti g ati o n al 
N e w Dr u g (I N D) N u m b er:  N/ A  
E ur o p e a n Cli ni c al Tri al s D at a b a s e 
( E u dr a C T) N u m b er:  N/ A  
Ot h er R e g ul at or y A g e n c y 
N u m b er:  N/ A  
P h a s e:  N/ A  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
T his d oc u me nt c o ntai ns c o nfi de ntialit y state me nts t hat are n ot rele va nt  f or t his 
p u blicl y a vaila ble versi o n 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 of 1 1 3   
S p o n s or I nf or m ati o n  
 
S p o n s or N a m e & L e g al 
R e gi st er e d A d dr e s s  
 H al e o n ( U K)  
T h e H ei g ht s ,  
B uil di n g [ADDRESS_116369] Fl o or ,  
W e y bri d g e ,  
S urr e y ,  
K T 1 3 0 N Y ,  
U nit e d Ki n g d o m  ( U K)  
S p o n s or C o nt a ct D et ail s  
 H al e o n  
St G e or g e s A v e n u e,  
W e y bri d g e,  
S urr e y,  
K T 1 3 0 D E,  
U K  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116370] or y  
 
D o c u m e nt  V er si o n  S u m m ar y of C h a n g e s  
Ori gi n al Pr ot o c ol  1. 0  N/ A  
Pr ot o c ol  2. [ADDRESS_116371] u d y O bj e cti v e s a n d E n d p oi nt s:  D H E Q -r el at e d e n d p oi nt s.  
S e cti o n [ADDRESS_116372] o n E v er y d a y Lif e ( Q 1 -3) c orr e ct e d t o  S e cti o n [ADDRESS_116373] o n E v er y d a y Lif e ( Q 7 -9).  
1 2. 3. 2. S e c o n d ar y E n d p oi nt A n al y s e s, D H E Q -4 8:   
S e cti o n  [ADDRESS_116374]  o n E v er y d a y Lif e: Q 1, Q 2 & Q 3 ( s e p ar at e 
s c or e s) c orr e ct e d t o  S e cti o n  [ADDRESS_116375]  o n E v er y d a y Lif e: Q 7, Q 8 
& Q 9 ( s e p ar at e s c or e s)  
   
   
 
A me n d me nts i nc or p orate all re visi o ns t o d ate, i ncl u di n g a me n d me nts ma d e at t he re q uest of t he 
c o u ntr y healt h a ut h orit y, i nstit uti o nal re vie w b oar d ( I R B), etc.   
 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 4 of 1 1 3  I n v e sti g at or Pr ot o c ol A gr e e m e nt P a g e  
• I c o nfir m a gree m e nt t o c o n d uct t he st u d y i n c o m plia nce wi t h t he pr ot oc ol a n d a n y 
a me n d me nts acc or di n g t o t he c urre nt I nter n ati o nal C o nfere nce o n Har m o nisati o n G o o d 
Cli nical Practice (I C H G C P) g ui deli nes , a n d a p plica ble me dic al de vice  re g ulati o n s. 
• I ac k n o wle d g e t hat I a m res p o nsi ble f or o verall st u d y c o n d uct. I a gree t o p ers o nall y 
c o n d uct or s u per vise t he descri be d st u d y.  
• I a gree t o e ns ure t hat all ass ociates, c ollea g ues a n d e m pl o yees assisti n g i n t he c o n d uct of 
t he st u d y are i nf or m e d a b o ut t heir o bli gati o ns. Mec ha nis ms are i n place t o e ns ure site staff 
recei v e al l a p pr o priate i nf or mati o n t hr o u g h o ut t he st u d y.  
• I a gree t o c o n d uct t his st u d y i n f ull c o nf or ma nce wit h t he la ws a n d re g ul ati o ns of t he 
c o u ntr y i n w hic h t he researc h is c o n d u cte d a n d t he Declarati o n of Helsi n ki.  
 
I n v e sti g at or N a m e:  
I n v e sti g at or Q u alifi c ati o n s:  
I n v e sti g at or Si g n at ur e:  
D at e of Si g n at ur e/ A gr e e m e nt:  
D D -M m m -Y Y Y Y  
 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI P P D 
P P D 
P P D P P D 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116376] u d y  ................................ ................................ .....  1 9  
2. 2  Be nefit/ Ris k Assess me nt  ................................ ................................ .......................  1 9  
2. 3  Mec ha nis m of Acti o n/I n dicati o n  ................................ ................................ ...........  [ADDRESS_116377] yle C o nsi derati o ns  ................................ ................................ ........................  3 2  
5. 5. 1  Oral H y gie ne R estricti o ns  ................................ ................................ .....  3 3  
5. 5. 2  Dietar y a n d Al c o h ol Restr icti o ns  ................................ ..........................  3 3  
5. 5. 3  C o ntrace pti o n  ................................ ................................ ........................  3 3  
5. 6  Scree n Fail ures ................................ ................................ ................................ .......  3 3  
5. 7  S p o ns or’s Q ualifie d Me dical Pers o n nel  ................................ ................................  3 3  
5. 8  Rater/ Cli nical Assess or Q ualificati o ns  ................................ ................................ ..  3 4  
6 I N V E S TI G A TI O N A L/ S T U D Y P R O D U C T S ................................ ................................ ...  [ADDRESS_116378] Dis pe nsi n g  ................................ ................................ ...............  3 6  
6. 2  A d mi nistrati o n  ................................ ................................ ................................ .......  3 7  
6. 2. 1  Me dicati o n/ D osi n g Err ors  ................................ ................................ .....  [ADDRESS_116379] ora ge  ................................ ................................ ...........................  3 8  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116380] S u p plies  ................................ .................  3 9  
6. 5  Bli n di n g a n d All ocati o n/ Ra n d o mizati o n  ................................ ...............................  3 9  
6. 6  Brea ki n g t he Bli n d  ................................ ................................ ................................ . 4 0  
6. 7  C o m plia nce  ................................ ................................ ................................ ............  4 1  
6. 8  C o nc o mita nt Me dicati o n/ Treat me nt  ................................ ................................ ......  4 1  
7 DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D S U BJ E C T 
DI S C O N TI N U A TI O N/ WI T H D R A W A L  ................................ ................................ .........  [ADDRESS_116381] Disc o nti n uati o n/ Wit h dra wal  ................................ ................................ .....  [ADDRESS_116382] t o F oll o w U p  ................................ ................................ ................................ ..  4 3  
8 S T U D Y P R O C E D U R E S  ................................ ................................ ................................ ...  4 3  
8. 1  Visit 1 / Scree ni n g  ................................ ................................ ................................ . [ADDRESS_116383] or y a n d Pri or Me dicati o ns/ Treat me nts  .............................  4 4  
8. 1. 5  Cli nical E xa mi nati o ns a n d Assess me nts  ................................ ...............  4 4  
8. 1. 6  I n cl usi o n/ E xcl usi o n Criteria  ................................ ................................ . [ADDRESS_116384] u d y Peri o d  ................................ ................................ ................................ ..........  4 6  
8. 2. 1  Visit 2 / Baseli ne ( Da y 0)  ................................ ................................ ......  4 6  
8. 2. 2  Visit 3 / Da y 2 8 ( ± 2 da ys)  ................................ ................................ ....  4 9  
8. 2. 3  Visit 4 / Da y 5 6 ( ± 3 da ys)  ................................ ................................ ....  [ADDRESS_116385]  ................................ ................................ ................................  5 2  
9 S T U D Y A S S E S S M E N T S  ................................ ................................ ................................ . 5 3  
9. 1  Scree ni n g E xa mi nati o ns/ D H Assess me nts  ................................ ............................  5 3  
9. 1. 1  Er osi o n , A brasi o n a n d R ecessi o n ( E A R)  ................................ ..............  5 3  
9. 1. 2  M o difie d Gi n gi val I n d e x ( M GI)  ................................ ...........................  5 3  
9. 1. 3  Cli nical M o bilit y  ................................ ................................ ...................  5 4  
9. 1. 4  Scree ni n g Tactile Se nsiti vit y Assess me nt  ................................ .............  5 4  
9. 1. 5  Scree ni n g E va p orati ve ( Air) Se nsiti vit y Asses s me nt  ...........................  5 6  
9. 2  D H Efficac y Ass ess me nts ................................ ................................ ......................  5 6  
9. 2. 1  De nti ne H y perse nsiti vit y E x perie nce Q uesti o n nair e ( D H E Q -4 8)  ........  5 6  
9. 2. 2  Tactile Se nsiti vit y Assess me nts  ................................ ............................  5 7  
9. 2. 3  E va p orati ve ( Air) Se nsiti vit y Assess me nts  ................................ ...........  5 8  
9. 2. 4  La belle d Ma g nit u de Scales ( L M Ss)  ................................ ......................  5 8  
9. 3  Safet y Assess me nts  ................................ ................................ ................................  5 9  
9. 3. 1  Oral S oft Tiss ue ( O S T) E xa mi nati o n  ................................ ....................  5 9  
9. 3. 2  Oral Har d Tiss ue ( O H T) E xa mi nati o n  ................................ ..................  5 9  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 7 of 1 1 3  9. 3. 3  Pre g na nc y  ................................ ................................ ..............................  5 9  
9. 3. 4  Satisfacti o n wit h Treat m e nt  ................................ ................................ ..  6 0  
1 0  A D V E R S E E V E N T S A N D S E RI O U S A D V E R S E E V E N T S  ................................ .........  6 0  
1 0. 1  Defi niti o n of a n A d verse E ve nt ( A E)  ................................ ................................ ....  6 0  
1 0. 2  Defi niti o n of a Seri o us A d verse E ve nt ( S A E)  ................................ .......................  [ADDRESS_116386] eristics  ................................ ...........  7 7  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116387] o p o uts a n d Missi n g Data  ................................ ..............  7 7  
1 2. 3. 8  I nteri m A nal ysis  ................................ ................................ ....................  7 8  
1 3  S T U D Y G O V E R N A N C E C O N SI D E R A TI O N S ................................ ..............................  7 8  
1 3. 1  Q ualit y C o ntr ol  ................................ ................................ ................................ ......  7 8  
1 3. 2  Q ualit y Ass ura nce  ................................ ................................ ................................ ..  7 8  
1 3. 3  Re g ulat or y a n d Et hical C o nsi derati o ns  ................................ ................................ . 7 9  
1 3. 3. 1  I nstit uti o nal Re vie w B oar d (I R B)  ................................ .........................  [ADDRESS_116388] u d y  ................................ ................................ ...  8 1  
1 4  R E F E R E N C E S  ................................ ................................ ................................ ..................  8 2  
1 5  A P P E N DI CI E S ................................ ................................ ................................ ..................  8 9  
1 5. 1  A b bre viati o ns  ................................ ................................ ................................ .........  8 9  
1 5. 2  De nti ne H y perse nsiti vit y E x perie nce Q uesti o n nair e ( E xa m ple D H E Q -4 8)  .........  9 1  
1 5. 3  La belle d Ma g nit u de Scales: I nt e nsit y, D urati o n, T olera bilit y & Descri pti o n 
( E xa m ple L M Ss)  ................................ ................................ ................................ ....  9 8  
1 5. 4  L M S Trai ni n g E xercise ( E xa m ple)  ................................ ................................ ......  1 0 0  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116389] of In-Te xt Ta bl e s  
Ta ble 1 -1 Sc he d ule of A cti vities  ................................ ................................ ...........  1 5  
Ta ble 6 -1 Accli matizati o n/I n vesti g ati o nal T o ot h pastes  ................................ ........  [ADDRESS_116390] y Ite ms  ................................ ................................ .........................  3 5  
Ta ble 1 5 -1 A b bre viati o ns  ................................ ................................ ........................  8 9  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0  of 1 1 3  1 P R O T O C O L S U M M A R Y  
1. 1  S y n o p si s  
S u m m ar y Titl e:  
Cli nical  st u d y t o eval u ate t he a nti -se nsiti vit y effi cac y of a sta n n o us fl u ori de  to ot h paste i n a 
p o p ulati o n of de nti n h y perse nsiti vit y s ufferers . 
B a c k gr o u n d a n d R ati o n al e  f or t h e St u d y : 
Sta n n o us fl u ori de ( S n F 2) has bee n i nc or p orate d i nt o oral h y gie ne pr o d ucts i n dicate d f or t h e 
relief  of de nti n h y p erse nsiti vit y ( D H ) si nce t he 1 9 90s ; it pr o vi des relief fr o m D H b y t he p h ysical 
occl usi o n of de nti n t u b ules t hr o u g h c he mical preci pi[INVESTIGATOR_32455] o n of sta n n o us o xi des a n d h y dr o xi des.  
Ra n d o mize d  c o ntr olle d cli nical trials  (ma n y  of  8 wee ks treat me nt d urati o n) s u p p ort t he l o n g er -
ter m a nti -se nsiti vit y  effic ac y of 0. 4 5 4 % S n F 2-c o ntai ni n g  t o ot h pastes wit h t wice dail y use. T h e 
ai m of t he c urre nt 8-w ee k st u d y is t o c o nfir m t he cli nical D H effic ac y of a 0. 4 5 4 % S n F [ADDRESS_116391] t he  occl usi o n m o de of acti o n  ( M o A)  of S n F 2 or  t he a nti -se nsiti vit y effic ac y of a 0. 4 5 4 % 
S n F [ADDRESS_116392]  of dail y use of a 0. 4 5 4 % S n F 2 t o ot h paste  o n t he n u m ber of ‘ Se nsiti ve 
Teet h’ , a n d s u bject  perce pti o n of pr o d uct be nefits .  
D H will be  assesse d at Baseli ne, a n d after [ADDRESS_116393] -Baseli ne ti me 
p oi nt, t he efficac y of t he 0. 4 5 4 %  S n F 2 t o ot h paste will be c o m pare d wit h t hat of  a re g ular 
fl u ori de t o ot h paste wit h n o k n o w n a nti -se nsiti vit y efficac y ( ne gati ve c o ntr ol).  
O bj e cti v e s a n d E n d p oi nt s : 
O bj e cti v e s  E n d p oi nt s  
Effi c a c y  
Pri m ar y  
T o de m o nstrate  t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste i n re d uci n g D H 
t o a n e va p orati ve  (air ) sti m ul us  (as meas ure d 
b y Sc hiff se nsiti vit y sc ore) , c o m pare d t o  a 
ne gati ve c o ntr ol t o ot h paste , after 8 wee ks  
t wice dail y use . C ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y 
sc ore at D a y 5 6 ( Wee k 8). 
S e c o n d ar y  
T o de m o nstrate  t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste  i n re d uci n g  D H  
t o a tactile sti m ul us  (as meas ure d b y ta ctile 
t hres h ol d  i n gra ms [ g] ), c o m pare d t o a 
ne gati ve c o ntr ol t o ot h paste , after  8 wee ks  
t wice dail y use . C ha n ge fr o m Baseli ne i n tactile t hres h ol d 
( g) at Da y 5 6 ( Wee k 8) . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 1  of 1 1 3  T o de m o nstrate  t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste  i n re d uci n g D H 
t o e va p orati ve (air ) a n d t actile sti m uli  (as 
meas ure d b y Sc hiff se nsiti vit y sc ore  a n d  
tactile  t hres h ol d  (g), res p ecti vel y ), c o m pare d 
t o a ne gati ve c o ntr ol t o ot h paste, after 4 wee ks  
t wice dail y use.  C ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y 
sc ore at D a y 2 8 ( Wee k 4). 
C ha n ge fr o m Baseli ne i n tactile t hres h ol d 
( g) at Da y 2 8  ( Wee k 4). 
T o descri be s u bject -percei ve d c ha n g es i n oral 
healt h -rel ate d q ualit y of life (O Hr Q o L ), as 
meas ure d b y t he De nti n H y perse nsiti vit y 
E x perie nce Q uesti o n nair e ( D H E Q -4 8 ), after 
4- a n d 8-w ee ks  t wic e dail y use  of t heir 
assi g ne d i n vesti gati o nal  t o ot h paste . At D ay 2 8  ( Week 4) & D ay 5 6 ( Week 8) : 
C ha n ge fr o m Baseli ne i n  D H E Q -4 8 
e n d p oi nts . 
Secti o n 1  
• I m pa ct o n Ever y da y Life ( Q 7-9)  
Secti o n 2  
• T otal Sc ore ( Q 1 -3 4)  
• I n di vi d ual Do mai n Sc ores  
- Restricti o ns ( Q 1 -4)  
- A da ptati o n ( Q 5 -1 6)   
- S ocial I m pa ct ( Q 1 7 -2 1)   
- E m oti o nal I m pa ct ( Q 2 2 -2 9)   
- I d e ntit y ( Q 3 0 -3 4)   
• Gl o bal Oral H ealt h Sc ore ( Q 3 5)  
• Effect o n Life O verall Sc ore ( Q 3 6 -3 9)  
E x pl or at or y  
T o deter mi ne  t he n u m ber of ‘ Se nsiti ve Teet h’  
(e va p orati ve (air) se nsiti vit y  o nl y ) i n t he p o ol 
of ‘ Eli gi ble Teet h’ i de ntifie d at Scree ni n g , at 
Scree ni n g, Baseli ne, a n d  after 4 a n d  8 wee ks 
t wice dail y use of assi g ne d i n vesti gati o nal  
t o ot h paste . At Scree ni n g, B aseli ne, D ay 2 8 ( Week 4) & 
D ay 5 6 ( Week 8) : 
N u m ber of ‘ Se nsiti ve Teet h’  
Defi ne d as t he n u m ber of ‘ Eli gi ble Teet h’ 
(i de ntifie d at Scree ni n g) wit h a Sc hiff Se nsiti vit y 
Sc ore ≥  2.  
T o i n vesti gate s u bject -percei ve d c ha n ges i n 
D H t o  a n e va p orati ve (air) sti m ul us , as 
meas ure d b y  L a belle d M a g nit u de Scales 
( L M S s), after 4 a n d 8 wee ks  t wice dail y use  
of t heir assi g ne d i n vesti g ati o nal  t o ot h paste.  At D ay 2 8  ( Week 4) & D ay 5 6 ( Week 8) : 
C ha n ge fr o m Baseli ne i n  L M S e n d p oi nts.  
• I nte nsit y  
• D urati o n  
• T olera bilit y  
• Descri pti o n  
T o i n vesti gate t he relati o ns hi p bet wee n 
s u bject res p o nses t o t he D H E Q -4 8 a n d t h e 
L M Ss at Baseli ne , a n d after 4 a n d 8 wee ks  
t wice dail y use of assi g ne d i n vesti gati o nal  
t o ot h p aste . At B aseli ne, D ay 2 8  ( Week 4) & D ay 5 6 
( Week 8) : 
• D H E Q -4 8 e n d p oi nts, as liste d a b o ve.  
• L M S e n d p oi nts, as liste d a b o ve.  
T o i n vesti gate t he relati o ns hi p bet wee n t he 
Sc hiff se nsiti vit y scale  a n d t he L M Ss at 
Baseli ne , a n d aft er 4 a n d 8 wee ks  t wice dail y 
use of assi g ne d i n vesti gati o nal  t o ot h paste . At B aseli ne, D ay 2 8  ( Week 4) & D ay 5 6 
( Week 8) : 
• Mea n Sc hiff se nsiti vit y sc ore  of t he t w o 
‘ Test Teet h’ . 
• L M S e n d p oi nts, as liste d a b o ve.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116394] satisfacti o n wit h t heir 
assi g ne d i n vesti gati o nal  t o ot h paste f or t he 
o verall ma na g e me nt of D H, as meas ur e d b y a 
N u meric Rati n g Scale ( N R S), after 8 wee ks 
treat me nt.  At D ay 5 6  ( Week 8) : 
Satisfacti o n N R S sc ore   
S af et y  
T o m o nit or  t he safet y a n d oral t olera bilit y of 
t he i n vesti gati o nal  t o ot h pastes  o ver 8 wee ks  
t wice dail y  use . Treat me nt e mer ge nt a d v erse e ve nts 
( T E A Es) . 
 
St u d y D e si g n : 
T his will be a si n gle ce nt er , 8-wee k, ra n d o mi ze d, c o ntr olle d, e x a mi ner -bli n d, 2-treat me nt ar m, 
parallel desi g n, stratifie d ( b y ma xi m u m Baseli ne Sc hiff se nsiti vit y sc ore of t he t w o  selecte d 
‘Test Teet h ’) cli nical st u d y  t o  e val uat e t he a nti -se nsiti vit y  efficac y of a 0. 4 5 4 %  S n F 2 t o ot h paste  
i n a D H  p o p ulati o n. T he cli nical effic ac y of t he 0. 4 5 4 %  S n F 2 t o ot h paste  (Test T o ot h paste ) will 
be c o m pare d wit h  t hat of a Refere nce T o ot h paste, a c o m merciall y a vaila ble, re g ular fl u ori d e 
t o ot h paste wit h n o k n o w n a nti -se nsiti vit y pr o perties  ( ne gati ve c o ntr ol) . 
At Scree ni n g ( Visit 1), f oll o wi n g pr o visi o n  of writte n i nf or m e d c o nse nt , suita bilit y t o 
partici pate will be re vie we d  a g ai nst t he pr ot oc ol i ncl usi o n/e xcl usi o n criteria . E li gi ble  s u bjects 
will e nter a n accli matizati o n peri o d ( 1 4 -2 8 da ys ) pri or t o Baseli ne assess me nts  d uri n g w hic h 
t he y will br us h t wice d ail y ( m or ni n g a n d e ve ni n g) wit h t he  accli matizati o n t o ot h paste ( a 
differe nt c o m merciall y a vaila ble, re g ular fl u ori de t o ot h paste  fr o m t he Refere nce T o ot h paste ). 
At Baseli ne  ( Visit 2), eli gi b ilit y t o c o nti n ue will be assesse d.  Su bjects w h o de m o nstrate t h e 
re q uire d q ualif yi n g le vels of D H at Scree ni n g ( Visit 1) a n d Baseli ne ( Visit 2) will b e  
ra n d o mize d t o st u d y  treat me nt a n d  i nstr ucte d  t o br us h wit h t heir assi g ne d i n vesti gati o nal 
t o ot h paste t wice dail y ( m or ni n g a n d e ve ni n g) f or t he d urati o n of t he 8-wee k treat me nt  peri o d.  
D H will be assesse d at Scree ni n g  ( Visit 1)  a n d Baseli ne  ( Visit 2) , a n d after 2 8 - a n d  5 6 -da ys 
treat me nt ( Visits 3 a n d  4, res pecti vel y ) usi n g t w o  i n de pe n de nt cli nical meas ure s: (i) ta ctile 
t hres h ol d ( g)  f oll o wi n g a tactile sti m ul us  a n d (ii) Sc hiff s e nsiti vit y sc ore f oll o wi n g a n 
e va p orati ve (air) sti m ul us .  
Oral healt h -rel ate d qu alit y of life ( O H R Q o L) will be m o nit ore d  o v er t h e treat me nt peri o d usi n g 
t he  De nti n H y p erse nsiti vit y E x perie nce Q u esti o n naire ( D H E Q -4 8 ), c o m plete d b y st u d y 
s u bjects at Baseli ne  ( Visit 2) , a n d after 2 8 - a n d 5 6 -da ys treat me n t ( Visits 3 a n d 4, res pecti vel y) . 
Su bject -percei ve d D H  will als o be i n v esti gate d  acr oss t he 8 -wee k treat me nt p eri o d usi n g f o ur 
La belle d Ma g nit u de Scales ( L M S s) t o ca pt ur e t he I nte nsity , D ur ati o n , T oler a bility  a n d 
Descri pti o n  of t heir res p o nse  t o t he  e va p orati ve (air) sti m ul us . At t he fi nal visit  ( Da y 5 6) , 
s u bjects will rate t heir le vel of satisfacti o n wit h t he ir  assi g ne d i n vesti gati o nal t o ot h p aste f or t he 
o verall ma na g e me nt of t heir D H , usi n g a N u meri c Rati n g Scale ( N R S) .  
Safet y a n d oral t olera bilit y of t he i n vesti gati o nal  t o ot h pastes  will be m o nit or e d o ver t he 8-wee k 
usa ge peri o d b y re vie w of treat me nt e mer ge nt  a d v erse e v e nts ( T E A Es) . 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116395] s : 
Descri pti o n  Test  
T o ot h p aste  Refere nce T o ot h p aste  
( Ne g ati ve C o ntr ol)  
N a me  0. 4 5 4 % w/ w S n F 2 t o ot h paste  Re g ular fl u ori de t o ot h paste  
( C rest  Ca vit y Pr otecti o n *)  
M aster 
F or m ul ati o n C o de   N/ A  
Fl u ori de Le vel  1 1 0 0  parts per milli o n ( p p m ) fl u ori de †  11 0 0  p p m fl u ori de ¥ 
R o ute of 
A d mi nistr ati o n  T o pi[INVESTIGATOR_104892]  
T o ot h p aste Us a ge 
I nstr ucti o ns  D ose t he t o ot h br us h wit h a ri b b o n of t o ot h paste, acr oss t he f ull br us h hea d.  
Br us h t he e ntire de ntiti o n t h or o u g hl y 
f or at least 1 -ti me d mi n ute, t wice dail y 
( m or ni n g & e ve ni n g), ma ki n g s ure t o 
br us h t he se nsiti ve areas of t he t w o 
' Test teet h' caref ull y first.    Br us h t he e ntire de ntiti o n 
t h or o u g hl y f or at least 1-ti me d 
mi n ute, t wice dail y ( m or ni n g & 
e ve ni n g).  
S u bjects w h o wis h t o ri nse a fter br us hi n g  will be i nstr ucte d t o ri nse wit h 1 0 
milliliter ( ml ) water usi n g gra d uate d ri nsi n g  c u p pr o vi de d.  
* C o m merciall y a v aila ble dail y use t o ot h paste , U S  mar ket .   
† As S n F 2  
¥ As s o di u m fl u ori de ( Na F)  
T y p e a n d Pl a n n e d N u m b er of S u bj e ct s : 
Male a n d fe male s u bjects a ge d 1 8 -6 5  y ears (i ncl usi ve), i n g o o d ge neral a n d oral healt h , wit h a 
mi ni m u m of [ADDRESS_116396] t w o teet h wit h cli nical l y  c o nfir me d D H , 
(tactile t hres h ol d ≤ 2 0 g  a n d Sc hiff se nsiti vit y sc ore ≥ 2  at b ot h Scree ni n g a n d  Baseli ne  visits ) 
will be ra n d o mize d t o treat me nt .  
Sufficie nt s u bjects  will b e scree ne d a n d e nt ere d i nt o t he accli matiz ati o n peri o d  t o ra n d o mi ze 
a p pr o xi matel y [ADDRESS_116397]  (a p pr o x i matel y 5 5  p er treat me nt gr o u p ) 
a n d s o e ns ure a p pr o xi matel y [ADDRESS_116398] u d y (a p pr o x i matel y 
50 per treat me nt gr o u p ), all o wi n g f or a p pr o xi matel y 10% dr o p o uts.  
St ati sti c al An al y si s Su m m ar y:  
A m o difie d I nte nt -T o -Treat ( mI T T) p o p ulati o n ( all ra n d o mize d s u bjects w h o recei ve at least 
o ne d ose of i n vesti gati o nal pr o d uct  a n d c o m plete at le ast o n e -p ost Baseli ne D H efficac y 
assess me nt ) will be use d f or t he efficac y a n al yses . Si g nifica nce testi n g will be c o n d u cte d at t he 
t w o -si de d 5 % si g nifica nce le vel . 
Sc hiff se nsiti vit y sc ore  a n d  tactile t hres h ol d ( g) will be deri ve d as t he me a n  sc ore /val u e  of  t he 
t w o  ‘ Test Teet h’  (selecte d  at Baseli ne). C ha n ge fr o m Baseli ne will be deri ve d f or eac h  
i n di vi d ual t o o t h first bef ore cal c ulati n g mea n  c h a n ge f or  t he t w o  ‘ Test Te et h’ . 
The pri mar y e n d p oi n t, c ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y sc ore at Da y 5 6 , will be 
a nal yze d  usi n g a Mi xe d M o del wit h Re peate d Meas ures ( M M R M) wit h i n vesti gati o nal pr o d uct, 
visit a n d [i n vesti gati o nal pr o d uct x visit] i nteracti o n as fi xe d effects, a n d Baseli ne Sc hiff 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116399] T o ot h paste 
c o m pare d t o R efere nce T o ot h paste ( ne g ati ve c o ntr ol) at Da y 5 6  fr o m t he M M R M wi ll be 
prese nte d , al o n g wit h  t he t w o -si de d p -val ue a n d 9 5 % c o n fi de n ce i nter val s ( CIs) . 
T he k e y sec o n dar y  e n d p oi nt, c ha n ge fr o m Baseli ne i n tactile t hres h ol d ( g) at Da y 5 6, will be 
a nal yse d usi n g t he sa me M M R M as t he pri mar y e n d p oi nt b ut wit h Baseli ne tactile t hres h ol d ( g) 
as c o variate . I n a d diti o n, t he ma xi m u m Baseli ne S c hiff se nsiti vit y sc ore of t he t w o  ‘ Test T eet h’  
( 2 or 3) will be fitte d as a fi xe d effect. T he differe nce bet w ee n t he least s q uare mea n  c ha n ges 
fr o m Baseli ne  f or t he Test T o ot h paste c o m pare d t o Refere n ce T o ot h paste ( ne gati ve c o ntr ol) at 
Da y 5 6 fr o m t he M M R M will be prese nte d , al o n g wit h t he t w o -si de d p -val ue a n d 9 5 %  CIs .  
S u m mar y statistics ( mea n, me dia n, sta n dar d err or ( S E ), sta n dar d de viati o n ( S D), mi ni m u m, 
ma xi m u m) will be prese nte d f or eac h  Sc hiff s e nsiti vit y sc ore a n d tactile t hres h ol d ( g) o utc o me 
varia ble at eac h assess me nt ti me p oi nt. Ra w mea ns ( ± S E) of Sc hiff se nsiti vit y sc ore  a n d  tactile 
t hres h ol d ( g) at e ac h assess me nt ti me p oi nt will be pl otte d b y treat me nt g r o u p.  
1. 2  S c h e d ul e of A cti viti e s  
T h e Sc he d ule of A cti vities  (Ta ble 1 -1) pr o vi des a n o ver vie w of t he s u bject visits , st u d y 
pr oce d ures  a n d assess m e nts . T he i n vesti gat or m a y sc he d ule a d diti o nal  ( u n pla n ne d ) visits  t o 
co n d uct a d diti o nal e val u ati o ns or assess me nts re q uire d t o pr otect t h e well -bei n g of t he s u bject.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 5  of 1 1 3  T a bl e 1-1 S c h e d ul e of A cti viti e s   
Pr oce d ure/ Assess me nt  St u d y Visits  
Visit 1  
Scree ni n g   Visit 2  
D a y 0  
B aseli ne  Visit 3 
D a y 2 8  
( ± 2 da y s)  Visit 4 
D a y 5 6  
( ± 3 da y s)   
I nf or me d C o nse nt  X Accli matizati o n Peri o d ( 1 4 -2 8 da ys )    
De m o gra p hics  X    
Re vie w S u bject’s Oral Care Pr o d ucts  X    
Re vie w Me dical Hist or y & C urre nt/ Pri or C o nc o mita nt Me dicati o n/ Treat me nt  1 X    
Re vie w C ha n ges i n Healt h & Me dicati o ns/ Treat me nts  1  X X X 
Ret ur n Accli matizati o n T o ot h paste, T o ot h br us h & Diar y  2  X   
Ret ur n I n vesti gati o nal  T o ot h paste, T o ot h br us h & Diar y  [ADDRESS_116400] -C o m plete d L M S Trai ni n g E xercise  X    
Oral S oft Tiss ue ( O S T) E xa mi nati o n  X X X X 
Oral Har d Tiss ue ( O H T) E xa mi nati o n  X   X 
Eli gi ble Teet h Assess me nts ( De ntiti o n E xcl usi o ns, Er osi o n/ A brasi o n/  Recessi o n [ E A R], 
M o difie d Gi n gi val I n de x [ M GI], T o ot h M o bilit y)  X    
Q ualif yi n g Cli nical Assess me nt of Tactile Se nsiti vit y 4 X X   
Q ualif yi n g Cli nical Assess me nt of E va p orati ve ( Air) Se nsiti vit y  ( Sc hiff se nsiti vit y sc ore)  [ADDRESS_116401] -Percei ve d E va p orati ve ( Air) Se nsiti vit y ( L M Ss)  6  X   
Cli nical Assess me nt of E va p orati ve ( Air) Se nsiti vit y of  t he Re mai ni n g ‘ Eli gi ble  Teet h’  
I de ntifie d at Scree ni n g  5   X   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 6  of 1 1 3  Pr oce d ure/ Assess me nt  St u d y Visits  
Visit 1  
Scree ni n g   Visit 2  
D a y 0  
B aseli ne  Visit 3 
D a y 2 8  
( ± 2 da y s)  Visit 4 
D a y 5 6  
( ± 3 da y s)   
Cli nical E xa mi ner Selects T w o ‘ Test Teet h’ ( Q ualif yi n g S u bjects O nl y)  7  X   
Re vie w I ncl usi o n/ E xcl usi o n Criteria  X X   
C o nfir m S u bject Eli gi bilit y / Q ualificati o n  X X   
Dis pe nse Accli matizati o n T o ot h paste, T o ot h br us h, Ti mer , Ri nsi n g C u ps  & Diar y  X    
S u per vi se d Br us hi n g wit h Accli matizati o n T o ot h paste  X    
Stratificati o n/ Ra n d o mizati o n   X   
Dis pe nse I n vesti gati o nal  T o ot h paste, T o ot h br us h , Ri nsi n g C u ps  & Diar y   X X8  
S u per vi se d Br us hi n g wit h I n vesti gati o nal  T o ot h paste   X   
Cli nical Assess me nt of Tactile Se nsiti vit y: T w o ‘ Test Teet h’ O nl y  4    X X 
Cli nical Assess me nt of E va p orati ve ( Air) Se nsiti vit y  ( Sc hiff se nsiti vit y sc ore) : Assess t he 
T w o ‘ Test Teet h’ First,  the n t he Re mai ni n g ‘ Eli gi ble  Teet h’  Ide ntifie d at Scree ni n g  [ADDRESS_116402] -Percei ve d E va p orati ve ( Air) Se nsiti vit y ( L M Ss): T w o ‘ Test Teet h’ O nl y 6   X X 
S u per vise d Br us hi n g wit h I n vesti gati o nal T o ot h paste     X  
Satisfacti o n wit h Treat me nt: S u bject -C o m plete d N R S      X 
St u d y C o ncl usi o n      X 
M o nit or A d verse E ve nts ( A Es)  a n d Me dical De vice I nci de nts 9 X  X X X 
F O O T N O T E S :  
1.  Fe male s u bjects of c hil d -beari n g p ote ntial s h o ul d be as ke d t o c o nfir m pre g na nc y stat us at eac h visit . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116403] u d y s u p plies ( mi n us ti mer & ri nsi n g c u ps) t o e ver y visit .  
Perf or m vis ual c hec k of ret ur ne d st u d y s u p plies, re vie w diar y & e val uate c o m plia nce .  
Visit 2:  Chec k c o m plia nce wit h use of accli matizati o n t o ot h paste .  
Visit 3 & Visit 4:  Chec k c o m plia nce wit h use of i n vesti gati o nal t o ot h paste .  
Visits 2 -4:  Chec k c o m plia nce wit h Lifest yle G ui deli nes/ Me dicati o n re q uire me nts.  
3.  D H E Q -[ADDRESS_116404] be c o m plete d  pri or t o t he O S T e xa mi nati o n  a n d cli nical assess me nts .  
Visit 2: Co m plete all q uesti o ns .  
Visits 3 & 4: Co m plete Secti o n 1 , Questi o ns 7-9 & Secti o n 2 , all q uesti o ns .  
4.  T actile T hres h ol d Assess me nt s: Visits 1 -2:  Ma xi m u m f orce 2 0 g ( Scree ni n g a n d Baseli ne); Visits 3 -7:  Ma xi m u m f orce 8 0 g.  
5.  Ev a p or ati ve ( air) se nsiti vit y  ( Sc hiff se nsiti vit y sc ore) s h o ul d be  assesse d after  tactile se nsiti vit y , e ns ure  mi ni m u m [ADDRESS_116405] e va p orati ve (air) assess me nt f or t o ot h rec o ver y.  
Visit 1  (Scree ni n g) : Assess e va p orati ve (air) se nsiti vit y f or  all teet h wit h a Scree ni n g  tactile t hres h ol d ≤ 2 0 g .  
Visit 2  ( Baseli ne) : First  assess e va p orati ve (air) se nsiti vit y f or  all ‘ Eli gi ble Teet h ’ i de ntifie d at Scree ni n g  wit h  a Baseli ne  tactile t hres h ol d of ≤  2 0 g , t he n  
assess  t he  re mai ni n g ‘Eli gi ble Teet h ’ (i.e.,  t he re mai ni n g teet h fr o m t he p o ol of ‘Eli gi ble Teet h ’ i de ntifie d at Scree ni n g , wit h a  Baseli ne  tactile 
t hres h ol d > 2 0 g ).  
Visit 3 ( Da y 2 8) & Visit 4 ( Da y 5 6) : First  assess e va p orati ve (air) se nsiti vit y f or  t he  t w o  ‘Test Teet h ’ first , t he n  assess  t he  re mai ni n g ‘Eli gi ble Teet h ’ 
i de ntifie d at Scree ni n g (e xcl u di n g t he t w o  ‘ Test Teet h’ ). 
‘ Eli gi ble Teet h’ = Teet h wit h  n o de ntiti o n excl usi o ns w hic h met E A R, M GI & m o bility  criteri a, wit h  Scree ni n g t actile t hres h ol d ≤ 2 0 g & Scree ni n g Sc hiff se nsitivity sc ore ≥ 2.  
6.  Visit 2 ( Baseli ne) : C o m plete 4 L M Ss (I nte nsity, D ur ati o n, T oler a bility & Descri pti o n ) f or eac h t o ot h  wit h a Baseli ne  Sc hiff se nsiti vit y sc ore ≥ 2  o nl y , 
i m me di atel y  after  t he  Baseli ne Sc hiff se nsiti vit y sc ore has bee n rec or de d  f or t hat  t o ot h . 
Visit 3 ( Da y 2 8) & Visit 4 ( Da y 5 6) : C o m plete 4 L M Ss  f or eac h  ‘ Test T o o t h’ , i m me di atel y  after  its Sc hiff se nsiti vit y sc ore has bee n rec or de d . 
7.  Selecte d ‘ Test Teet h’ s h o ul d be i n differe nt  q ua dra nts , wit h t he re q uisite  q ualif yi n g le vels of D H  at b ot h Scree ni n g ( Visit 1) a n d  Baseli ne ( Visit 2) , i.e.,  tactile 
t hres h ol d ≤ 2 0 g a n d  Sc hiff se nsiti vit y sc ore ≥ 2.  
8.  Visit 3:  S u p pl y ne w diar y o nl y . 
9.  A Es , a n d t heref ore all seri o us a d verse e ve nts ( S A Es)  will be rec or de d  fr o m i m me diatel y after si g ni n g t he i nf or me d c o nse nt f or m (I C F) u ntil [ADDRESS_116406] use of t he me dical de vice (t he ma n ual t o ot h br us h use d t o a p p l y t he 
accli matizati o n a n d i n vesti gati o nal t o ot h pastes). 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 8  of 1 1 3  2 I N T R O D U C TI O N  
De nti n h y perse nsiti vit y  ( D H)  is a c o m m o n de ntal c o n diti o n ; pre vale nce is re p orte d t o ra n g e 
fr o m 3% t o 5 7 % i n t he ge neral p o p ulati o n ( A d d y, 2 0 0 2 ). It is  t y pi[INVESTIGATOR_1306] y ass ociate d wit h t h e 
e na mel w ear a n d/ or gi n gi val recessi o n e x perie n ce d i n a d ult h o o d ( b ot h of w hic h l ea d t o 
e x p os ure of  t he u n derl yi n g de nti n) (West, 2 0 2 2 ) a n d has b ee n descri be d as a ‘s h ort, s har p pai n 
arisi n g fr o m e x p ose d de nti ne i n res p o nse t o sti m uli t y pi[INVESTIGATOR_1306] y t her mal, e va p orati ve, t actile, 
os m otic or c he mical a n d w hic h ca n n ot be ascri b e d t o a n y ot her f or m of d e nt al defect or diseas e ’ 
(Ad d y, 1 9 8 5 ; Ca n a dia n A d vis or y B oar d o n De nti n H y perse nsiti vit y, 2 0 0 3 ). Cli nicall y, t h e  
pri mar y dia g n osis of t o ot h h y perse nsiti vit y is ma de w he n a p atie nt c o m pl ai n s of brief, w ell -
l ocalize d p ai n res ulti n g fr o m t her mal (t y pi[INVESTIGATOR_1306] y c ol d), tactile, or os m otic sti m ulati o n of e x p os e d 
de nti n i n t he a bse nce of a n y ot her de ntal  pat h ol o g y ( A d d y, 2 0 0 2 ).   
T he m ost wi del y acce pte d t he or y t o e x plai n  D H  is t he h y dr o d y na mic t he or y, first descri be d i n 
t he literat ure b y G ysi ( G ysi, 1 9 0 0 ) a n d e x p a n de d o n later b y Brä n nstr ö m ( Brä n nstr ö m, 1 9 6 3 ). 
T he h y dr o d y n a mic t he or y pr o p oses t hat a n e xter nal s ti m ul us , s uc h as a te m perat ur e (c ol d  or  
h ot ) or os m otic differe nti al , or tactile press ur e , a p plie d t o e x p ose d de nti n disr u pts t he m o ve me nt 
of fl ui d wit hi n de nti n t u b ules. T his disr u pti o n is t h o u g ht t o sti m ulate mec ha n orece pt ors 
ass ociate d wit h o d o nt o blast pr ocesses a n d ner ve fi bers  l ocate d near t he cer vical p ul p -de nti n 
c o m ple x, tri g geri n g t he s h ort, s har p pai n c haract eristic of D H  (A bsi, 1 9 8 7; Pas hle y, 1 9 9 4 ). 
Ot her me c ha nis ms f or D H  ha v e b ee n pr o p ose d, h o we ver o nl y t he h y dr o d y na mic t he or y 
e x plai ns t he para d o xical fi n di n g t hat t he de nti n -e na mel j u ncti o n is se nsiti ve  t o e xter nal sti m uli, 
e ve n t h o u g h t he de nti n itself a p pears n ot t o be hi g hl y i n ner vate d ( Da ba b n e h, 1 9 9 9 ). T he t he or y 
is als o c o nsiste nt wit h t h e o bser vati o n t hat tr eat me nt of h y p erse nsiti ve d e nti n wit h a ge nts t hat 
eit her occl u de t he e x p ose d de nti n t u b ules or re d uce mec ha n orece pt or/ ner ve acti vit y , res ults i n 
a re d ucti o n i n t he disc o mf ort  or  pai n o bser ve d cli nicall y ( West, 2 0 1 4 ).  
T wice dail y use of a n a nti -h y perse nsiti vit y  t o ot h paste  is ge nerall y rec o m me n de d as t he first li ne 
treat me nt f or D H ; treat m e nt m o dalities are base d o n eit her de nti n t u b ule occl usi o n or i ntra -
de ntal ner ve d ese nsitizati o n ( A d d y, 2 0 0 2 ; Pereira, 2 0 1 5 ). S n F [ADDRESS_116407] o ye d t u b ule occl u di n g a ge nts use d i n Over -t he -Co u nter ( O T C)  t o ot h pastes  a n d has bee n 
wi del y mar kete d as a t o ot h dese nsitizer i n O T C  dail y use t o ot h pastes  ( 0. 4 5 4 %  w/ w  S n F 2) i n t he 
U S f or ma n y years . T he sta n n o us (ti n [II]) i o n reacts wit h water a n d p h os p hate mi nerals f o u n d 
i n t he sali va a n d de nti n t u b ule fl ui d t o ra pi [INVESTIGATOR_2478] y f or m i ns ol u ble de p osits  o ver t he s urface of t he 
de nti n ( Ma ki n, 2 0 1 3 ; Miller, 1 9 9 4 ).  T hese  d e p o sits act as barriers t o e xter nal sti m uli  f or D H , 
p h ysicall y bl oc ki n g or narr o wi n g t he o pe ni n gs of e x p ose d t u b ules, t here b y re d uci n g de nti n fl ui d 
m o ve me nt a n d decreasi n g t he a bilit y of t he sti m ul us t o acti vate t he i ntra -de ntal ner ves a n d 
e v o ke a p ai n res p o n se ( A d d y M, 2 0 0 2; B ur nett G R, 2 0 1 3 ; Miller S, 1 9 9 4 ; Par ki ns o n , 2 0 1 1 ).   
T he use of S n F [ADDRESS_116408] use d as a n a nti -caries a ge nt i n de ntifrices ( Ma ki n, 2 0 1 3 ). N u mer o us cli nical st u dies 
re p orte d i n t he scie ntific literat ure si nc e t he n ha v e esta blis he d t he safet y a n d cli nical efficac y 
of S n F 2, n ot o nl y as a n a nti -caries acti ve, b ut als o as a n  a nti -D H a n d a nti -pla q ue/ gi n gi vitis a ge nt.  
Citize ns Petiti o ns were s u b mitte d b y Pr octer & Ga m ble i n 2 0 0 6 , a n d  Gla x o S mit h Kli ne 
C o ns u mer Healt hcare ( G S K C H n o w Hal e o n ) i n [ADDRESS_116409] u g Pr o d ucts T F M a d mi nistrati ve  rec or d a n d re vie w ne w effi cac y d ata s u p p orti n g 
t he recl assificati o n of S n F 2 ( 0. 4 5 4 %  w/ w ) as a Cate g or y I s afe a n d effecti ve t o ot h se nsitizer , i n 
a d diti o n t o its rec o g niz e d a nti -caries G R A S E stat us. T he o utc o me of t h e F D A re vi e w of t hese 
citize ns petiti o ns a n d t h e fi nalizati o n of t he Oral Healt h Care Dr u g Pr o d uct m o n o gra p h is 
pe n di n g.     3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116410] u d y   
Sta n n o us fl u ori de ( S n F2) has bee n i nc or p orate d i nt o oral h y gie ne pr o d ucts i n dicate d f or t h e 
relief  of D H si nce t he 1 9 90s (Sc hiff, 2 0 0 6 ); it pr o vi des relief fr o m D H b y t he occl usi o n of t he 
de nti n t u b ules via t he  c he mical preci pi[INVESTIGATOR_32455] o n of i ns ol u ble ti n salts  o n t o t he s urface of e x p ose d 
de nti n  (Ma ki n, 2 0 1 3 ; Miller, 1 9 9 4 ). H ale o n  (t he s p o ns or  of t his st u d y) h as mar kete d  0. 4 5 4 % 
S n F [ADDRESS_116411] u dies of 4-2 4  wee ks treat me nt d urati o n  (t y pi[INVESTIGATOR_1306] y 8 wee ks ) d e m o nstrat e 
t he l o n git u di nal a nti -se nsiti vit y  efficac y of S n F 2-c o ntai ni n g f or m ulati o ns  (e. g., A mi ni, 2 0 1 9 ; 
C ha k nis, 2 0 1 1 ; Creet h, 2 0 2 1 ; Da y, 2 0 1 0 ; D u, 2 0 1 1 ; Gall o b, 2 0 1 7 ; Haze n, 1 9 6 8 ; He, 2 0 1 4 [a] ; 
He, 2 0 1 9 ; Hi nes, 2 0 1 9 ; Ki m, 2 0 2 1 ; Mas o n, 2 0 1 9 ; Ni, 2 0 1 0; Ni, 2 0 1 1; Par ki ns o n, 2 0 1 3 ; 
Par ki ns o n, 2 0 1 5 [a]; Sc hiff, 2 0 0 5 ; Sc hiff, 2 0 0 6 ; S har ma, 2 0 1 0 ; Vi na y a, 2 0 1 0 ). Re vie ws  a n d 
p o ole d/ meta -a nal ys es of ra n d o mize d c o ntr olle d trials als o re p ort S n F 2-c o n tai ni n g t o ot h pastes 
t o be cli nicall y effecti ve i n t he treat me nt of D H ( Ba da d he, 2 0 2 3 ; Bae, 2 0 1 5 ; Creet h, 2 0 1 9 [a]; 
Creet h, 2 0 1 9 [b]; E xter kate 2 0 2 2 ; Gerlac h, 2 0 1 7 ; Ka n o uté, 2 0 2 2 ; K o nra dss o n, 2 0 2 0 ; Marti ns, 
2 0 2 0 ; Marti ns, 2 0 2 2 ; Mart o, 2 0 2 0 ; P ollar d, 2 0 2 3 ; West, 2 0 1 5 ; West, 2 0 1 9 ; West, 2 0 2 1 ; Ya n g, 
2 0 1 6 ).  T he  l o n g er -ter m cli nical efficac y of t he s p o ns or’s  mar k ete d  0. 4 5 4 % S n F [ADDRESS_116412] u dies (Par ki ns o n, 2 0 1 3; Par ki ns o n, 2 0 1 5 [a] ).  
T he  ai m of t his  8-w ee k  cli nical st u d y is t o c o nfir m t he l o n git u di nal a nti -se nsiti vit y  efficac y  of 
a 0. 4 5 4 % S n F [ADDRESS_116413] t he M o A  
of S n F 2 ( de nti n t u b ule occl usi o n) or  t he a nti -se nsiti vit y efficac y of a 0. 4 5 4 % S n F [ADDRESS_116414] -Bas eli ne assess me nt  ti me p oi nt, t he efficac y of t h e 0. 4 5 4 % S n F 2 t o ot h paste will be 
c o m pare d wit h t hat of a re g ular fl u ori de t o ot h paste wit h  n o k n o w n a nti -se nsiti vit y efficac y 
( ne gati ve c o ntr ol).  
2. 2  B e n efit/ Ri s k A s s e s s m e nt  
S n F 2 ha s bee n i ncl u de d as a t hera p e utic  a ge nt (a nti -caries) i n dail y use t o ot h pastes si nce t he 
1 9 50s  (Ma ki n, 2 0 1 3 ). N u mer o us cli nical st u dies re p orte d  i n t he s cie ntific literat ure si nc e t he n 
ha ve esta blis he d t he safet y a n d cli nical efficac y of S n F 2, n ot o nl y f or  a nti -caries, b ut als o f or 
a nti -h y perse nsiti vit y  a n d a nti -pla q ue/ a nti -gi n gi vitis i n dicati o ns .  
S n F [ADDRESS_116415] e at 0. 4 5 4 % w/ w t o pr o vi de relief fr o m t he p ai n 
a n d disc o mf ort of D H.  T he f or m ulati o n  c o ntai n s o nl y i n gre die nts wit h a hist or y of safe use i n 
oral healt hcare pr o d ucts  a n d is desi g ne d f or d ail y use b y D H s ufferers . C o m plete safet y 
i nf or mati o n f or t his 0. 4 5 4 % S n F [ADDRESS_116416] u d y is t he I n vesti gat or ’s  Br oc h ure  (I B) .  
N u mer o us c li nic al st u dies s u p p ort t he l o n ger -ter m cli nical effic ac y a n d safet y of 0. 4 5 4 % S n F 2 
t o ot h paste s i n re d uci n g t he pai n  a n d disc o mf ort  ass ociate d wit h D H f oll o wi n g e x p os ure t o a 
ra n ge of acce pt e d sti m uli (t her mal  a n d tactile  (H olla n d, 1 9 9 7 )), s ee Secti o n 2. [ADDRESS_116417] u dies , 
0. 4 5 4 % S n F 2 t o ot h paste s were  a p plie d t wice d ail y  b y t o ot h br us hi n g f or 4 t o 2 4 wee ks  (t y pic all y 
8 wee ks)  a n d were w ell t olerate d .  
Re vie w of t he s p o ns or’s  i nter ve nti o nal cli nical st u dies i n v ol vi n g 0. 4 5 4 % S n F 2 t o ot h pastes has 
n ot i de ntifie d a n y si g nifi ca nt safet y iss ues.  As p er t he s p o ns or's Gl o b al D ata S heet ( G D S)  f or 
0. 4 5 4 % S n F [ADDRESS_116418] -mar keti n g 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 0  of 1 1 3  s ur veilla nce acti vities, t he fre q ue n c y of a d verse reacti o ns is  rare or ver y rare. T he s p o ns or 
c o nsi ders t he o v erall be n efit -ris k pr ofile of 0. 4 5 4 % S n F 2 t o ot h paste t o be fa v ora ble w h e n us e d 
as directe d i n its i nte n de d tar get treat me nt p o p ulati o n.  
T he Accli matizati o n a n d Refere n ce To ot h pastes will be dail y use, re g ular fl u ori de t o ot h pastes  
(t w o differe nt pr o d ucts) ; eac h will be c o m merci all y a vaila ble i n t he U S. T h e i n gre die nts liste d 
o n b ot h c o m mercial pac ks ha ve a hist or y of safe use i n oral healt hcare pr o d ucts. T he usa g e 
i nstr ucti o ns gi ve n t o st u d y s u bjects will be c o nsiste nt wit h t he i nstr ucti o ns o n t he c o m merci al 
pac ks. N o s pecific cli nical be nefits, ris ks or a d verse effects are a ntici pat e d fr o m t heir use i n t his 
st u d y . 
T he ma n ual t o ot h br us h ( Oral B Se nsi -S oft t o ot h br us h) t o be use d t o a p pl y t he st u d y t o ot h pastes  
b y t o ot h br us hi n g is a me dical de vice i n  t he U S . De vice u sa g e i nstr ucti o ns will be  c o nsiste nt 
wit h its c o m mercial pac k i nstr ucti o ns.  N o s pecific  cli nical be nefits , ris ks or a d verse de vic e 
effects are a ntici pate d  fr o m its use i n t his cli nical st u d y.  
Base d o n c urre ntl y a vail a ble data, t he i n v esti gati o nal a n d accli matizati o n t o ot h paste s, a n d t he 
ma n ual t o ot h br us h ( me dical de vice ) t o be use d t o a p pl y t he m, are c o nsi d ere d safe f or use u n der 
t he c o n diti o ns of t he pr o p ose d cli nical st u d y.  
2. 3   M e c h a ni s m of A cti o n/I n di c ati o n  
De nti n t u b ule occl u di n g a ge nts, s uc h as sta n n o us salts, are u n d erst o o d t o act b y  p h ysicall y 
bl oc k i n g  or narr o w i n g  t he e x p ose d e n ds of de nti n t u b ules, t here b y re d u ci n g  de nti nal fl ui d 
m o ve me nt  i n res p o nse t o a n e xter n al sti m ul us  f or D H a n d  decreasi n g t he eff ect of t h at  sti m ul us  
(Ma ki n, 2 0 1 3 ).  
• I n t he pres e nce of water (sali va) a n d sali va -deri ve d i o ns , s ta n n o us ( S n  [II]) i o ns ra pi [INVESTIGATOR_2478] y 
o xi dize t o sta n nic ( S n  [I V]) i o ns a n d h y dr ol yze t o f or m i ns ol u ble ti n c o m p o u n ds 
( h y dr o xi des, o xi des, p h os p hates a n d fl u or o p h os p h ates) ( Ma ki n, 2 0 1 3 ).  
• T he c he mical preci pi[INVESTIGATOR_32455] o n of i ns ol u ble ti n salts o nt o t he s urface of e x p os e d de nti n  a n d 
wit hi n e x p ose d d e nti n t u b ules ser ves t o o ccl u de pate nt de nti n  t u b ules ( B ur nett , 2 0 1 3 ; 
Earl, 2 0 1 3 ), t here b y pr o vi di n g relief fr o m D H .  
• S n  [II] i o ns ha ve bee n s h o w n i n vitr o  t o f or m i ns ol u ble preci pi[INVESTIGATOR_14263] o n t he d e nti n s urfac e 
a n d wit hi n e x p ose d de nti n t u b ules (Elli n gse n, 1 9 8 7 ; Miller, 1 9 9 4 ; Par ki ns o n, 2 0 1 1 ; S hi,  
2 0 1 2 ; W hite, 2 0 0 7 ; Zsis ka, 2 0 1 2 ).   
T he s mear la yer is a n a m or p h o us de p osit of or g a nic ( h y dr o x ya p atite)  a n d i n or ga nic (e. g., fr o m  
t o ot h pastes/ t o ot h br us hi n g or de ntal tr eat me nts s uc h as pr o p h yl a xis) matt er w hic h c o vers t he 
s urface of e x p ose d de nti n a n d pr o vi des a de gree of nat ural occl usi o n of  pate nt de nti n t u b ules. 
T he s mear la yer is v ul nera ble t o aci d c halle n ge ( e. g. , fr o m di etar y aci ds). Sta n n o us i o ns are 
k n o w n t o pr otect t he s mear la yer fr o m aci d diss ol uti o n b y i nteracti n g wit h h y dr o x ya patite t o 
preci pi[INVESTIGATOR_104893] d -resista nt la yers of sta n n o us o xi d e, h y dr o xi de, p h os p hate or fl u or o p h os p hate 
(B ur nett, 2 0 1 3 ).  
T o ma xi mise deli ver y of bi oa vaila ble sta n n o us (ti n  [II] ) i o ns t o  t he oral ca vit y, S n F 2 t o ot h pastes  
are oft e n ‘sta bilize d’ b y re d uc i n g t he  p H  of t he f or m ulati o n , b y t he a d diti o n of c o m ple xi n g 
a ge nts , a n d/ or b y de vel o p i n g  l o w water c o nte nt/a n h y dr o us f or m ulati o ns. T he i n vesti gati o nal 
0. 4 5 4 % S n F [ADDRESS_116419] o us f or m ulati o n.  
T he l o n git u di nal e x p os ure of ra dic ular or c or o nal pri mar y de nti n  (d ue t o  e na mel er osi o n, e na mel 
a brasi o n a n d/ or g u m recessi o n ) res ults i n t he  s y nt hesis of tertiar y  or re p arati ve d e nti n ; t he 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116420] t he p ul p tiss ue w here t he t o ot h’s n or mal 
pr otecti ve tiss ues (e na mel a n d g u m) ha ve bee n irre versi bl y l ost ( Li n de, 1 9 9 3 ).  T h e re parati ve 
pr ocess ca n be  i niti ate d i n  res p o nse t o  t he effect of e xter n al sti m uli at t he  de nti n s urface , as 
e x perie n ce d b y D H s ufferers  (C o x, 1 9 9 2; D’ S o u za, 1 9 9 5; Ma gl oire, 1 9 9 2; Mj or, 2 0 0 2 ). T he 
occl u di n g la yer  f or me d o ver  t he de nti n s urface , a n d  wit hi n de nti n t u b ules , wit h dail y use of a 
0. 4 5 4 % S n F [ADDRESS_116421]  t h e de nti n a n d t he u n d erl yi n g p ul p tiss ue fr o m e xter nal 
pai n -i n d uci n g sti m uli  w here e n a mel a n d/ or gi n gi v al  tiss ue has bee n l ost . 
3 S T U D Y O B J E C TI V E S A N D E N D P OI N T S  
 
O bj e cti v e s  E n d p oi nt s  
Effi c a c y  
Pri m ar y  
T o de m o nstrate t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste i n re d uci n g D H 
t o a n e va p orati ve  (air ) sti m ul us  (as meas ure d 
b y Sc hiff se nsiti vit y sc ore) , c o m pare d t o  a 
ne gati ve c o ntr ol t o ot h paste , after 8 wee ks  
t wice dail y use . C ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y 
sc ore at D a y 5 6 ( Wee k 8) . 
S e c o n d ar y  
T o de m o nstrate  t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste  i n re d uci n g  D H  
t o a tactile sti m ul us  (as meas ure d b y ta ctile 
t hres h ol d  i n gra ms [ g] ), c o m pare d t o a 
ne gati ve c o ntr ol t o ot h paste , after  8 wee ks  
t wice dail y use . C ha n ge fr o m Baseli ne i n tactile t hres h ol d 
( g) at Da y 5 6 ( Wee k 8) . 
T o de m o nstrate  t he cli nic al efficac y of a 
0. 4 5 4 % w/ w S n F 2 t o ot h paste  i n re d uci n g D H 
t o e va p orati ve (air ) a n d t actile sti m uli  (as 
meas ure d b y Sc hiff se nsiti vit y sc ore  a n d  
tactile  t hres h ol d  ( g), res p ecti vel y ), c o m pare d 
t o a ne gati ve c o ntr ol t o ot h paste, after 4 wee ks  
t wice dail y use.  C ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y 
sc ore at D a y 2 8 ( Wee k 4) . 
C ha n ge fr o m Baseli ne i n tactile t hres h ol d 
( g) at Da y 2 8 ( Wee k 4) . 
T o descri be s u bject -percei ve d c ha n g es i n oral 
healt h -rel ate d q ualit y of life ( O Hr Q o L) , as 
meas ure d b y t he De nti n H y perse nsiti vit y 
E x perie nce Q uesti o n nair e ( D H E Q -4 8 ), after 
4- a n d 8-w ee ks  t wic e dail y use  of t heir 
assi g ne d i n vesti gati o nal  t o ot h paste.  At D ay 2 8  ( Week 4) & D ay 5 6 ( Week 8) : 
C ha n ge fr o m Baseli ne i n  D H E Q -4 8 
e n d p oi nts.  
Secti o n 1  
• I m pa ct o n Ever y da y Life ( Q 7-9)   
Secti o n 2  
• T otal Sc ore ( Q 1 -3 4)  
• I n di vi d ual Do mai n Sc ores  
- Restricti o ns ( Q 1 -4)  
- A da ptati o n ( Q 5 -1 6)   
- S ocial I m pa ct ( Q 1 7 -2 1)   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116422] ( Q 2 2 -2 9)   
- I d e ntit y ( Q 3 0 -3 4)   
• Gl o bal Oral H ealt h Sc ore ( Q 3 5)  
• Effect o n Life O verall Sc ore ( Q 3 6 -3 9)  
E x pl or at or y  
T o deter mi ne t he n u m ber of ‘ Se nsiti ve Teet h’ 
(e va p orati ve (air) se nsiti vit y o nl y) i n t he p o ol 
of ‘ Eli gi ble Teet h’ i de ntifie d at Scree ni n g, at 
Scree ni n g, Baseli ne, a n d after 4 a n d 8 wee ks 
t wice dail y use of assi g ne d i n vesti gati o nal  
t o ot h paste . At Scree ni n g,  B aseli ne, D ay 2 8 ( Week 4) & 
D ay 5 6 ( Week 8):  
N u m ber of ‘ Se nsiti ve Teet h’  
Defi ne d as t he n u m ber of ‘ Eli gi ble Teet h’ 
(i de ntifie d at Scree ni n g) wit h a Sc hiff Se nsiti vit y 
Sc ore ≥  2.   
T o i n vesti gate s u bject -percei ve d c ha n ges i n 
D H t o  a n e va p orati ve (air) sti m ul us , as 
meas ure d b y  L a belle d M a g nit u de Scales 
( L M S s), after 4 a n d 8 wee ks  t wice dail y use  
of t heir assi g ne d i n vesti g ati o nal  t o ot h paste.  At D ay 2 8  ( Week 4) & D ay 5 6 ( Week 8) : 
C ha n ge fr o m Baseli ne i n  L M S e n d p oi nts.  
• I nte nsity  
• D ur ati o n  
• T oler a bility  
• Descri pti o n  
T o i n vesti gate t he relati o ns hi p bet wee n 
s u bject res p o nses t o t he D H E Q -4 8 a n d t h e 
L M Ss at Baseli ne a n d aft er 4 a n d 8 w ee ks  
t wice dail y use of assi g ne d i n vesti gati o nal  
t o ot h paste . At B aseli ne, D ay 2 8  ( Week 4) & D ay 5 6 
( Week 8) : 
• D H E Q -4 8 e n d p oi nts, as liste d a b o ve.  
• L M S e n d p oi nts, as liste d a b o ve.  
T o i n vesti gate t he relati o ns hi p bet wee n t he 
Sc hiff se nsiti vit y scale  a n d t he L M Ss at 
Baseli ne , a n d aft er 4 a n d 8 wee ks  t wice dail y 
use of assi g ne d i n vesti gati o nal  t o ot h paste . At B aseli ne, D ay 2 8  ( Week 4) & D ay 5 6 
( Week 8) : 
• Mea n Sc hiff se nsiti vit y sc ore of t he t w o 
‘ Test Teet h’ . 
• L M S e n d p oi nts, as liste d a b o ve.  
T o i n vesti gate s u bject satisfacti o n wit h t heir 
assi g ne d i n vesti gati o nal  t o ot h paste f or t he 
o verall ma na g e me nt of D H, as meas ur e d b y a 
N u meric Rati n g Scale ( N R S), after 8 wee ks 
treat me nt.  At D ay 5 6  ( Week 8) : 
Satisfacti o n N R S sc ore   
S af et y  
T o m o nit or  t he safet y a n d oral t olera bilit y of 
t he i n vesti gati o nal  t o ot h pastes  o ver 8 wee ks  
t wice dail y  use . Treat me nt e mer ge nt a d v erse e ve nts 
( T E A Es) . 
T his st u d y will be c o nsi dere d s uccessf ul if t he 0. 4 5 4 % S n F 2 t o ot h paste de m o nstrates 
statisticall y si g nifica nt, s u peri or a nti -h y perse nsiti vit y efficac y, c o m pare d t o t he ne gati ve c o ntr ol  
t o ot h paste , as meas ur e d b y Sc hiff se nsiti vit y sc ore at Da y 5 6 ( Wee k 8). 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116423] u d y  treat me nts : 
0. 4 5 4 % S n F 2 t o ot h paste ( Test  T o ot h paste ) or a re g ular fl u ori de t o ot h paste  (Refere n ce  
T o ot h paste ) 
Tw o i n de pe n d e nt sti m ul us -base d cli nical me as ur es will be e m pl o ye d t o assess t he effic ac y of 
t he i n vesti gati o nal  t o ot h pastes .  
• A tactile sti m ul us will be a d mi nistere d usi n g a c o nsta nt press ure pr o be - Y ea ple Pr o be 
(P ols o n, 1 9 8 0 ); s u bject res p o nse t o t he sti m ul us deter mi nes t he tactile t hres h ol d i n 
gra ms ( g).  
• A n e va p orati ve (air) sti m ul us (i.e., a t her mal sti m ul us) will be a d mi nistere d usi n g a 
de ntal air s yri n ge; s u bject res p o nse t o t he sti m ul us will be e xa mi ner -e val uat e d usi n g t he 
Sc hiff se nsiti vit y scale ( Sc hiff, 1 9 9 4 ).  
D H  will be assesse d at S cree ni n g, Da y 0 ( Bas eli ne), D a y 2 8  ( Wee k 4)  a n d Da y 5 6  ( Wee k 8) . 
O n c o m pleti o n of t he Baseli ne assess me nts , t he cli nical e xa mi ner will sele ct t w o ‘ Test T eet h ’ 
f or assess me nt of tactile a n d e va p orati ve (air) s e nsiti vit y at all s u bse q ue nt visits . T o q ualif y f or 
selecti o n as a ‘ Test T o ot h’ , t he t o ot h m ust meet t he pr ot oc ol -s pecif ic  i ncl usi o n/e xcl usi o n 
criteria  (Secti o n  5. 2  Incl usi o n Criteria 6 & 7 ; Secti o n 5. 3  E xcl usi o n Criteri o n 2 6) , s pecificall y 
tactile t hres h ol d ≤ 2 0 g a n d  Sc hiff se nsiti vit y sc ore ≥ 2 at b ot h  Scree ni n g a n d  Baseli ne visits.  
I n a d diti o n, t he n u m ber of ‘ Se nsiti ve Teet h’ will be deter mi ne d at eac h st u d y visit ( Sc hiff 
se nsiti vit y sc ore  ≥ 2) as d escri be d i n Secti o ns 8. 1. 5 , 8. 2. 1. 5 , 8. 2. 2. 5  a n d 8. 2. 3. 5 . 
A p pr o xi matel y 1 1 0  qualif yi n g s u bjects will be stratifie d acc or di n g t o t he ma xi m u m Baseli ne 
Sc hiff se nsiti vit y sc ore of t heir t w o ‘ Test Teet h’  a n d ra n d o mize d t o tr eat me nt  (a p pr o xi matel y 
5 5  s u bjects per treat me nt gr o u p) . Ra n d o mize d s u bjects will be i nstr ucte d t o br us h t wice da il y 
( m or ni n g a n d e v e ni n g) wit h t heir assi g ne d i n vesti gati o nal  t o ot h paste f or t he ne xt 5 6 da ys 
(8 wee ks ) a n d rec or d eac h br us hi n g i n t he diar y pr o vi de d . First use  will be perf or me d u n der 
s u per visi o n at t he i n vesti gat or  site ; t o facilitate c o m plia nce a n a d diti o nal  s u per vise d o n -site 
br us hi n g will be c o m plete d at t he e n d of Visit 3 . 
C ha n ges i n O H R Q o L will be m o nit ore d o ver t he treat me nt peri o d usi n g t he vali date d De nti n 
H y perse nsiti vit y E x perie nce Q uesti o n nair e ( D H E Q -4 8) . T he D H E Q -[ADDRESS_116424] -percei ve d D H will als o 
be i n vesti gate d  f or t he t w o selecte d ‘ Test Teet h’  usi n g La belle d Ma g nit u de Scales ( L M Ss ). 
S u bjects will c o m plete f o ur L M Ss  t o ca pt u re t he I nte nsity , D ur ati o n , T oler a bility  a n d 
Descri pti o n  of t heir res p o nse t o t he e va p orati ve (air) sti m ul us  a d mi nistere d  at Baseli ne, Da y 2 8 
a n d Da y 5 6 . At t he fi nal visit ( Da y 5 6), after all cli nical pr oce d ures ha v e bee n c o m plete d, 
s u bjects will rate t heir le vel of satisfacti o n wit h t heir assi g ne d i n vesti gati o nal t o ot h paste f or t he 
o verall ma na g e me nt of D H usi n g a N R S.  
T o sta n dar dize oral h y gi e ne practic e i n t he st u d y p o p ulati o n  pri or t o treat me nt a n d t o hel p 
mi ni mize t he p ote ntial i m pact of ‘ place b o’/‘ n o treat me nt’ effects , eli gi ble s u bjects will 
c o m plete a n accli matizati o n peri o d ( 1 4 -2 8 da ys d urati o n) bet wee n t he Scree ni n g a n d Baseli n e 
visits  d uri n g w hi c h t he y will br us h t wice dail y ( m or ni n g a n d e ve ni n g) wit h a re g ular fl u ori de 
t o ot h paste  (a differe nt c o m merciall y a vaila ble pr o d uct  fr o m t he Refere nce T o ot h paste ).  First 
use of accli matizati o n t o ot h paste will be perf or me d u n der s u per visi o n at t he i n vesti gat or site . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116425] s (H olla n d, 1 9 9 7 ). In li ne wit h t h es e sa m e rec o m me n dati o ns, 
t w o i n de pe n de nt , c o ntr olla ble  D H sti m ul i (tactile a n d t her mal ) will be e m pl o ye d t o assess  t he 
perf or ma n ce  of t h e  0. 4 5 4 % S n F [ADDRESS_116426] s e vere sti m ul us (t actile) a p plie d first  
(H olla n d, 1 9 9 7 ). T o  a v oi d i nter -e xa mi ner  varia bilit y, t he sa me cli nical e xa mi ner will  a d mi nist er  
a gi ve n  sti m ul us (tactile a n d/ or e va p orati ve (air)) a n d assess its  ass ociate d D H  meas ur e  (tactil e 
t hres h ol d ( g) or Sc hiff se nsiti vit y sc ore) t hr o u g h o ut  t he st u d y .  
D H will be cli nicall y assesse d at Scree ni n g  a n d  Baseli ne ( pre -tr eat me nt)  t o deter mi ne  s uita bilit y  
t o partici pate  a n d c o nfir m s u bject q ualificati o n , a n d a gai n  after [ADDRESS_116427]  T o ot h paste  will be c o m pare d wit h  t hat of a 
Refere n ce T o ot h paste - a c o n v e nti o nal , dail y us e  fl u ori de t o ot h paste wit h n o k n o w n a nti -
se nsiti vit y efficac y ( i.e., a n o n -dese nsitisi n g t o ot h paste  will act as  t he ne gati ve c o ntr ol ). 
Q ualif yi n g s u bjects will be ra n d o mi ze d t o o n e of t he t w o i n vesti gati o nal  treat me nt s usi n g a 1: 1 
all ocati o n rati o.  
• Da y [ADDRESS_116428] e d as t he pri mar y ti me p oi nt t o c o nfir m  t he a nti -se nsiti vit y  
effic ac y  of t he i n vesti gati o nal 0. 4 5 4 % S n F 2 t o ot h paste ; 5 6 -da y ( 8-w ee k) st u d y d urati o n 
is acce pt e d as a p pr o priat e t o e val uat e t he l o n g -ter m effic ac y of m ost a nti -se nsiti vit y 
pr o d ucts (H olla n d, 1 9 9 7 ). 
• Eva p orati ve (air) is a t her mal sti m ul us  re prese ntati ve of t he i m pact of c hille d f o o d s a n d 
dri n ks , or  a n i nta ke of c ol d air , o n se nsiti ve teet h . ‘Col d’ is  re p orte d t o be t he m ost 
c o m m o n  sti m uli f or  D H  pai n ( Fisc h er, 1 9 9 2 ; Fl y n n, 1 9 8 5 ; Gilla m, 2 0 0 2 ). T h us, cha n ge 
fr o m Baseli ne i n Sc hiff se nsiti vit y sc ore at Da y [ADDRESS_116429] u d y s uccess  defi n e d as statisticall y si g nifica nt, s u peri or a nti -
h y perse nsiti vit y effic ac y  f or t he  0. 4 5 4 % S n F 2 t o ot h paste , vs.  ne gati ve c o ntr ol, as 
meas ure d b y Sc hiff se nsiti vit y sc ore at Da y 5 6 ( Wee k 8 ).  
O n c o m pleti o n of t he Baseli ne assess me nts, t he cli nical e xa mi ner will sele ct t w o ‘ Test T eet h’  
fr o m t h ose t hat q ualif y at b ot h Scree ni n g ( Visit 1) a n d Baseli ne ( Visit 2) f or ass ess me nt of 
tactile a n d e va p orati ve (air) se nsiti vit y at all s u bse q ue nt visits. Q ualif yi n g s u bjects will be 
stratifie d acc or di n g t o t he ma xi m u m Sc hiff se nsiti vit y sc ore of t heir t w o selecte d ‘Test Teet h ’ 
t o e ns ure treat me nt gr o u ps are bala n ce d f or D H se veri t y.  Re peate d  sti m ulati o n of m ulti ple 
se nsiti ve teet h ma y  alt er t he pai n  res p o nse  as testi n g c o nti n ues ar o u n d t he m o ut h ; t he 
antici pati o n of pai n or disc o mf ort  wit h pr otracte d testi n g, al o n g wit h t he disc o mf ort of h a vi n g 
t o kee p t he m o ut h o p e n f or a n e xt e n de d p eri o d of ti me,  ma y  als o affect  s u bject perce pti o n of 
pai n  (H olla n d, 1 9 9 7 ). T h us, t he sele cti o n of t w o re prese ntati ve ‘ Test T eet h’  t o e val uate c ha n g es 
i n D H wit h treat me nt is c o m m o n practice i n D H effi cac y st u dies.  T o b e  re prese nt ati ve of 
differe nt areas of t he m o ut h , wit h i n de pe n de nt  i n ner vati o n, t he ‘ Test Teet h’  s h o ul d  be n o n -
a djace nt a n d  i n differe nt q ua dra nts .  
T he n u m ber of teet h se nsiti ve t o a n e va p orati ve (air) sti m ul us  i n t he p o ol of ‘ Eli gi ble Teet h’ 
i de ntifie d at Scree ni n g will be m o nit ore d  acr oss t he st u d y  p eri o d . T h e e va p orati ve (air) 
se nsiti vit y of a ll ‘Eli gi ble Teet h ’ i de ntifie d at Scree ni n g ( i.e., teet h wit h n o de ntiti o n e xcl usi o ns 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 5  of 1 1 3  w hic h meet t he E A R, M GI a n d  m o bilit y i ncl usi o n criteria, a n d h a ve  a Scree ni n g tactile 
t hres h ol d ≤ 2 0 g a n d a Scree ni n g Sc hiff s e nsiti vit y sc ore ≥ 2 ) will b e ass esse d at Baseli ne, a n d 
after 2 8 - a n d 5 6 -da ys treat me nt . F or t his p ur p ose,  a ‘ Se nsiti ve T o ot h’ will be defi ne d as ha vi n g 
a mar ke d res p o nse t o t he e va p orati ve (air) sti m ul us ( Sc hiff se nsiti vit y sc ore  ≥ 2).  
T o hel p mi ni mize e x p os ure t o e n vir o n me ntal  tri g gers f or se nsiti vit y  pri or t o cli nical D H  
assess me nt , s u bjects will be i nstr uct e d t o refrai n fr o m oral h y gi e ne, c he wi n g g u m , eati n g a n d 
dri n ki n g f or a peri o d of ti me pri or t o t heir arri val at t he i n vesti gat or site.  
Cli nical trials e val uati n g pai n -relat e d e n d p oi nts ca n be pr o ne t o ‘ place b o effects’ (A d d y, 1 9 8 5 ; 
West, 1 9 9 7 ); s u c h effects are fre q ue ntl y o bs er ve d i n D H st u dies. A st u d y c o n d ucte d t o e val uate 
t he nat ural hist or y of t he D H  c o n diti o n als o hi g hli g hte d t he e xiste nce of a ‘ n o treat me nt’ effect , 
c haracteri ze d b y a n i m pr o ve me nt i n se nsiti vit y si m pl y as a res ult  of st u d y partici pati o n (Lei g ht, 
2 0 0 8 ).  T o hel p mi ni mi ze t he p ote ntial i m pact of s uc h effects , a n accli mati zati o n peri o d (1 4 -2 8 
da y s d urati o n) will prece de t he Baseli ne visit . D uri n g t his peri o d , st u d y  s u bjects will br us h 
t wice dail y wit h t h e re g ular fl u ori de t o ot h paste  a n d t o ot h br us h pr o vi de d ( i n place of t h eir o w n  
oral h y gie ne pr o d ucts ) a n d rec or d eac h br us hi n g occasi o n i n a diar y. T he accli mati zati o n peri o d 
will als o ser ve t o s ta n dar di ze oral h y gie ne practice  acr oss t he st u d y p o p ulati o n a n d fa miliariz e  
partici pa nts wit h  s e veral  i m p orta nt st u d y pr oce d ures (e. g., t o ot h paste d osa g e, ti me d br us hi n g s, 
diar y c o m pleti o n) pri or t o treat me nt .  
D H is a n e pis o dic c o n diti o n; s y m pt o ms are k n o w n t o var y s p o nta ne o usl y ( West, [ADDRESS_116430], 
2 0 1 3) . Baseli ne cli nical val ues t hat w o ul d s u p p ort e nr ol me nt ma y re prese nt ra n d o m hi g hs t hat 
c o ul d be f oll o we d b y re gressi o n t o t he mea n, lea vi n g t he s u bject or select e d test t o ot h wit h o ut 
t he c o n diti o n u n der i n vesti gati o n (i.e., D H) d uri n g t he treat me nt peri o d. T o hel p mi ni mize  t he 
p ote ntial f or t his t o occ ur in t he c urre nt st u d y, ra n d o mize d  s u bjects will be re q uire d t o 
de m o nstrate c o nsiste nc y  i n res p o nse t o b ot h D H sti m uli at b ot h t he Scree ni n g a n d  Baseli ne 
visits. Q ualif yi n g s u bjects will ha ve a mi ni m u m of t w o q ualif yi n g  teet h wit h a tactile t hr es h ol d 
≤ 2 0 g  a n d  a Sc hiff se nsiti vit y sc ore ≥ [ADDRESS_116431] s, i nc o nsiste nt res p o n ders will be e xcl u de d  (H olla n d, 1 9 9 7 ). 
T he eti ol o g y of D H  re q uires t o ot h w ear (l oss of e n a mel) a n d/ or gi n gi val recessi o n (wit h l oss of 
ce me nt u m) t o e x p ose t he u n derl yi n g de nti n ( A d d y, 1 9 8 7) . In t he a bse nce of a n u n derl yi n g 
c o n diti o n  or pat h ol o g y, t hese  pr ocess es are sl o w a n d pr o gressi ve , lea di n g t o de nti n e x p os ure i n 
earl y a d ult h o o d; t h us, D H  is  rarel y s ee n i n c hil dre n (West, 2 0 2 2 ).  W hile t he  a ge ra n ge o v er  
w hic h a n i n di vi d ual ca n e x perie n ce D H is wi de (earl y te e ns t o 7 0s), p ea k i nci de nce is k n o w n 
t o occ ur bet wee n t he a ges of 2 0 -4 0 years  a n d d ecli n e t hereafter  (B art ol d, 2 0 0 6 ; Da ba b ne h, 1 9 9 9; 
Fisc her, 1 9 9 2 ; Fl y n n, 1 9 8 5 ; West, 2 0 1 4 ).  T he fall i n pre vale nce  o bser ve d i n later deca d es 
reflects a ge -relate d c ha n ges i n t he de nti n a n d p ul p of t he t o ot h w hic h act t o re d uce b ot h de nti n 
per mea bilit y a n d t he t o ot h’s res p o nse t o e xter nal tri g gers of D H (Seltzer, 1 9 7 5 ; S pliet h, 2 0 1 3 ). 
De ntal pai n e x p erie n ce d b y  ol der me m bers of t he p o p ulati o n is less li kel y t o be dia g n ose d as  
D H (Rees, 2 0 0 0 ), t h us a n  a ge ra n g e of [ADDRESS_116432] u d y p o p ulati o n will c o m prise male a n d fe male s u bjects  a n d t he pr ot oc ol 
i ncl usi o n/e xcl usi o n criteria will n ot u n necessaril y precl u de  a n y s u b ject fr o m partici pati o n . T o 
f urt her i ncreas e t he di versit y of e nr olle d s u bjects : (i) t he i n vesti gat or site will be e nc o ura g e d t o 
e m pl o y a ra n ge of a d vertisi n g met h o ds (e. g., p osters i n l ocal c o m m u nit y ce nters, retail o utlets 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 6  of 1 1 3  a n d healt hcare facilities, l oca l ra di o, s ocial me dia) t o ma xi mize  t heir a bilit y t o reac h a di verse 
p o p ulati o n wit hi n t heir g e o gra p hic l ocati o n; (ii) w here v er p ossi ble, t h e i n vesti gat or site will 
e ns ure accessi bilit y t o cli nical areas f or  s u bjects wit h m o bilit y iss ues; (iii) fle xi bilit y will  be 
a d de d t o Visit  [ADDRESS_116433] atte n da nce at site ( Da y 2 8 ± 2 da ys; 
Da y 5 6 ± 3 da ys );  (i v) st u d y pa y me nt will a p pr o priatel y c o m pe nsate p ot e ntial s u bjects f or t he 
a ntici pa te d c osts of partici pati o n (e. g., tra vel t o t he i n vesti gat or  site f or sc he d ule d visits) t o 
e ns ure fi na n cial c o nsi derati o ns d o n ot i m pe de partici pati o n . 
Fe male s u bjects w h o are pre g na nt  (or i nte n di n g t o bec o me pre g n a nt d uri n g t he st u d y ) or breast -
fee di n g will be e xcl u d e d  fr o m partici pati o n i n t he st u d y . The st u d y t o ot h pastes  are n ot c o ntr a -
i n dicate d f or pre g na nc y or  breastfee di n g (t heir us e w o ul d n ot b e e x p ecte d t o ca use har m t o t he 
m ot her, t he f oet us or a b a b y), h o we ver, pre g na nt a n d la ctati n g fe m ales will be e xcl u d e d d ue t o 
t he i ncrease d pre vale n ce /se verit y of gi n gi vitis a n d peri o d o ntal disease re p orte d  d uri n g 
pre g na nc y a n d breastfee di n g w hic h, t o get her wit h t he i ncreas e d a m o u nts of calc ul us a n d pla q ue 
o bser ve d o n t h e teet h d uri n g pre g n a n c y, c o ul d affect  D H assess me nt  (A g haza d e h, 2 0 1 9 ; 
Sa ma nt, 1 9 7 6 ).   
P ote ntial st u d y s u bjects  will  be  as ke d t o bri n g t heir c urre nt oral h y gie ne pr o d ucts t o Scree ni n g 
( V isit  1)  w h ere t he y will be c h ec ke d f or pres e nce of k n o w n a nti -se nsiti vit y i n gre die nts . 
I n di vi d uals alr ea d y  usi n g a nti -se nsiti vit y pr o d uct (s) as part of t heir n or m al  oral h y gie ne r o uti ne 
will be e xcl u de d . If t he y are usi n g s uc h pr o d ucts a n d c o nti n ui n g t o e x perie nce D H , t he y w o ul d  
be  u nli kel y t o res p o n d t o f urt her use of a nti -se nsiti vit y t o ot h paste  i n t his st u d y a n d will be 
a d vise d t o see k hel p fr o m t heir de ntal healt hcare pr o vi der.  
‘Patie nt -re p ort e d o utc o me s’ ( P R O s) ca n pr o vi de val ua ble i nf or mati o n a b o ut  t he effect  of a 
c o n diti o n , a n d its treat me nt , o n da y -t o -da y life  fr o m t he pers pecti ve  of t he p ers o n s ufferi n g wit h 
t he c o n diti o n . T he i ncl usi o n of well -defi ne d , relia ble ‘P R O s’  i n  cli nical st u dies  is i ncreasi n gl y 
e nc o ura g e d t o e ns ure t he i m pact of tr eat me nt  o n q ualit y of life  a n d s u bject -re p orte d  s y m pt o ms  
is assesse d  al o n gsi de c o n ve nti o nal cli nical o utc o mes . I n dee d, p u blis he d g ui d eli nes  f or t he 
desi g n a n d c o n d uct of st u dies  i n vesti gati n g  t he cli nical efficac y of a nti -se nsiti vit y pr o d uct s 
(H olla n d, 1 9 9 7 ), rec o m me n d t hat treat me nt e val uati o n s i ncl u de s u bject -assess me nt of o verall 
c ha n ge t o e v er y  da y tri g gers f or D H . Three ‘P R O ’ meas ur es will be i ncl u de d i n t his st u d y : 
(i)  t he De nti ne H y perse nsiti vit y E x perie nce Q uesti o n naire ( D H E Q) ; (ii) a series of  La belle d 
Ma g nit u de Scales ( L M S s); ( iii)  a Treat me nt Satisfacti o n N R S . Gi ve n st u d y partici pa nts  will n ot 
be patie nts, f or t he p ur p oses of t his st u d y, t hes e m eas ures will be d escri b e d  as ‘s u bject -re p orte d 
o utc o mes’ . 
T he D H E Q a n d t he L M Ss  were de vel o p e d wit h D H s ufferers a n d ca n be  use d t o assess t he 
i m pact of D H o n d ail y life , t o meas ure D H pai n  a n d / or  assess  s u bject res p o ns e t o D H  treat me nt .  
St u d y s u bjects will c o m plete a D H E Q -4 8 ( A p pe n di x 1 5. 2 ) at Baseli ne ( Visit 1), a n d after 2 8 - 
a n d 5 6 -da ys treat me nt ( Visits 6 a n d 7), pri or t o a n y cli nical e xa mi nati o ns or assess me nts.  
• T he D H E Q is a v ali date d, c o n diti o n -s pecific meas ure of O H R Q o L use d t o i n vesti gate 
t he i m pacts of t o ot h se nsiti vit y o n e ver y da y life . It was  d e vel o pe d b y t h e s p o ns or i n 
c olla b orati o n wit h S heffi el d U ni versit y t hr o u g h a r o b ust t he oretical fra me w or k, ( Ba k er, 
2 0 1 4 ; B oi k o, 2 0 1 0 ; R o bi ns o n, 2 0 1 4 ) a n d has s h o w n relia bilit y a n d vali dit y i n b ot h a 
ge neral p o p ulati o n ( P orritt, 2 0 1 6 ) a n d i n cli nical st u dies ( B oi k o 2 0 1 0 ; Gi bs o n, 2 0 1 5 ).  
It has b ee n  vali dat e d as  b ot h l o n g - a n d s h ort -f or m versi o ns  (D H E Q -4 8 a n d D H E Q -1 5 ),  
co m prisi n g 4 8 ( Ba ker, 2 0 1 4; B oi k o, 2 0 1 0 ) a n d 1 5 ( Mac h u ca, 2 0 1 4 ) q uesti o ns , 
res pecti vel y , a n d has bee n tra nslate d i nt o m ulti ple la n g ua ges (e. g., C hi nese, T ur kis h, 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 7  of 1 1 3  P ort u g uese), c o nfir mi n g its gl o bal rele va n ce ( B aşara n, 2 0 1 8 ; D o u glas -De -Oli veira ; 
2 0 1 8 ; He, 2 0 1 5 [a]; H e, 2 0 1 5 [b]).  
St u d y s u bjects will c o m plete  f o ur LM Ss  (A p pe n di x 1 5. 3 ) relati n g t o  c o n diti o n -s pecifi c 
c haracteristics of t h e D H pai n res p o ns e ( i nte nsity , d ur ati o n , t oler a bility  a n d  descri pti o n ) at 
Baseli ne ( f or eac h t o ot h w hic h q ualifies f or e va p orati ve (air) ass ess me nt ), a n d after 2 8 - a n d 5 6 -
da ys treat me nt  (f or t he t w o  selecte d  ‘ Test Teet h’  o nl y ). L M Ss will be c o m plete d s h ortl y after 
t he e va p orati ve (air) sti m ul us  has bee n a d mi nistere d , a n d after t he cli nical e x a mi ner has 
rec or de d t heir Sc hiff se nsiti vit y sc ore . T o a v oi d bi as , t he e xa mi ner a n d  t he s u bject will ha v e n o 
visi bilit y of  t heir res pecti ve ‘sc ores’ .  
• Vis ual A nal o g ue Scales ( V A Ss)  wit h t w o a nc h or p oi nts  at 0 milli meters ( m m) a n d 1 0 0 
m m  (t y pi[INVESTIGATOR_1306] y la belle d ‘ n o pai n’ a n d  ‘ w orst i ma gi na ble pain’ ) are fre q ue ntl y e m pl o ye d 
i n t he cli nical st u d y of  pai n . W hile are effecti ve  f or meas uri n g  c ha n g e i n hi g h i nte nsit y 
pai n (e. g., p ost -o perati ve pai n  G a gliese, 2 0 0 5 ), t h e y ca n be less  us ef ul  f or l o w -le vel , 
e pis o d ic  pai n , s u c h as t hat  ass ociate d wit h D H . T h e L M Ss  t o be use d i n t his st u d y were 
de vel o pe d b y t he s p o ns or i n c olla b orati o n wit h t he U ni versit y  of Was hi n gt o n  (Seattle , 
U S) , s pecificall y t o discri mi nate bet wee n differe nt le vels of D H pai n , a n d ha ve bee n 
pil ote d, vali date d, a n d utilize d i n o bser vati o nal a n d i nter ve nti o nal cli nic al D H st u dies 
(C u n ha -Cr uz, 2 0 1 3; Heat o n, 2 0 1 3; Mas o n, 2 0 1 7; Mas o n, 2 0 1 9 ).  Rec urri n g , c o nsiste nt  
desc ri pt ors of D H p ai n (fr o m t he  mil dest t o t he m ost se vere ) w ere i de ntifie d  d uri n g  
f oc us gr o u ps wit h  cli nicall y c o nfir me d  D H  s ufferers . Ps yc h o p h ysical pr oce d ures 
( ma g nit u de esti mati o n a n d cr oss -m o dalit y ma g nit u de matc hi n g) w ere t he n a p plie d t o 
ali g n  t hese c o n diti o n -s p ecific des cri pt ors  al o n g V A S s at dista nces reflect i n g  t he 
ps yc h ol o gical dista nces b et wee n t he d escri pti ve ter ms .  
T o i n vesti gate satisfacti o n wit h t heir assi g ne d i n vesti gati o nal t o ot h paste f or t h e o verall 
ma na ge me nt of D H, s u bjects  will be as ke d t o c o m plete a N R S  (a n 1 1 -p oi nt or di nal scale) at t he 
e n d of t he treat me nt peri o d . T he y will rec or d t he n u meric val ue (fr o m 0 t o 1 0) t hat best descri bes 
t heir le vel of satisfacti o n a n d descri b e w h y t he y ga ve t he pr o d uct t hat r ati n g (free te xt) . 
Per I nter n ati o nal C o nfere nce o n Har m o nizati o n (I C H ) GCP g ui da nce  (I C H E 6 ( R 2) G o o d 
Cli nical Practice ),  f or a st u d y t o be cl ass ifi e d as d o u ble bli n d , t he s u bjects, i n vesti gat or(s)  a n d 
staff i n v ol ve d i n t he  treat me nt or cli nical e val uati o n of s u bjects  s h o ul d be u na ware of treat me nt 
recei v e d; t his i ncl u des staff i n v ol ve d i n t he deter mi n ati o n of  s u bject eli gi bilit y, e val uati on of  
e n d p oi nts  (cli nical e xa mi ner s), or assess me nts of pr ot oc ol  c o m plia nce  (e. g.,  m o ni t or s, data 
a nal yst s). I n s u m mar y, n eit her t he s u bject  n or t he researc her s s h o ul d k n o w  if  t he s u bject has 
bee n assi g ne d t o Test  or Refere n ce  treat me nt . I n a d diti o n, t he pr o d ucts u n der test s h o ul d ha ve 
t he sa me a p peara nce , s mell a n d taste  (i.e., st u d y ar ms s h o ul d n ot be disti n g uis ha ble fr o m eac h 
ot her ). Gi ve n t his will n ot be p ossi ble f or t he i n vesti gati o nal  pr o d ucts e val uate d i n t his st u d y 
(a n e x p eri me nt al t o ot h paste  a n d c o m merciall y a vaila ble re g ular fl u ori de t o ot h paste ), t he st u d y 
is descri be d as ‘e xa mi ner bli n d’. H o we ver , gi v e n desi g n of t he st u d y a n d t he pr oce d ures i n 
place at t he i n vesti gat or site to mai ntai n t he bli n d d uri n g st u d y c o n d uct , it is hi g hl y u nli kel y 
t hat t he s u bject s, i n vesti gat or, cli nical e xa mi ner(s)  or a n y me m ber of t h e site staff i n v ol ve d i n 
effic ac y a n d s afet y assess me nts  will be a ware of treat me nt all oc ati o n.  
• In t his parallel -desi g n st u d y , s t u d y s u bjects will see a n d use o nl y o ne of t he t w o 
i n vesti gati o nal  t o ot h pastes  f or t he d urati o n of t he treat me nt peri o d . T h e y will be 
i nstr ucte d n ot t o disc uss t he a p peara nce , usa ge  or percei ve d perf or ma nce of t heir 
assi g ne d i n vesti gati o nal  t o ot h paste wit h t he cli nic al e xa mi ner (s) , wit h  staff i n v ol ve d i n 
cli nical  assess me nts or wit h ot her st u d y s u bjects .  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 2 8  of 1 1 3  • B ot h  i n vesti gati o nal  pr o d ucts are bl ue  t o ot h pastes . T he y  will be pr o vi de d  t o t he 
i n vesti gat or  site o ver wra p pe d i n w hite vi n yl t o mas k t heir i de ntit y , a n d t o o bsc ure a n y 
bra n di n g  o n t he Refere n ce T o ot h paste , wit h a st u d y la bel affi x e d.  
• T he i n vesti gati o nal  t o ot h pastes  will be s u p plie d i n c art o n s, eac h cart o n will  c o ntai n 4 
o ver -wra p pe d t u bes of t o ot h paste. T he c art o n a n d its 4 t u bes will be la belle d wit h t he 
sa me  u ni q ue ra n d o mizati o n n u m ber . Su bjects will be ce ntrall y ra n d o mi ze d t o treat me nt  
i n or der of q ualificati o n usi n g a n I nteracti ve Res p o nse Tec h n ol o g y (I R T) ; pr o d uct c o des 
will n ot be use d . 
• T he cli nical e x a mi ner(s) a n d site  staff i n v ol ve d i n effic ac y a n d safet y assess me nts  will 
n ot be p er mitte d i n a n y area w here t h e i n vesti gati o nal  t o ot h pastes  or diari es  are  st ore d , 
dis pe nse d  or i n use . 
• Site  staff i n v ol ve d i n t he dis pe nsi n g  of i n vesti gati o nal  t o ot h pastes , pr o vi di n g  br us hi n g 
a n d diar y c o m pleti o n i nstr ucti o n , s u per visi o n of o n -site  br us hi n gs , treat me nt 
c o m plia nce c hec ks a n d pr o d uct acc o u nta bilit y  will n ot be  i n v ol ve d i n cli nical effic ac y 
a n d safet y ass ess me nts  a n d will w or k i n a se parate area fr o m t h e cli nic al e xa mi ner(s) 
a n d site  staff i n v ol ve d i n effic ac y a n d s afet y assess me nts.  
• S u bjects  will be i nstr ucte d n ot t o re m o ve t heir assi g ne d i n vesti gati o nal  t o ot h paste  or 
diar y fr o m t he o pa q ue carrier ba g pr o vi de d  o utsi de of t he dis pe nsi n g/s u per vi se d 
br us hi n g r o o m , w hile at t he i n vesti gat or  site . 
• W here  cert ai n staff will  be u n bli n de d t o carr y o ut t heir res p o nsi bilities ( e. g. , staff  
i n v ol ve d i n S A E  re p orti n g , m o nit ors ), t he  i n vesti g at or a n d s p o ns or are  re q uire d t o  p ut  
a de q uate pr oce d ures i n place t o pre ve nt i na p pr o priate disse mi nati o n of treat me nt 
i de ntificati o n .  
4. 3  J u stifi c ati o n f or D o s e  
T he i n vesti gati o nal  pr o d ucts are t o ot h pastes ; t he y are i nte n de d f or t o pi[INVESTIGATOR_1064] a n d will be 
a p plie d b y t o ot h br us hi n g usi n g a ma n u al t o ot h br us h.  
I n li ne wit h wi del y r ec o m me n de d oral h y gie ne practice a n d t y pi[INVESTIGATOR_2855] c o ns u mer ha bit, q u alif yi n g 
s u bjects will be i nstr ucte d t o br us h t wice dail y ( m or ni n g a n d e ve ni n g) wit h t heir assi g ne d 
i n vesti gati o nal t o ot h paste, c o veri n g t he t o ot h br us h hea d wit h f ull ri b b o n of t o ot h paste 
(a p pr o xi matel y 1. 5 g) o n eac h br us hi n g o ccasi o n.  
• S u bjects ra n d o mize d t o T est T o ot h paste will b e i nstr ucte d t o br us h t heir e ntire de ntiti o n 
t h or o u g hl y f or at least 1 -ti me d mi n ute, ma ki n g s ure t o br us h t he se nsiti ve areas of t heir 
t w o ' Test teet h' caref ull y first.  
• S u bjects ra n d o mize d t o Refere n ce T o ot h paste will be i nstr ucte d t o br us h t heir e ntire 
de ntiti o n t h or o u g hl y f or at least [ADDRESS_116434] u die s (D oci m o, 2 0 0 9 ; Hall, 2 0 1 7 ; 
He, 2 0 1 4[ b]);  Par ki ns o n, 2 0 1 3; Par ki ns o n, 2 0 1 5 [a] ).  
After 8 wee ks ( i.e., 5 6 ±  3 da ys) t wic e dail y usa ge, eac h s u bj ect s h o ul d c o m plete bet wee n 1 0 6-
1 1 8 br us hi n gs.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116435] sc he d ule d pr oce d ure s h o w n i n t he Sc he d ule of 
Acti vities  (Ta ble 1 -1). T he e n d of t his st u d y is defi ne d as t he date of t he last sc he d ule d 
pr oce d ure  f or t h e last s u bject , as descri be d  i n t he Sc he d ule of A cti vities  (Ta ble 1 -1).  
[ADDRESS_116436] u d y will be c o n d u cte d i n male a n d fe male s u bjects i n g o o d ge neral /oral  healt h , wit h pr e -
e xisti n g self -re p orte d t o ot h se nsiti vit y , a n d at least t w o se nsiti ve teet h ( wit h cli nicall y c o nfir me d 
D H ) t hat meet st u d y  eli gi bilit y  criteria at b ot h Scree ni n g ( Visit 1) a n d Baseli ne ( Visit 2).  
S ufficie nt s u bjects will be scree ne d a n d e ntere d i nt o t he accli matizati o n  p hase  t o e ns ure 
a p pr o xi matel y [ADDRESS_116437] (a p pr o xi matel y 5 5  
s u bjects per tr eat me nt gr o u p ) a n d a p pr o xi matel y [ADDRESS_116438] u d y 
(a p pr o xi matel y 5 0  s u bjects per tr eat me nt  gr o u p ), all o wi n g  f or 1 0 %  dr o p o uts . S u bjects will be 
recr uite d pri maril y fr o m t he i n vesti gat or  site data base.  
F or t his st u d y, a n e nr olle d s u bject is defi ne d as a s u bject  w h o has a gree d t o partici pate i n t he 
st u d y f oll o wi n g c o m pleti o n of t he i nf or me d c o nse nt pr ocess a n d s uc cessf ull y met t he st u d y 
eli gi bilit y criteria t o pr ocee d be y o n d t he s cree ni n g visit .  
T he i n vesti gat or site will ma ke e v er y eff ort t o e nr oll  s u bjects re prese ntati ve of t he a d ult 
p o p ulati o n w h o w o ul d be nefit fr o m use of a n a nti -se nsiti vit y t o ot h paste ; t he r ati o nale f or st u d y 
p o p ulati o n selecti o n is pr o vi de d i n t he Scie ntific Rati o nale f or St u d y Desi g n  (Secti o n 4. 2 ). 
A cli nical  st u d y ca n o nl y f u lfill its o bjecti ves if a p pr o priate s u bjects are e nr olle d . T he f oll o wi n g 
eli gi bilit y criteria ha ve b ee n  d esi g ne d t o sel ect s u bjects f or w h o m partici pati o n i n t he st u d y is 
c o nsi dere d a p pr o priate  w hile n ot u n necessaril y precl u d i n g a n y s u bject  fr o m st u d y part ici pati o n . 
All rele va nt me dical a n d n o n -me dical c o n diti o ns s h o ul d be ta ke n i nt o c o nsi derati o n w he n 
deci di n g w het h er or n ot a s u bject is s uita ble.  Eli gi bilit y t o partici pate will  be re vie we d a n d 
d oc u me nte d b y t he i n vesti gat or (or m e dicall y q ualifie d desi g ne e) b ef ore eac h s u bject is 
i ncl u de d i n t he st u d y.  
5. [ADDRESS_116439] t he ir  safet y  or  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116440] u d y re q uir e me nts . 
6.  S C R E E NI N G (Visit 1)  
S u bject m ust ha ve : 
a)  Hist or y of t o ot h se nsiti vit y lasti n g m ore t ha n si x m o nt hs b ut n ot m ore t ha n 1 0 years  
(self -re p orte d ). 
b)  G o o d ge neral oral he alt h , wit h a m i ni m u m of 2 0 nat ural teet h.  
c)  Mi ni m u m of 2 accessi ble, n o n -a djace nt te et h (i ncis ors, ca ni nes, pre m olars), i n differe nt 
q ua dra nts, w hic h  me et all  of t he f oll o wi n g criteria:  
• Ex p ose d de nti n d ue t o facial/cer vical er osi o n, a brasi o n or gi n gi val recessi o n ( E A R).  
• M GI = 0 dir ectl y a djace nt t o t he e x p ose d d e nti n  (i.e., t he test area  o nl y ) (L o be ne, 
1 9 8 6 ). 
• Cli nical m o bilit y = 0  (Laster, 1 9 7 5 ).    
• Cli nicall y c o nfir me d D H t o b ot h  tactile a n d  e va p orati ve (air) sti m uli:  
- Qualif yi n g tactile t hres h ol d ≤ 2 0 g   
- Qualif yi n g Sc hiff se nsiti vit y sc ore ≥ 2.  
7.  B A S E LI N E (Visit 2, Pre -Tre at me nt ) 
S u bject m ust ha ve a mi ni m u m of t w o, n o n -a dja ce nt accessi ble teet h (i ncis ors, ca ni nes, 
pre m olars ), i n differe nt q ua dra nts,  wit h cli nicall y c o nfir me d D H t o b ot h tactile a n d 
e va p orati ve (air) sti m uli at b ot h  Scree ni n g  ( Visit 1)  a n d  Baseli ne  (Visit 2) . 
• Qualif yi n g tactile t hres h ol d ≤ 2 0 g  at Scree ni n g & Baseli ne  
• Q ualif yi n g Sc hiff se nsiti vit y sc ore ≥ 2 at Scree ni n g & Baseli ne  
T he cli nical e xa mi ner will select t w o ‘Test T eet h ’ fr o m t h ose w hic h meet t he tactile 
t hres h ol d a n d Sc hiff se nsiti vit y sc ore i ncl usi o n criteria at b ot h Scree ni n g a n d Baseli ne.  
N ote s: All teet h wit h cli nic ally c o nfir me d , q u alifyi n g levels of  D H at Scree ni n g ( i.e., a 
Scree ni n g t a ctile t hres h ol d ≤ 2 0 g a n d a S cree ni n g Sc hiff se nsitivity sc ore ≥ 2 ) will be 
assesse d f or t actile se nsitivity  at B aseli ne . Teet h wit h a B aseli ne t actile t hres h ol d ≤ 2 0 g will 
t h e n be assesse d f or B aseli ne ev a p or ative ( air) s e nsitivity.   
5. [ADDRESS_116441] u d y  (self -
re p orte d ).   
4.  Fe male s u bje ct  w h o is br eastfee di n g  (self -re p ort e d ). 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116442] u d y pr o d ucts , a n y 
of t heir state d i n gre di e nts  or cl osel y relat e d c o m p o u n ds  (self -re p orte d ).  
6.  S u bject wit h a rece nt hist or y ( wit hi n t he last year) of alc o h ol or ot her s u bsta nce a b use  (s elf -
re p orte d ). 
7.  Su bject is partici pati n g i n or has partici pate d i n ot her st u dies (i ncl u di n g n o n -me dici nal 
st u dies) i n v ol vi n g i n vesti gati o nal pr o d uct (s)  wit hi n  3 0 da ys of Scree ni n g ( Visit 1)  or pla ns 
t o partici pate i n ot her st u dies (i ncl u di n g n o n -me dici nal s t u dies) d uri n g t his st u d y.  
8.  S u bject has partici pate d i n a t o ot h se nsiti vit y st u d y wit hi n 8 wee ks of Scree ni n g  ( Visit 1) . 
9.  S u bject is c urre ntl y usi n g a n oral care pr o d uct i n dicate d f or D H  relief or care of se nsiti ve 
teet h  or has use d  a n a nti -se nsiti vit y pr o d u ct  wit hi n 8 wee ks of Scree ni n g ( Visit 1)  
Su bject s will be re q uire d t o bri n g t heir c urre nt or al c are pr o d ucts t o Scr ee ni n g ( Visit 1 ) f or 
st aff t o verify t he a bse nce of k n o w n a nti -se nsitivity i n gre die nts a n d se nsitivity -rel ate d  cl ai ms  
o n  t he pr o d uct p ack a gi n g/ l a bel  text . 
[ADDRESS_116443] ta kes  d ail y d oses of me dicati o n s/treat me nts w hic h, i n t h e o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or 
or me dicall y q ualifie d d esi g nee, c o ul d i nterfere wit h t heir perce pti o n of t o ot h se nsiti vit y 
(e. g.,  a nal g esics, a ntic o n v ulsa nts, a nti hista mi nes t hat ca use mar ke d or m o derate se d ati o n, 
se dati ves, tra n q uili zers , a nti de pressa nts, m o o d -alteri n g a n d a nti -i nfla m mat or y dr u gs).  
1 1.  S C R E E NI N G ( Visit 1)  
S u bject has ta ke n a nti bi otics i n t he 2 wee ks pri or t o Scree ni n g ( Visit 1) . 
1 2.  B A S E LI N E (Visit 2 , Pre -Tre at me nt ) 
S u bject has ta ke n a nti bi otics i n t he 2 wee ks pri or t o Baseli ne ( Visit 2), i.e., d uri n g t he 
accli mati zati o n  peri o d.  
[ADDRESS_116444] ha s ha d pr ofessi o nal t o ot h de -se nsitisi n g treat me nt wit hi n 8 wee ks of Scree ni n g 
( Visit 1) . 
[ADDRESS_116445] has ha d a to ot h  bleac hi n g pr oce d ure wit hi n 8 wee ks of Scree ni n g  ( Visit 1) . 
[ADDRESS_116446] has ha d de ntal pr o p h yla xis wit hi n 4 wee ks of Scree ni n g  ( Visit 1) . 
[ADDRESS_116447] has ha d treat me nt f or peri o d o n tal disease (i ncl u di n g s ur ger y) wit hi n 1 2 m o nt hs of 
Scree ni n g  ( Visit 1) . 
[ADDRESS_116448] has ha d scali n g or r o ot pla n ni n g wit hi n 3 m o nt hs of Scree ni n g  ( Visit 1) . 
[ADDRESS_116449] u d y o utc o mes.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116450] wit h fi xe d or re m o va ble ort h o d o ntic braces/ ba n ds or a fi xe d ort h o d o ntic retai ner.  
2 6.  S P E CI FI C D E N TI TI O N E X C L U SI O N S F O R ‘ T E S T T E E T H’:  
a)  T o ot h wit h e vi de nce of c urre nt /rece nt c aries  
b)  T o ot h wit h  (self -re p ort e d ) treat me nt f or  deca y wit hi n 1 2 m o nt hs of Scree ni n g  ( Visit 1) . 
c)  T o ot h wit h e x p ose d de nti n a n d  dee p, d efecti ve or facial rest or ati o ns.  
d)  T o ot h wit h a f ull cr o w n or ve neer.  
e)  T o ot h a djace nt t o a bri d g e a b ut me nt or cr o w n w hi c h, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or  
or de ntall y  q ualifie d  desi g nee , co ul d i m pact st u d y o utc o mes.  
f)  Se nsiti ve t o ot h wit h c o ntri b uti n g eti ol o gies ot her t ha n E A R  t o e x p ose d de nti n.  
g)  Se nsiti ve t o ot h n ot e x pecte d t o be nefit fr o m use of a n a nti -se nsiti vit y t o ot h paste , i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or  or de ntall y  q ualifie d  d esi g nee . 
[ADDRESS_116451] w h o, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or or desi g nee , is u na ble t o pr o vi de a p pr o pri ate  
res p o nses t o t he L M S trai ni n g q uesti o ns  (A p pe n di x 1 5. 4 ).  
[ADDRESS_116452] e d ‘ Test Teet h’ . T he str atificati o n fact or will gi ve rise t o t w o strata.  
• Str at u m 1:  Ma xi m u m Sc hiff se nsiti vit y sc ore = 2.  
• Str at u m 2:  Ma xi m u m Sc hiff se nsiti vit y sc ore = 3.  
5. [ADDRESS_116453] ricti o n ( oral h y gie ne, dietar y or alc o h ol -relat e d) pri or t o a st u d y visit, e ver y 
eff ort will be ma de t o re -a p p oi nt t he m wit hi n t he per mitte d visit t olera nces , as defi ne d i n t he 
Sc he d ule of A cti vities  (Ta ble 1 -1)). T he reas o n f or re -a p p oi nt me nt will be d oc u me nte d i n t h e 
electr o nic case re p ort f or m  (e C R F).   
If re -a p p oi nt me nt is n ot p ossi ble, t he f oll o wi n g visit s pecific acti o ns s h o ul d be ta ke n.  
• B aseli ne ( Visit 2):  t h e s u bject will be wit h dr a w n fr o m t he st u d y ( Secti o n 7. 1 ). N o 
cli nical assess me nts will be perf or me d. T he s u bject ma y  be re pla ce d.  
• D a y  2 8 ( Visit  3) : t he s u bject will c o nti n ue i n t he st u d y. N o cli nical assess m e nts will be 
perf or me d.  
• D a y 5 6  ( Visit 4): if t h e s u bject ca n n ot b e rea p p oi nte d, t he y will be wit h dr a w n f r o m t he 
st u d y ( Secti o n 7. 1 ). N o cli nical assess me nts will b e perf or me d. T he s u bject will n ot be 
re place d.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116454] u d y:  Fr o m Scree ni n g ( Visit 1) t o t he S u bject’s L ast Visit   
• S u bjects s h o ul d n ot use a n y ot her oral care pr o d ucts (e. g., t o ot h pastes, t o ot h br us hes, 
oral ri nses, t o n g ue cle a ners, w hite ni n g/ bleac hi n g pr o d ucts, i nter -de nt al clea ni n g 
pr o d ucts) t ha n t h ose pr o vi de d d uri n g t he st u d y.  
N ote:  Use of d e nt al fl oss is per mitte d  t o re m ove i m p acte d f o o d  o nly .  
• S u bjects s h o ul d n ot use a n y ot her pr o d ucts i nte n de d f or treati n g or cari n g f or se nsiti ve 
teet h (i ncl u di n g her bal re me dies) t ha n t h ose pr o vi de d d uri n g t he st u d y.  
• S u bjects s h o ul d n ot  c he w g u m.  
Bef ore a Cli nic al Assess me nt Vis it:  Fr o m B aseli ne ( Visit 2)  t o t he S u bject’s L ast Visit    
• Su bjects will refrai n fr o m all oral h y gie ne pr oce d ures f or at le ast [ADDRESS_116455] u d y 
visit . 
5. 5. 2  Di et ar y a n d Al c o h ol R e stri cti o n s  
Bef ore a Cli nic al Assess me nt Visit : B aseli ne ( Visit 2)  t o t he S u bject’s L ast Visit  
• S u bjects m ust n ot eat or dri n k f or at least 2 h o urs bef ore a cli nical ass ess me nt visit.  
N ote:  S m all si ps of r o o m -te m per at ure w ater ar e per mitte d t o t a ke me di c ati o ns or t o 
relieve a dry m o ut h u p t o 1 h o ur bef ore t heir a p p oi nt me nt ti me  
• S u bjects s h o ul d refrai n fr o m e xcessi ve alc o h ol c o ns u m pti o n f or [ADDRESS_116456] u d y t o ot h pastes are n ot c o ntra -i n dicate d f or pre g na nc y or  breastf ee di n g (t heir use w o ul d 
n ot be e x pect e d t o ca use h ar m t o t he m o t her, t he f oet us or a ba b y)  a n d there will be  n o pre g na nc y 
war ni n g s o n t he la belli n g of a n y of t he st u d y pr o d ucts . T h us, st u d y -s pecific c o ntrace pti v e 
re q uire me nts are n ot de e me d necess ar y  f or st u d y s u bjects (fe mal e or male) .  
5. [ADDRESS_116457] u d y b ut are 
n ot s u bse q ue ntl y  ra n d o mize d . T o e ns ur e tra ns p are nt re p orti n g of s cree n fail ure s u bjects, a 
mi ni mal set o f scree n fail ure i nf or mati o n will i ncl u de de m o gra p h y, scree n fail ure reas o n  (e. g. , 
wit h dra wal of c o nse nt), eli gi bilit y criteria, a n y pr ot oc ol de viati o ns a n d a n y A Es , as a p plica ble.  
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y ( scree n fail ure) will n ot 
be re -s cree ne d.  
5. 7  S p o n s or’ s Q u alifi e d M e di c al P er s o n n el  
C o ntact i nf or mati o n f or t he s p o ns or's a p pr o priatel y q ualifie d a n d e x peri e n ce d me dical/ de ntal 
pers o n nel or Cli nical Researc h Scie ntist ( C R S) f or t h is  st u d y is d oc u me nte d i n t he  St u d y 
C o ntact List l ocate d i n t he i n vesti gat or site file hel d at t he i n vesti gat or  site.  
T he c o ntact n u m ber  is o nl y t o be use d b y i n vesti gat or  staff see ki n g a d vic e o n me dical/ de ntal 
q uesti o ns or pr o ble ms i n t he e v e nt t hat t he esta blis he d c o m m u nicati o n pat h wa ys bet w ee n t h e 
i n vesti gat or  site a n d t he s p o ns or’s st u d y tea m are n ot a vaila ble.   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116458] u d y -rel ate d 
me dical/ de ntal q u esti o ns or pr o ble ms, s u bjects will be pr o vi de d wit h a c o ntact car d.   T h e 
c o ntact car d will pr o vi de, as a mi ni m u m, pr ot oc ol i de ntifiers, t he s u bj ect’s st u d y i de ntificati o n 
n u m ber, c o nta ct i nf or mati o n f or t he i n vesti gat or  site, a n d c o ntact d etails i n t he e ve nt t hat t h e 
i n vesti gat or  site ca n n ot be reac he d t o pr o vi de a d vice o n a me dical q uesti o n or pr o ble m 
i de ntifi e d b y a healt hcare pr ofessi o nal ot her t ha n t he i n vesti gat or.    
5. 8  R at er/ Cli ni c al A s s e s s or Q u alifi c ati o n s  
T he e xa mi ner res p o nsi ble f or t he cli nical effic ac y meas ures will be a q ualifie d de ntal h y gie nist  
trai ne d i n t he cli nical  ass ess me nt of D H (ta ctile a n d / or  e va p orati ve (air) se nsiti vit y).  
The oral ( O S T  a n d O H T ) e xa mi nati o ns  will be c o m plete d  b y a qualifie d de ntist , or  a de ntal 
h y gie nist , as nee de d .   
6 I N V E S TI G A TI O N A L/ S T U D Y P R O D U C T S  
F or t he p ur p os es of t his st u d y, per I C H g ui deli nes a n d s p o ns or  p olic y, st u d y i nter ve nti o n  is 
defi ne d as a n y i n vesti g ati o nal i nter ve nti o n(s), mar kete d pr o d uct(s), place b o, or me dical 
de vice(s) i nte n d e d t o be a d mi nistere d t o a st u d y s u bject  acc or di n g t o t he st u d y pr ot oc ol.  T his 
i ncl u des a pr o d uct wit h a mar keti n g a ut h orizati o n w he n use d or ass e m ble d (f or m ulate d or 
pac ka g e d) i n a wa y differe nt fr o m t he a p pr o ve d f or m, or w he n use d f or a n u na p pr o ve d 
i n dicati o n, or w he n use d t o gai n f urt her i nf or m ati o n a b o ut a n a p pr o ve d use.  
6. [ADDRESS_116459] u d y pr o d ucts (accli matizati o n a n d i n vesti gati o nal t o ot h pastes) 
will be s u p plie d b y t he s p o ns or’s Cli nical S u p plies de part me nt  (T a ble 6-1).  
T he t o ot h paste u sa ge i nstr ucti o ns are  c o nsiste nt wit h t he pr o p ose d la belli n g f or t he Test 
T o ot h paste , w he n mar k et e d,  a n d wit h t he c o m mercial pac k i nstr ucti o ns f or  t he Refere nce a n d 
Accli matizati o n T o ot h paste s.  
T a bl e 6-1 A c cli m ati z ati o n/ I n ve sti g ati o n al  T o ot h p a st e s  
Descri pti o n  Accli m atiz ati o n  
T o ot h p aste  Test  
T o ot h p aste  Refere nce T o ot h p aste 
( Ne g ati ve C o ntr ol)  
Pr o d uct N a me  Re g ular fl u ori de 
t o ot h paste  
(C ol g ate Ca vit y 
Pr otecti o n *)  0. 4 5 4  % w/ w S n F 2 
t o ot h paste  Re g ular fl u ori de 
t o ot h paste  
(Crest Ca vit y Pr otecti o n *)  
Fl u ori de Le vel  100 0  p p m fl u ori de †  1 1 0 0 p p m fl u ori de ¥ 1 1 0 0  p p m fl u ori de ≠ 
M aster 
F or m ul ati o n C o de  N/ A    N/ A  
Dis pe nsi n g Det ails  O ne cart o n c o ntai ni n g 
2 t u bes of t o ot h paste  at 
Scree ni n g ( Visit 1)  O ne cart o n c o ntai ni n g 4 o ver -wra p pe d t u bes of 
t o ot h paste  at Baseli ne ( Visit 2)  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 3 5  of 1 1 3  R o ute of 
A d mi nistr ati o n  T o pi[INVESTIGATOR_104892]  
T o ot h p aste Us a ge 
I nstr ucti o ns  Dose t he t o ot h br us h wit h a ri b b o n of t o ot h paste, acr oss t he f ull br us h hea d . 
Start t he ti mer ( pre -set f or 1 -mi n ute).  
Br us h t he e ntire 
de ntiti o n t h or o u g hl y 
f or at least 1 -ti me d 
mi n ute, t wice dail y 
( m or ni n g & e ve ni n g).  Br us h t he e ntire 
de ntiti o n t h or o u g hl y f or 
at least 1 -ti me d mi n ute, 
t wice dail y ( m or ni n g & 
e ve ni n g), ma ki n g s ure t o 
br us h t he se nsiti ve areas 
of t he t w o ' Test teet h' 
caref ull y first.   Br us h t he e ntire 
de ntiti o n t h or o u g hl y 
f or at least 1 -ti me d 
mi n ute, t wice dail y 
( m or ni n g & e ve ni n g).  
S u bjects w h o wis h t o ri nse after  br us hi n g will be i nstr ucte d t o ri nse wit h  
1 0 ml water usi n g gra d uate d ri nsi n g  c u p pr o vi de d.  
D ur ati o n of 
Tre at me nt  A p pr o xi matel y 8 wee ks ( 5 6 ± 3 da ys)  
Ret ur n 
Re q uire me nts  All use d/ u n use d t u bes  t o be ret ur ne d  t o t he s p o ns or  
* Co m merciall y  a v aila ble dail y use , re g ular fl u ori de t o ot h paste, U S  mar ket .   
†  As s o di u m m o n ofl u or o p h os p hate    ¥ As S n F 2    ≠ As Na F   
Sufficie nt s u p pl ies  of t h e f oll o wi n g s u n dr y ite ms  (Ta ble 6-2) will b e s u p plie d t o c o m plete t h e 
st u d y  b y t he s p o ns or’s Cli nical S u p plies de part me nt  (t o  be dis pe ns e d  b y site  staff , as re q uire d ). 
T a bl e 6-[ADDRESS_116460] y It e m s  
Ite m  P ac k Desi g n  Dis pe nsi n g Det ails  Ret ur n/ Dis p os al Det ails  
Use d S a m ples  U n use d 
S a m ples  
Oral B Se nsi -Soft  
(U S  mar ket)  
M a n u al, fl at tri m, 
me di u m t o ot h br us hes  O ne t o ot h br us h i n 
its c o m mercial 
pac k  Scree ni n g ( Visit 1):  
O ne t o ot h br us h  
B aseli ne ( Visit 2):  
O ne t o ot h br us h   Destr o y at site 
usi n g site dis p osal 
pr oce d ures.    
Ret ur n t o 
s p o ns or  C o u nt d o w n 
Ti mers  O ne ti mer i n its 
c o m mercial pac k  Scree ni n g ( Visit 1):  
O ne ti mer   S u bject t o kee p or 
destr o y at site 
usi n g site dis p osal 
pr oce d ures .   
Gra d uate d 
Ri nsi n g  C u ps  N/ A  Scree ni n g ( Visit 1):  
4 c u ps  
B aseli ne ( Visit 2):  
[ADDRESS_116461] t o kee p or 
destr o y at site 
usi n g site dis p osal 
pr oce d ures . O pa q ue Carrier 
Ba gs  N/ A  Scree ni n g ( Visit 1):  
O ne ba g  
B aseli ne ( Visit 2):  
O ne ba g  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116462] u d y is t he ma n ual t o ot h br us h  ( Oral 
B Se nsi -Soft t o ot h br us h , U S  mar ket) t o be use d t o a p pl y t he st u d y pr o d ucts  b y t wice dail y 
t o ot h br us hi n g . T he de vice  will be s u p plie d t o st u d y s u bjects  i n its c o m mercial pac k ; usa ge 
i nstr ucti o ns will be  c o nsiste nt wit h t he  c o m mercial pac k i nstr ucti o ns.   
De vice d eficie n cies, (i n cl u di n g malf u ncti o n, use err or a n d i na de q u ate la belli n g) will  be 
d oc u me nte d a n d re p orte d b y t he i n vesti gat or t hr o u g h o ut t he st u d y  a n d a p pr o priatel y ma na ge d 
b y t he s p o ns or  (see Secti o n 1 0. 1 0 ). T he de vice d oes n ot i ncl u de a n y me dici nal, h u ma n or a ni mal 
or bi ol o gicall y acti ve materials .  
6. 1. [ADDRESS_116463] u d y  pr o d ucts  are t o ot h pastes . T he y are  i nte n de d f or t o pi[INVESTIGATOR_1064] a n d will be a p plie d 
usi n g a ma n ual t o ot h br us h.  
T he i n vesti gati o nal t o ot h pastes  will be pr o vi de d t o t he i n vesti gat or site i n la mi nate t u bes , 
o ver wra p pe d i n w hite vi n yl  (t o mas k t he ir  i de ntit y , a n d t o o bsc ure a n y bra n di n g , i ma ges  a n d 
te xt  o n t he c o m mercial pac k of t he  Refere n ce To ot h paste ) wit h a st u d y la bel affi xe d. T he 
accli matizati o n t o ot h paste will be s u p plie d i n its c o m mercial pac k , wit h o ut o ver wra p pi n g , wit h 
a st u d y la bel affi xe d . T he c o nte nt  of t he pr o d uct la bel s will be i n acc or da nce wit h all a p plica ble 
re g ulat or y re q uire me nts a n d will be t he res p o nsi bilit y of t he s p o ns or’s Cli nical S u p plies 
de part me nt. E ac h st u d y la bel will c o ntai n  (b ut n ot be li mite d t o ) t h e  pr ot oc ol n u m ber  a n d 
st ora ge re q uire me nts.   
Care s h o ul d b e t a ke n t o e ns ure all  s u p plie d st u d y pr o d uct  is mai ntai ne d i n g o o d c o n diti o n.  It is 
i m p orta nt t hat all pr o d uct la bels re m ai n i ntact a n d l e gi ble f or t h e d urati o n of t he st u d y. S u bjects 
s h o ul d be i nstr ucte d t o n ot re m o ve or deface a n y part of t he st u d y la bel.  
St u d y pr o d uct s will be recei ve d at site  b y me m b ers of t he i n vesti gat or te a m res p o nsi ble f or 
pr o d uct a d mi nistrati o n. T hese i n di vi d uals  will n ot be i n v ol ve d i n a n y safet y  or  effic ac y 
assess me nts or a n y ot her as pect of t he  st u d y t hat c o ul d be i nf l ue nce d b y k n o wle d ge of t he 
i n vesti gati o nal t o ot h paste  a s u bject has b ee n assi g ne d t o.  
St u d y  pr o d ucts s u p plie d are f or use i n t his cli nical st u d y o nl y a n d s h o ul d n ot be use d f or a n y 
ot her p ur p ose.  
6. 1. [ADDRESS_116464] dis pe nsi n g area (s)  will be se parate fr o m t h e cli nical e xa mi nati o n area (s) . 
I n v esti gati o nal  t o ot h pastes will be dis pe ns e d t o t h e s u bject, p er pr ot oc ol , i n bli n de d fas hi o n b y 
trai ne d st u d y pers o n nel. T hese staff me m bers will n ot be i n v ol ve d i n a n y safet y or cli nical 
effic ac y assess me nts or a n y ot her as pect of t h e st u d y t hat c o ul d b e i nfl ue n ce d b y k n o wi n g w hic h 
pr o d uct a s u bject has bee n assi g ne d t o. A n a d diti o nal me m ber of t he dis pe nsi n g  staff will verif y 
t he dis pe nsi n g pr oce d ure has bee n c o m plet e d c orrectl y  f or eac h s u bject.   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116465] will be mai ntai ne d i n t he dis pe nsi n g l o g; 
c o m pleti o n of t he dis pe nsi n g pr oce d ure will be rec or de d i n t he eC R F.  
6. [ADDRESS_116466] ore d i n a sec ure, 
e n vir o n me ntall y c o ntr oll e d, a n d m o nit ore d ( ma n u al or a ut o mat e d) area i n acc or da nce wit h t he 
pr o d uct la bel st ora g e c o n diti o ns wit h access  li mite d t o t he a ut h orize d site st aff  o nl y . 
S u bjects will self -a d mi nister t he accli matizati o n t o ot h paste (fr o m Visit 1 t o Visit 2) a n d t heir 
assi g ne d i n vesti gati o nal  t o ot h paste (fr o m Visit 2 t o Visit 4) acc or di n g t o t he usa ge i nstr ucti o ns 
pr o vi de d b y  t he dis pe nsi n g staff  at t he i n vesti gat or  site a n d as descri be d  i n t he ir  diar y. S u bjects 
will be i nstr ucte d t o rec or d eac h br us hi n g  wit h st u d y pr o d uct i n t heir diar y.  
T o hel p e ns ur e s u bjects f ull y u n dersta n d t h e a m o u nt of t o ot h paste t o use, t he br us hi n g 
instr ucti o ns a n d h o w t o c o m plete t he diar y:  
• Scree ni n g ( Visit 1):  Staff will de m o nstrate dis pe nsi n g a f ull ri b b o n of t o ot h paste al o n g 
t he le n gt h of t he t o ot h br us h hea d t o eac h e nr olle d  s u bject a n d s u per vise t heir first ti me d 
br us hi n g wit h t he accli matizati o n t o ot h paste  a n d diar y c o m pleti o n at t he e n d of t he visit, 
after all cli nical assess me nts ha ve bee n c o m plete d.  
• B aseli ne ( Visit 2):  Staff will s u per vise  t he dis pe nsi n g of a f ull ri b b o n of t o ot h paste b y 
eac h ra n d o mize d s u bject a n d s u per vise t he first ti me d br us hi n g wit h t heir assi g ne d 
i n vesti gati o nal t o ot h paste  a n d diar y c o m pleti o n. Staff will s h o w eac h s u bject 
ra n d o mize d t o T est T o ot h paste t he l ocati o n of  t heir ‘ Test T eet h ’ a n d  c o nfir m t he s u bject 
ca n c orrectl y l ocate t h e t w o ‘ Test T eet h’  t he ms el ves,  pri or t o starti n g t heir o n -site  ti me d 
br us hi n g .  
• D a y 2 8 ( Visit 3 ): Staff will s u per vise eac h s u bject br us hi n g wit h t heir assi g ne d 
i n vesti gati o nal t o ot h paste  an d c o m pleti n g t heir diar y at t he e n d of t he visit, after all 
cli nical assess me nts ha ve bee n c o m plete d. Staff will c hec k  t hat  s u bjects ra n d o mize d t o 
Test T o ot h paste ca n c orrectl y i de ntif y  t heir ‘ Test Teet h’  pri or t o starti n g t heir o n -site 
ti me d br us hi n g.  If a s u bject  ca n n ot c orrectl y i de ntif y t heir t w o ‘ Test Teet h’ , t he y  will 
be re -i nstr ucte d i n t he ir  l ocati o n a n d a d e viati o n will be rec or de d.  
O n -site a d mi nistrati o n of st u d y pr o d ucts will be rec or de d i n t he dis pe nsi n g l o g a n d t he e C R F . 
6. 2. 1  M e di c ati o n/ D o si n g Err or s  
I n t his st u d y, d osi n g err ors ma y res ult fr o m t he a d mi nistrati o n or use  of  t he wr o n g st u d y pr o d uct,  
b y t he wr o n g s u bject, at t he wr o n g ti me, i n  t he wr o n g wa y . S uc h d osi n g err ors s h o ul d  be 
ca pt ure d i n t he eC R F.   
Dosi n g err ors are re p orta ble irres pecti ve of t he prese nce of a n ass oci ate d A E, i ncl u di n g:  
• Dosi n g err ors i n v ol vi n g s u bject e x p os ure t o a n y of t he st u d y pr o d ucts.  
• P ote ntial d osi n g err ors or uses o utsi de of w h at is f oresee n i n t he p r ot oc ol t hat d o or d o 
n ot i n v ol ve t he partici pati n g s u bject.  
If a d osi n g err or is acc o m pa nie d b y a n A E, as d eter mi ne d b y t he i n vesti gat or  or me dicall y 
q ualifie d desi g nee , t h e d osi n g err or a n d a n y ass ociate d A Es  are t o be rec or de d  i n t he eC R F.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116467] u d y.  
O ver d ose p er se is n ot a n A E. H o we v er, a n y cli nical se q uelae of a n o v er d os e s h o ul d  be re p ort e d 
as a n A E ( or  seri o us a d v erse e v e nt ( S A E), as  a p pr o priate)  p er pr ot oc ol  f oll o w i n g  t he A E a n d 
S A E re p orti n g i nstr ucti o ns.  
6. [ADDRESS_116468] be ca pa bl e of me as uri n g a n d d oc u me nti n g ( e. g. , via a l o g), as  a 
mi ni m u m, dail y mi ni m u m a n d ma xi m u m te m perat ures f or all st u d y pr o d uct  st ora ge l ocati o ns 
(i ncl u di n g fr oze n, refri gerate d, a n d/ or r o o m -te m perat ur e pr o d ucts).  T his s h o ul d be ca pt ur e d 
fr o m t he ti me of first pr o d uct recei pt t hr o u g h o ut t he st u d y.  For c o nti n u o us m o nit ori n g s yste ms, 
a l o g or site pr oce d ure t hat e ns ures acti ve d ail y e val uati o n f or e xc ursi o ns s h o ul d be i n place .  
T he o perati o n of te m perat ure -m o nit ori n g de vice s a n d te m pera t ure -c o ntr olle d st ora ge u nit s 
(e. g. , refri gerat or s) s h o ul d be re g ularl y i ns pecte d t o e ns ure t he y are  mai ntai ne d i n w or ki n g 
or der.  
A n y e xc ursi o ns fr o m t he pr o d uct -la bel st ora ge c o n diti o ns s h o ul d be re p orte d t o a p pr o priate sit e 
staff u p o n disc o ver y a n d c o m m u nicate d t o s p o ns or as s o o n as p ossi ble.  T he i n vesti gat or site 
s h o ul d acti vel y p urs ue o pti o ns f or ret ur ni n g t he st u d y pr o d uct t o t he st ora ge c o n diti o ns 
descri be d o n  its  la bel as s o o n as p ossi ble.  E xc ursi o ns fr o m st ora ge re q uire me nts, i ncl u di n g a n y 
acti o n s ta ke n, m ust be d o c u me nte d as a pr ot oc ol d e viati o n a n d re p orte d t o t he sp o ns or.   
O nce a n e x c ursi o n is i de ntifie d, t he affecte d st u d y pr o d uct ( or pr o d ucts) m ust be q uara nti ne d 
a n d n ot use d u ntil t he s p o ns or pr o vi des d oc u me ntati o n of per missi o n t o use. Use  of a n y of t he 
affecte d st u d y pr o d uct(s) pri or t o s p o ns or a p pr o val will be c o nsi dere d a pr ot oc ol de viati o n.   
Site staff will i nstr uct s u bjects o n t he pr o per st ora ge re q uir e me nts f or all ta ke -h o me st u d y 
pr o d ucts , i n acc or da nce  wit h  t he la bel re q uir e me nts .  
6. [ADDRESS_116469] u d y pr o d ucts will  be dis pe nse d t o e nr olle d /ra n d o mize d s u bjects  o nl y , i n acc or da nce wit h t h e 
pr ot oc ol, b y a ut h orize d site staff.  S u bjects will ret ur n all  use d / u n use d  t u be s of  accli mati zati o n 
t o ot h paste  t o t he i n vesti gat or site at t heir Bas eli ne  visit  ( Visit 2). S u bjects will bri n g all  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 3 9  of 1 1 3  use d /u n use d t u bes of t heir assi g ne d i n vesti gati o nal t o ot h paste  t o eac h of t heir sc he d ule d visits 
t o t he i n vesti gat or site  (per Sc he d ule of Acti vities , Ta ble 1 -1) a n d ret ur n  all use d/ u n use d st u d y 
pr o d uct t o t he i n vesti gat or site  at st u d y c o ncl usi o n. Ret ur ne d st u d y pr o d ucts s h o ul d n ot be re -
dis pe nse d t o a n y s u bject.  
T he i n vesti gat or  site m ust mai ntai n a de q uat e rec or ds (e. g., pr o d uct acc o u nta bilit y f or m s) 
d oc u me nti n g t he recei pt, use, l oss, ret ur n or ot her dis p ositi o n of all st u d y pr o d uct a n d  s u p plies . 
Acc o u nta bilit y rec or ds m ust be a vaila ble f or i ns pe cti o n b y t he st u d y m o nit or d uri n g t he st u d y. 
Pr o d uct acc o u nta bilit y will be m o nit ore d  d uri n g i n vesti gat or site visits a n d o n  t he c o m pleti o n 
of t he st u d y , as re q uir e d b y  t he st u d y m o nit ori n g pla n .  
6. 4. [ADDRESS_116470] u d y, t he in vesti gat or or a n a p pr o priate desi g ne e a n d t he  s p o ns or ’s  
re pres e ntati ve (st u d y m o nit or) will i n ve nt or y all use d a n d u n us e d st u d y pr o d ucts a n d t h e st u d y 
pr o d uct acc o u nta bilit y rec or d f or ret ur ne d st u d y pr o d ucts will be c o m plete d.  
All st u d y pr o d uct ( use d a n d u n use d) f or t his cli nical st u d y will be ret ur ne d t o t he s p o ns or  or 
desi g nate d ve n d or f or d estr ucti o n usi n g t he ret ur n i nstr ucti o ns pr o vi de d  b y t he s p o ns or’s 
Cli nical S u p plies De part me nt .  
U n use d s u n dr y ite ms will be ret ur ne d t o t he s p o ns or; u se d ite ms will be  dis p ose d of at t he 
i n vesti gat or site as descri be d i n Secti o n 6.1 (Ta ble 6. 2 ). D oc u me nte d a p pr o val f or dis p osal of 
use d s u n dr y ite ms m ust be recei ve d fr o m t he s p o ns or’s Cli nical S u p plies De part me nt  pri or t o 
des tr ucti o n.  
Detaile d i nstr ucti o ns f or t he ret ur n of st u d y pr o d uct s a n d t he destr u cti o n of s u n dr y  ite ms , will 
be pr o vi de d b y t he s p o ns or pri or t o t he  st u d y cl ose o ut visit.  
6. 5  Bli n di n g a n d All o c ati o n/ R a n d o mi z ati o n  
Q ualif yi n g s u bjects will be ce ntrall y ra n d o mi ze d t o o ne of t w o  i n vesti gati o nal  t o ot h pastes  usi n g 
a n I nteracti ve Res p o nse Tec h n ol o g y (I R T). Bef ore t h e st u d y is i nitiat e d, trai ni n g, l o gi n 
i nf or mati o n a n d directi o ns f or t he I R T will be pr o vi de d t o t he i n vesti gat or site.  In v esti gati o nal 
t o ot h paste  will be dis pe nse d acc or di n g t o t he i nstr ucti o n recei ve d t hr o u g h t he I R T at t he 
Baseli ne visit ( Visit 2) . Ret ur ne d st u d y pr o d ucts s h o ul d n ot be re -dis pe nse d t o a n y s u bject.  
O nl y s u bjects w h o meet t he st u d y  selecti o n criteria will  be ra n d o mi ze d  t o treat me nt . Q ualif yi n g 
su bjects will be stratifie d b y t he ma xi m u m Baseli ne Sc hiff se nsiti vit y sc ore of t heir t w o select e d 
‘ Test Teet h’ ; t his  stratificati o n fact or will gi ve rise t o t w o strata.  
• Str at u m 1:  Ma xi m u m Sc hiff se nsiti vit y sc ore = 2.  
• Str at u m  2:  Ma xi m u m Sc hiff se nsiti vit y sc ore = 3.  
T his st u d y is descri be d as e xa mi ner -bli n d ( t h e cli nical e xa mi ner (s) will be bli n de d t o treat me nt  
recei v e d). H o we ver, s t u d y s u bjects, i n vesti gat or site staff  i n v ol ve d i n safet y or effic ac y 
assess me nts , st u d y statisticia n (s) , d ata ma n a ge m e nt staff, ot her e m pl o yees of t he S p o ns or 
(i ncl u di n g t he C R S ) a n d ve n d ors acti n g o n be h alf of t he s p o ns or w h o m a y i nfl ue nce st u d y 
o utc o mes will als o be bli n de d t o treat me nt  all ocati o n.  Mo nit ors a n d t he s p o ns or’s Cli nical St u d y 
Ma na ger ( C S M) ca n n ot be f ull y bli n de d as t he y ma y  o bser ve s u bjects br us hi n g wit h t heir 
all ocate d treat me nt  w hile at t he i n vesti gat or  site.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116471] u d y : 
• St u d y s u bjects will see a n d use o nl y o ne of t he t w o i n vesti gati o nal  t o ot h pastes  f or t he 
d urati o n of t he treat me nt peri o d . T he y will be i nstr ucte d n ot t o disc uss t he a p peara n ce , 
usa ge  or percei ve d p erf or ma nce of t h eir assi g ne d i n vesti gat i o nal  t o ot h paste wit h t he 
cli nical e xa mi ner (s), wit h  staff i n v ol ve d i n cli ni cal  ass ess me nts or wit h ot her st u d y 
s u bjects .  
• T he i n vesti gati o nal  t o ot h pastes  will be pr o vi de d  t o t he i n vesti gat or site o ver wra p pe d i n 
w hite vi n yl t o mas k t heir i de ntit y , a n d t o o bsc ure a n y bra n di n g  o n t he Refere nce 
T o ot h paste , wit h a st u d y la bel affi x e d.  
• T he i n vesti gati o nal  t o ot h pastes  will be s u p plie d i n c art o n s; eac h cart o n will  c o ntai n 4 
o ver -wra p pe d t u bes of t o ot h paste. T he c art o n a n d its 4  t u bes will be la belle d wit h t he 
sa me  u ni q ue ra n d o mizati o n n u m ber . Su bjects will be ce ntrall y ra n d o mi ze d t o treat me nt  
i n or der of q u alificati o n usi n g a n I R T ; pr o d u ct c o des will n ot be use d . 
• T he c li nical e x a mi ner(s) a n d site staff i n v ol ve d i n effic ac y a n d safet y assess me nts  will 
n ot be p er mitte d i n a n y area w here t h e i n vesti gati o nal  t o ot h pastes or diari es  are  st ore d , 
dis pe nse d  or i n use . 
• Site s taff i n v ol ve d i n t he dis pe nsi n g  of i n vesti gati o nal  t o ot h pastes , pr o vi di n g  br us hi n g 
a n d diar y c o m pleti o n i nstr ucti o n , s u per visi o n of o n -site  br us hi n gs , treat me nt 
c o m plia nce c hec ks a n d pr o d uct acc o u nta bilit y  will n ot be  i n v ol ve d i n cli nical effic ac y 
a n d safet y ass ess me nts  a n d will w or k i n a s e parate area fr o m t h e cli nic al e xa mi ner(s) 
a n d i n vesti gat or staff i n v ol ve d i n effic ac y a n d s afet y assess me nts.  
• S u bjects will be i nstr ucte d n ot t o re m o ve t heir assi g ne d i n vesti gati o nal  t o ot h paste  or 
diar y fr o m t he o pa q ue carrier ba g pr o vi de d  o utsi de of t he  dis pe nsi n g/ s u per vi se d  
br us hi n g r o o m, w hile at t he i n vesti gat or  site.  
• W here  cert ai n staff will  be u n bli n de d t o carr y o ut t heir res p o nsi bilities ( e. g. , staff  
i n v ol ve d i n S A E  re p orti n g , m o nit ors ), t he  i n vesti g at or a n d s p o ns or are re q uire d t o  p ut  
a de q uate pr oce d ures i n place t o pre ve nt i na p pr o priate disse mi nati o n of treat me nt 
i de ntificati o n .  
6. [ADDRESS_116472] u d y  i nitiati o n, t he i n vesti gat or  site will be i nstr ucte d o n t he met h o d f or brea ki n g t he bli n d ; 
t his  will be a n electr o nic pr ocess.  
T h e ele ctr o nic s yste m will be pr o gra m me d wit h bli n d -brea ki n g i nstr ucti o ns. I n case of a n 
e mer ge n c y, t he i n vesti gat or has s ole res p o nsi bilit y f or deter mi ni n g if t he u n bli n di n g of t he  
s u bject’s treat me nt  assi g n me nt is warra nte d. S u bject safet y m ust al wa ys be t he first 
c o nsi derati o n i n m a ki n g s uc h a det er mi nati o n. If t he i n v esti gat or deci des t hat u n bli n di n g is 
warra nte d, t he y s h o ul d ma ke e ver y eff ort t o c o ntact t he s p o ns or pri or t o u n bli n di n g t he  s u bject’s 
treat me nt  assi g n me nt u nless t his wo ul d dela y e mer ge nc y tr eat me nt of t he s u bject.  
O nce  tr eat me nt  assi g n m e nt is u n bli n de d, t he s p o ns or m ust be n otifie d wit hi n [ADDRESS_116473] be rec or de d a n d re p orte d p er  pr ot oc ol.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116474] will be pr o vi de d wit h t hree  diar i es , o ne  at Scree ni n g 
( Visit 1) , o ne at Baseli ne ( Visit 2) a n d o ne at Da y 2 8 ( Visit 3) , t o rec or d eac h br us hi n g wit h t he 
accli matizati o n a n d i n vesti ga ti o nal  t o ot h paste s. T he diaries will als o pr o vi de  pr o d uct  usa g e 
i nstr ucti o ns f or t he s u bject t o refer t o t hr o u g h o ut t heir partici pati o n i n t he st u d y.  
• S u bjects will be i nstr uct e d t o n ote a n y misse d/a d diti o nal br us hi n gs  a n d  t he reas o ns f or 
misse d/a d diti o nal br us hi n gs  i n t he diar y . 
• S u bjects will als o be i nstr ucte d  t o rec or d a d diti o nal i nf or mati o n i n t he diar y s uc h as 
c ha n ges i n healt h, oral pr o ble ms, c ha n ges i n  me dicati o ns/treat me nts , ne w me dicati o ns/  
treat me nts  a n d  a n y  iss ue s wit h t he t o ot h paste t he y are us i n g i n t he diar y.  
S u bjects will be i nstr ucte d t o bri n g t heir c o m plete d diar y  t o eac h sc h e d ule d st u d y visit. 
C o m plete d diaries will be re vie we d b y i n vesti gat or staff at t he start of eac h st u d y visit  (t o 
mai ntai n t he bli n d, staff perf or mi n g diar y re vie ws s h o ul d n ot be i n v ol ve d i n a n y safet y or 
effic ac y ass ess me nts) . A n y m isse d or a d diti o nal br us hi n gs  will be rec or de d  i n t he e C R F as 
pr ot oc ol de viati o ns  a n d s u bjects will be re -i nstr uct e d i n c orrect pr o d uct usa ge re q uir e me nts  a n d 
diar y c o m pleti o n , as nee de d .  
I nf or mati o n rec or de d  i n t he diar y relati n g  t o c ha n g es i n healt h , me dicati o ns  a n d treat me nts will  
be re vie we d b y t he i n vesti gat or , or me dicall y  q ualifie d desi g nee , wit h t he s u bject a n d 
tra nscri be d i n t o t he eC R F , as a p pr o priate  (e. g., as a n A E) . I nf or mati o n relat e d t o pr o d uct use  or 
iss ues  s h o ul d als o tra nscri be d i n t o t he eC R F , as nee de d , ta ki n g care t o mai ntai n t he bli n d.  
S u bjects will be i nstr uct e d t o bri n g all t u bes of st u d y pr o d uct  ( us e d a n d u n use d) a n d t heir  
t o ot h br us h t o eac h sc he d ule d st u d y visit. St u d y staff will perf or m a vis ual c hec k of pr o d uct 
usa ge  a n d t o ot h br us h c o n diti o n . A n y s us pecte d o ver or u n der us e will be d oc u me nte d i n t he 
e C R F a n d t he s u bject will be re -i nstr uct e d i n t he c orrect usa g e re q uire m e nts.  
T o  c o nfir m  t he s u bject u n dersta n d s t he usa ge i nstr ucti o ns  pr o vi de d at Scree ni n g ( Visit 1)  a n d 
Baseli ne ( V isit  2) , t he ir first use of st u d y pr o d uct (accli matizati o n t o ot h paste a n d i n vesti gati o nal  
t o ot h paste, res pecti vel y ) will be s u p er vise d  o n -site . T o facilitate c o m plia nce, a furt her 
su per vi se d br us hi n g will be c o m plete d  o n -site at t he e n d of Visit  3 ( Da y 2 8) . S u bjects dee m e d 
n o n -c o m plia nt wit h a n y as pect of t he usa g e  re q uire me nts or diar y c o m pleti o n  will be re -
i nstr ucte d i n c orrect pr oce d u re . A n y de viati o n fr o m pr ot oc ol re q uir e me nts will be rec or de d  i n 
t he e C R F .  
6. 8  C o n c o mit a nt M e di c ati o n/ Tr e at m e nt  
A n y me dicati o ns, treat me nts or vacci ne s (i n cl u di n g o ver -t he -c o u nter or pres cri pti o n me dici nes, 
vita mi ns a n d/ or her bal s u p ple me nts) ta ke n  or recei ve d  d uri n g t he st u d y, fr o m t he si g ni n g of  
i nf or me d c o nse nt, m ust be rec or de d i n t he eC R F wit h i n dicati o n, reas o n f or use, u nit d ose, dail y 
d ose a n d st art /s t o p dates of a d mi nistrati o n. Su bjects will be q uesti o ne d a b o ut c ha n ges i n t heir 
me dicati o ns/treat me nts at t he start of eac h st u d y  visit.  
Me dicati o n s a n d treat me nts ta ke n or recei v e d i n t he  3 0 da ys pri or t o  si g ni n g t he i nf or me d 
c o nse nt will be d oc u me nt e d as pri or me dicati o n/treat me nt. Me dicati o ns  a n d treat me nts ta ke n 
or recei ve d aft er si g ni n g t he i nf or m e d c o ns e nt will be d o c u me nte d as c o nc o mita nt 
me dicati o n/treat me nts .  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116475] u d y: Scree ni n g ( Visit 1) t o t he S u bject’s L ast St u d y Vis it  
• S u bjects s h o ul d dela y a n y n o n -e mer ge n c y,  electi ve de ntal treat me nt s u ntil after st u d y 
c o m pleti o n (i ncl u di n g de ntal pr o p h yla xis).  
• S h o ul d a n e nr olle d/ ra n d o mi ze d s u bject start a c o urse of treat me nt w hic h i n cl u des dail y , 
re g ular  or i nter mitte nt use of a n y me dicati o n , details of t hat treat me nt will be rec or de d 
i n t he e C R F . T h e i n vesti gat or  or t h eir me dicall y q ualifie d desi g ne e will d eci de if t he 
s u bject s h o ul d  c o nti n ue i n t he st u d y or be wit h dra w n.  
• S h o ul d a s u bject ta ke a me dicat i o n w hic h, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or or t heir 
me dicall y q ualifie d desi g nee, c o ul d i m pact t he  s u bject’s  perce pti o n of pai n  (e. g. , a n 
a nal gesic) wit hi n [ADDRESS_116476] u d y visit, e ver y eff ort will be ma de t o 
rea p p oi nt t he m wit hi n per mitte d visit t olera nces  (s ee Sc h e d ule of A cti vities , Ta ble 1 -1). 
T he reas o n f or re -a p p oi nt me nt will be d oc u me nte d i n t he e C R F. T he m e dicati o n a n d 
a n y ass ociate d A E s h o ul d be rec or de d i n t he e C R F.   
If re -a p p oi nt m e nt is n ot p ossi ble, t he f oll o wi n g visit s pecific acti o ns s h o ul d be ta ke n : 
- Scree ni n g ( Visit 1):  Th e s u bject will be wit h dra w n fr o m t he st u d y. N o t o ot h 
se nsiti vit y assess me nts will be perf or me d. T h e s u bject ma y be re place d.  
- B aseli ne ( Visit 2):  The s u bject w ill b e wit h dra w n fr o m t h e st u d y. N o t o ot h 
se nsiti vit y assess me nts will be perf or me d. T h e s u bject will n ot be re place d.  
- D a y 2 8 ( Visit 3 ) & D a y 5 6 ( Visit 4) : The s u bject will c o nti n ue i n t he st u d y. T o ot h 
se nsiti vit y assess me nts will be perf or me d . 
S u bjects s h o ul d n ot partici pate i n a n y ot her cli nical st u d y (i ncl u di n g c os metic st u dies) or be i n 
recei pt of a n ot her i n vesti gati o nal pr o d uct  f or t he d urati o n of t his st u d y . 
7 DI S C O N TI N U A TI O N O F S T U D Y I N T E R V E N TI O N A N D 
S U B J E C T DI S C O N TI N U A TI O N/ WI T H D R A W A L  
7. [ADDRESS_116477] Di s c o nti n u ati o n/ Wit h dr a w al  
A s u bject ma y wit h dra w fr o m t he st u d y at a n y ti me at t heir  o w n re q u est or ma y be wit h dra w n 
fr o m t he st u d y at a n y ti me at t he discreti o n of t he i n vesti gat or or t he s p o ns or f or safet y  or  
be ha vi or al reas o ns, or d u e t o t he i n a bilit y of t he s u bject t o c o m pl y wit h t h e pr ot oc ol -re q uire d 
sc he d ule of st u d y visits or pr oce d ures.   
T he f oll o wi n g cir c u msta nces will re q uire disc o nti n uati o n of st u d y pr o d uct a n d/ or pre m at ure 
s u bject wit h dra wal . 
• Pr ot oc ol vi olat i o n t hat c o ul d i m pact t he s u bject’s s afet y  
• Wit h dra wal of i nf or me d c o nse nt  
• S u bject l ost t o f oll o w -u p  
• U n bli n di n g of t he s u bject  
• Pre g na nc y  
If a s u bj ect is disc o nti n ue d or pre mat urel y wit h dra ws fr o m t he st u d y, t he reas o n(s) f or 
disc o nti n uati o n or wit h dra wal , a n d t he ass ociate d date , m ust be d oc u me nte d i n t he eC R F.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116478] wis hes t o a n d/ or s h o ul d c o nti n ue i n t he st u d y.  
A s u bject will be c o nsi dere d l ost t o f oll o w u p if t he y  re peate dl y fail t o atte n d  sc he d ule d visits 
a n d ca n n ot  be c o ntacte d b y t he st u d y staff . Bef ore t he  s u bject is  dee me d l ost t o f oll o w u p, t he 
i n vesti gat or or desi g nee m ust ma ke e ver y eff ort t o re gai n c o ntact wit h t he m ( w here p ossi ble  
t hree  tele p h o ne calls a n d, if necessar y, a certifi e d letter t o t he s u bject’s last k n o w n maili n g 
a d dress or e q ui vale nt l oc al met h o ds). Eac h  c o ntact atte m pt s h o ul d be d oc u me nte d. If c o ntact is 
ma de, t he i n vesti gat or or desi g nee s h o ul d i n q uire a b o ut t he reas o n f or  t heir wit h dra wal, re q u est 
t hat t he s u bject ret ur n all pr o d ucts pr o vi d e d  a n d , if a p pr o priate , re q uest t hat t he s u bject ret ur n 
f or a fi nal visit a n d f oll o w -u p a n y u nres ol ve d A Es.  Fi nal safet y assess me nts ma y be carrie d o ut 
w he n t he s u bject ret ur ns t o t he i n v esti gat or site, at t he i n v esti gat or’s discreti o n, w hic h ma y 
i ncl u de a n oral e xa mi nati o n.  
S h o ul d t he s u bject c o nti n ue t o be u nreac h a ble, t he y  will be c o nsi dere d t o ha ve wit h dra w n fr o m 
t he st u d y a n d l ost t o f oll o w u p. T his will be d oc u me nte d i n t he eC R F . La c k of c o m pleti o n of 
all or a n y of t he earl y ter mi nati o n pr oce d ures will n ot be vie we d as pr ot oc ol de viati o ns pr o vi de d  
s u bject safet y w as pres er ve d.  
If t he s u bject wit h dra ws fr o m t he st u d y a n d  wit h dra ws c o ns e nt f or discl os ure of f ut ure 
i nf or mati o n, n o f urt h er e val uati o ns s h o ul d be p erf or me d,  a n d n o a d diti o nal data s h o ul d be 
c ollecte d.  T h e s p o ns or m a y retai n a n d c o nti n ue t o use a n y d ata c ollecte d bef ore t he  wit h dra wal 
of c o nse nt.  
[ADDRESS_116479] u d y visit.  T he ti mi n g of 
eac h pr oce d ure is liste d i n t he Sc he d ule of Acti vities  (Ta ble 1 -1). A d h ere n ce t o t he st u d y desi g n 
re q uire me nts, i ncl u di n g all pr oce d ures is  ess e ntial a n d re q uir e d f or st u d y c o n d uct.  
8. 1  Vi sit 1  / S cr e e ni n g  
Scree ni n g pr oce d ures will be c o n d ucte d b y t he in vesti gat or , t he cli nical e xa mi ner(s)  or s uita bl y 
q ualifie d /e x perie n ce d a n d  trai ne d  desi g nee s, 1 4 -2 8 da ys pri or t o t he Baseli ne visit (Visit 2) . 
W here practicall y feasi ble, t he y s h o ul d be c o m plete d i n t he or der liste d bel o w. Data c ollecte d 
will be rec or de d i n t he e C R F . 
8. 1. 1. [ADDRESS_116480] u d y t o e na ble t he m t o c o nfir m t he y 
are n ot a ware of a n y aller g y or h y perse nsiti vit y t o a n y of t he i n gre di e nts liste d.  
T w o c o pi[INVESTIGATOR_1309] t he i nf or me d c o nse nt f or m (I C F) will be si g ne d a n d date d b y t he s u bject . T he 
i n vesti gat or or d esi g nee will als o  si g n a n d date eac h c o p y of t he I C F , after t he s u bject has 
si g ne d , t o c o nfir m t hat t he c o nse nt pr ocess was c o m p lete d c orrectl y. The s u bject will retai n o ne 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 4 4  of 1 1 3  c o p y a n d t he ot her will be ke pt at t he i n vesti gat or  site.  T he ti me of c o nse nt will als o be ca pt ure d 
o n t he I C F ; A Es will be ca pt ure d fr o m t his p oi nt.  T he date a n d ti me of c o nse nt will be rec or de d 
i n  t he eC R F.  A p pr o priat e f or ms f or d o c u me nti n g i nf or me d c o nse nt will be pr o vi de d b y t he 
i n vesti gat or or b y t he s p o ns or . 
If ne w i nf or mati o n be c o mes a vaila ble d uri n g t he c o n d uct of t he st u d y t hat mi g ht  affect s u bject 
willi n g ness t o partici pate i n t he st u d y, eac h o n g oi n g s u bject s h o ul d recei v e a  ver bal  e x pla n ati o n 
a n d writte n s u m mar y  of t h e ne w i nf or mati o n  a n d  be re -c o nse nte d i nt o t he st u d y. Eac h s u bject 
will  be pr o vi de d wit h a c o p y of t he ir  si g ne d /dat e d  a me n de d I C F . Dat e of re -c o ns e nt will be 
rec or de d in t he eC R F.  
After si g ni n g t he I C F, eac h s u bject will u n der g o a series of scree ni n g pr oce d ures a n d cli nic al 
assess me nts t o c o nfir m t hat t he y meet t he pr ot oc ol re q uire d i ncl usi o n criteria a n d n o ne of t he 
e xcl usi o n criteria.  
8. 1. 2  D e m o gr a p hi c s  
T he f oll o wi n g de m o gr a p hic i nf or mati o n will be rec or de d i n t he eC R F: year of birt h, ge n der , 
race  a n d et h nicit y .  
8. 1. [ADDRESS_116481] s   
S u bjects will be re q u ire d t o bri n g t heir c urr e nt oral care pr o d ucts t o Scree ni n g ( V isit  1)  f or 
i n vesti gat or staff t o c o nfir m  t he a bse nce of k n o w n a nti -se nsiti vit y i n gre die nts  a n d se nsiti vit y -
relate d clai ms o n t he pr o d uct pac k a gi n g/la bel te xt . S u bjects w h o are c urre ntl y usi n g a nti -
se nsiti vit y oral car e pr o d uct(s) will be e xcl u d e d .  
S u bjects will als o be as ke d a b o ut t he oral care pr o d ucts t he y ha ve bee n usi n g i n t he last 8 wee ks; 
t h ose w h o re p ort usi n g a nti -se nsiti vit y pr o d uct (s) i n t he [ADDRESS_116482] or y a n d Pri or M e di c ati o n s/ Tr e at m e nt s 
T he f oll o wi n g will be d oc u me nte d i n t he e C R F:  
• Details of rele va nt me dical hist or y a n d rece nt s ur g er y  ( wit hi n t he last year), i ncl u di n g 
aller gies a n d dr u g s e nsiti vities.  
• Fe male s u bjects: p re g na n c y stat us (sel f-re p orte d).  
• Pri or me dicati o ns/treat m e nts, i ncl u di n g prescri pti o n a n d n o n -pres cri pti o n dr u gs, dietar y 
s u p ple me nts a n d her bal re me dies, ta ke n i n t he [ADDRESS_116483] will c o m plete t he L M S Trai ni n g 
E xercise (s o urce ), see  A p pe n di x 1 5. 4  (t rai ni n g e x ercise res p o nses will n ot  be tra nscri be d i n t o 
t he e C R F ). A n y s u bject w h o, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or or desi g nee , is u na ble t o pr o vi de 
a p pr o priate res p o nses t o t he L M S trai ni n g q uesti o ns, will be e xcl u de d fr o m partici pati o n i n t he 
st u d y (Secti o n 5. 3 E xcl usi o n Criteri o n 2 7). 
T he f oll o wi n g cli nical e xa mi nati o ns a n d D H assess me nts will be c o m ple te d as descri be d i n 
St u d y Assess me nts  (Secti o n 9) a n d t he fi n di n gs rec or de d i n t he e C R F. T o facilitate s u bject fl o w, 
s o urce d oc u me nts ca n b e use d t o rec or d cli nical  data f or later tr a nscri pti o n i nt o t he eC R F . 
Tra nscri pti o n i nt o t he e C R F  m ust be c o m plet e d wit hi n [ADDRESS_116484].  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 4 5  of 1 1 3  • Oral s oft tiss ue ( O S T ) e x a mi nati o n  
• Oral har d tiss ue ( O H T ) e xa mi nati o n  
• Cli nical assess me nt of i n cis ors, ca ni n es a n d pre -m olars f or de ntiti o n e xcl usi o ns, er os i o n 
a brasi o n a n d attriti o n ( E A R ), M o difie d Gi n gi val I n d e x ( M GI ), a dja ce nt t o t he test area 
o nl y , a n d cli nical m o bilit y t o i de ntif y a p pr o priate  t eet h f or D H assess me nt.  
• Cli nic al assess me nt of t actile se nsiti vit y  (t actile t hres h ol d ( g );  m a xi m u m f orce 2 0 g ):   
Assess  all teet h wit h  n o d e ntiti o n e xcl usi o ns ( Secti o n 5. 3 E xcl usi o n Criteri o n 2 6 ) w hic h  
meet E A R, M GI a n d  t o ot h m o bilit y re q uire me nts  (Secti o n 5. 2  I n cl usi o n Criteria 6 (c)). 
E ns ure at le ast a [ADDRESS_116485] arti n g t he ev a p or ative ( air) assess me nts.  
• Cli nic al assess me nt of e v a p or ati ve ( air) s e nsiti vit y ( Sc hiff se nsiti vit y sc ore) : 
Assess  eac h t o ot h wit h a Scree ni n g tactile t hres h ol d of ≤ [ADDRESS_116486] h a ve  a mi ni m u m of t w o ‘Eli gi ble Teet h ’ i n differe nt q u a dr a nts  t o  c o nti n ue  
i n t he st u d y  (Secti o n 5. 2 I ncl usi o n Criteri o n 6 c); ‘ Eli gi ble Teet h ’ m ust h a ve a Scree ni n g 
t actile t hres h ol d ≤ 2 0 g a n d  a Scree ni n g Sc hiff se nsiti vit y sc ore ≥ 2   
S u bjects wit h fe wer t ha n t w o ‘Eli gi ble  Teet h ’ will be disc o nti n ue d . 
8. 1. 6  I n cl u si o n/ E x cl u si o n Crit eri a  
I nf or mati o n rel ati n g t o i n cl usi o n /e xcl usi o n criteria will be c o m plete d  i n t he eC R F . 
8. 1. [ADDRESS_116487] or y, pri or 
me dicati o ns /treat me nts , cli nical e xa mi nati o n/ass ess me nt data a n d t h e i ncl usi o n/e xcl usi o n 
criteria  f or eac h s u bject t o deter mi ne  t heir  eli gi bilit y t o partici pate i n t he st u d y . T he e li gi bilit y  
decisi o n will be d oc u me nte d i n t he eC R F.   
If c o nfir m e d as eli gi ble t o partici pate , t he  s u bject will be c o nsi dere d e nr olle d i n t he st u d y.  
T o pre pare f or st u d y partici pati o n, e nr olle d s u bjects will be i nstr ucte d i n  t he Lifest yle 
G ui deli nes  (Secti o n 5. 5 ) a n d C o nc o mita nt Me dicati o ns/ Treat me nts  (Secti o n 6. 8 ) re q uire me nts 
of t he st u d y (as alrea d y detaile d i n t h e I C F a n d descri b e d d uri n g t h e c o nse nt pr ocess). 
A d here n ce t o t he re q uire me nts of t he st u d y pr ot oc ol is esse ntial f or s uccess f ul st u d y c o n d uct . 
8. 1. 7. [ADDRESS_116488] br us hi n g will b e d oc u me nte d i n t he e C R F.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116489] t o res p o n d t o n o n -
lea di n g q uesti o n s (s uc h as ‘ ho w d o y o u feel?’ ) o n c o m pleti o n of t he s u per vise d  br us hi n g will 
be rec or de d i n t he e C R F.  
Dis pe nsi n g staff will re mi n d  s u bjects  t o n ote a n y c ha n ges i n t heir healt h , me dicati o ns or 
treat me nts i n t he diar y  (or re p ort s uc h c ha n ges t o t he i n vesti gat or staff  bet wee n visits  usi n g t he 
c o ntact n u m bers pr o vi de d or  i nf or m staff  at t heir ne xt visit , if preferre d)  a n d t o bri n g t heir 
accli mati zati o n  t o ot h past e , t o ot h br us h a n d c o m plete d diar y  t o t he ir  ne xt st u d y visit . 
8. [ADDRESS_116490] u d y P eri o d  
8. 2. 1  Vi sit 2  / B a s eli n e  (D a y  0)  
T he f oll o wi n g pr oce d ures a n d assess me nts will be c o m plete d  b y t he i n vesti ga t or, t he cli nical 
e xa mi ner (s) or a s uita bl y q ualifie d/e x perie nce d a n d trai ne d desi g nee . W here practicall y 
feasi ble , t he  pr oce d ures a n d assess me nts s h o ul d be c o m plete d i n t he or der liste d bel o w . All data 
c ollecte d will  be rec or de d i n t he e C R F.  
8. 2. 1. [ADDRESS_116491] or y a n d C o n c o mit a nt M e di c ati o n s / Tr e at m e nt s  
In v esti gat or staff will as k s u bjects if t here ha ve b ee n a n y c ha n g es i n t heir healt h, c o nc o mita nt 
me dicati o ns a n d n o n -dr u g trea t me nts ; f e male s u bj ects of c hil d -beari n g p ote ntial will self -re p ort 
pre g na nc y st at us. All c ha n ges w ill be d oc u me nte d i n t he e C R F.  
S p o nta ne o usl y re p ort e d A Es a n d a n y A Es elicite d d uri n g q uesti o ni n g a b o ut c ha n ges i n healt h 
or b y as ki n g s u bjects t o res p o n d t o n o n -lea di n g q uesti o n s (s uc h as ‘ ho w d o y o u feel?’ ) will 
rec or de d i n t he e C R F . AEs a n d/ or c ha n ges i n me dicati o ns/treat me nts i de ntifie d d uri n g re vie w 
of t he diar y will be rec or de d i n t he e C R F.   
8. 2. 1. [ADDRESS_116492] s a b o ut a d here nce t o t he  re q uire me nts of t he pr ot oc ol ; 
an y de viati o ns fr o m st u d y re q uire me nts  will be rec or de d i n t he eC R F . S u bject c o nti n ua nce will 
be c o nfir me d.  
8. 2. 1. [ADDRESS_116493] will 
i n de pe n de ntl y ( wit h o ut s u per visi o n) c o m plete  a h ar d c o p y of t he D H E Q -4 8  (s o urce ), Secti o ns 
1 a n d 2  (i.e.,  all q uesti o n s i n b ot h secti o ns ), see A p pe n di x  [ADDRESS_116494] res p o nses will be 
tra nscri be d i n t o t he e C R F.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116495] u d y Assess me nts  (Secti o n 9). T o facilitate s u bj ect fl o w, s o urce d oc u me nts ca n be use d t o 
rec or d cli nical data  f or later tra nscri pti o n i nt o t he e C R F.  
• O S T e xa mi nati o n  
• Cli nic al assess me nt of t actile se nsiti vit y (t actile t hres h ol d ( g); m a xi m u m f orce 2 0 g) :  
Assess  eac h ‘eli gi ble t o ot h ’ i de ntifie d at Scree ni n g (Scree ni n g  ta ctile t hres h ol d of ≤ 2 0 g 
a n d  a Scree ni n g  Sc hiff s e nsiti vit y sc ore ≥ 2 ). 
E ns ure at le ast a [ADDRESS_116496] arti n g t he ev a p or ative ( air) se nsiti vity assess me nts.  
• Cli nic al assess me nt of e v a p or ati ve ( air) s e nsiti vit y  ( Sc hiff se nsiti vit y sc ore) :  
- First  assess  eac h t o ot h wit h a Baseli ne  tactile t hres h ol d of ≤ [ADDRESS_116497] will  co m plete  t he f o ur L M Ss  (I nte nsity, D ur ati o n, T oler a bility & 
Descri pti o n ) f or eac h  t o ot h  wit h a Baseli ne  Sc hiff se nsiti vit y sc ore ≥ 2  i m me di atel y 
after t h e  Sc hiff se nsiti vit y sc ore f or t hat  t o ot h  is rec or de d . 
- W he n Sc hiff se nsiti vit y sc ore s ha ve  bee n rec or de d , a n d L M Ss c o m plete d , f or  all 
teet h wit h a Baseli ne  tactile t hres h ol d of ≤ 2 0 g , t h e n  assess Sc hiff s e nsiti vit y sc ore 
f or a n y re mai ni n g ‘Eli gi ble Teet h ’ i de ntifie d at Scree ni n g  (i. e., t he ‘Eli gi ble Teet h ’ 
wit h a Baseli ne  tactile t hres h ol d > 2 0 g) . 
‘ Eli gi ble Teet h’ = Teet h wit h n o de ntiti o n excl usi o ns w hic h met E A R, M GI a n d m o bility i ncl usi o n 
criteri a, wit h a Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d a Scree ni n g  Sc hiff se nsitivity sc ore ≥ 2.  
N ote: L M Ss s h o ul d  n ot  be c o m plete d f or t he  re m ai ni n g  ‘Eli gi ble  Teet h ’. 
Su bjects m ust h a ve  at le ast t w o ‘ q u alif yi n g  teet h ’, i n differe nt q u a dr a nts,  wit h a t actile 
t hres h ol d ≤ 2 0 g a n d  a Sc hiff se nsiti vit y sc ore ≥ [ADDRESS_116498] u d y  Secti o n 5. 2 I n cl usi o n Criteri o n 7 .  
S u bjects wit h fe wer t ha n t w o ‘ q ualif yi n g  teet h ’ will be disc o nti n ue d .  
Tra nscri pti o n of data fr o m s o urce d oc u me nts i nt o t he e C R F m ust be c o m plete d wit hi n [ADDRESS_116499] T e et h  
T he cli nical e xa mi ner res p o nsi ble f or e va p orati ve (air) assess me nts will sel ect  t w o ‘ Test Teet h’ 
f or assess me nt of b ot h tactile a n d e va p orati ve (air) se nsiti vit y at all s u bse q ue nt st u d y visits.  
‘Test Teet h ’ s h o ul d  o nl y be selecte d fr o m  teet h w hic h met t he E A R, M GI a n d t o ot h m o bilit y 
re q uire me nts a n d ha d n o de ntiti o n e xcl usi o ns  at Scree ni n g , wit h t he re q uir e d q ualif yi n g le vels 
of D H  at b ot h  Scree ni n g ( Visit 1) a n d  Baseli ne ( Visit 2) : 
• Tactile t hres h ol d ≤ 2 0 g at Scree ni n g a n d  Baseli ne.  
• Sc hiff se nsiti vit y sc ore ≥ 2 at Scree ni n g a n d  B aseli ne.  
T o be re prese ntati ve of differe nt areas of t he m o ut h wit h i n de pe n de nt i n ner vati o n, ‘ Test Teet h ’ 
s h o ul d be n o n -a dj ace nt a n d i n differe nt q ua dra nts.  T he i de ntit y of t h e t w o ‘Test Teet h’  will be 
rec or de d i n t he e C R F.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116500] Eli gi bilit y  
T he i n vesti gat or, or me dicall y q ualifie d d esi g nee, will re vie w t he i ncl usi o n/e xc l usi o n criteri a 
a n d verif y t he prese nce of t w o  q u alif yi n g  ‘T est Teet h’  w hic h  m eet all st u d y criteri a b ef ore 
c o nfir m i n g eac h  s u bject ’s  s uita bilit y  t o c o nti n ue  i n t he st u d y ; t he eli gi bilit y decisi o n will be 
d oc u me nte d i n t he eC R F . 
8. 2. 1. [ADDRESS_116501], re mi n d i n g  t he m 
t o  c o ver t he f ull br us h hea d wit h a ri b b o n of t o ot h paste a n d use t he ti mer  eac h ti me t he y br us h .  
• S u bjects ra n d o mize d t o t he Test T o ot h paste will be s h o w n t he l ocati o n of t h eir  t w o ‘ Test 
Teet h’ wit hi n t he m o ut h ( usi n g a t o ot h dia gra m/ m o del a n d a mirr or, as  nee de d) . 
T he y will be t h e n i nstr ucte d t o start t h eir ti mer ( pre -set f or 1 -mi n ute) a n d br us h t heir 
e ntire de ntiti o n t h or o u g hl y f or at least 1 -ti me d mi n ute, ma ki n g s ure t o br us h t he 
se nsiti ve areas of t heir t w o selecte d ' Test teet h' caref ull y first.  
• S u bjects ra n d o mi ze d t o t he Refere nce T o ot h paste will be i nstr ucte d t o start t heir ti mer 
( pre -s et f or 1 -mi n ute) a n d br us h t heir e ntire de ntiti o n t h or o u g hl y f or at le ast [ADDRESS_116502] t o res p o n d t o n o n -
lea di n g q uesti o ns (s uc h as ‘ h o w d o y o u feel?’) o n c o m pleti o n of t he s u per vise d br us hi n g will 
be rec or de d i n t he e C R F.  
Dis pe nsi n g staff will re mi n d  s u bjects  t o n ote a n y c ha n ges i n t heir healt h , me dicati o ns or 
treat me nts i n t he diar y  (or re p ort s uc h c ha n ges t o t he i n vesti gat or  staff  bet wee n visits  usi n g t he 
c o ntact n u m bers pr o vi de d or  i nf or m staff  at t heir ne xt visit , if preferre d) a n d t o bri n g t heir 
i n vesti gati o nal t o ot h paste , t o ot h br us h a n d c o m plete d dair y  t o t he ir  ne xt st u d y visit . 
Ra n d o mize d s u bjects will als o be re -i nstr ucte d i n t he Lifest yle G ui deli nes  (Secti o n 5. 5 ) a n d 
C o nc o mita nt Me dicati o ns/ Treat me nts  (Secti o n 6. 8 ) re q uire m e nts  of t he st u d y .  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 4 9  of 1 1 3  8. 2. 2  Vi sit 3  / D a y  2 8  ( ± 2 d a y s)  
T he f oll o wi n g pr oce d ures a n d assess me nts will be c o m plete d  b y t he i n vesti gat or, t he cli nical 
e xa mi ner (s) or a s uita bl y q ualifie d/e x perie nce d a n d trai ne d desi g nee . W here practicall y 
feasi ble , t he  pr oce d ures a n d assess me nts s h o ul d be c o m plete d i n t he or der liste d bel o w . All data 
c ollecte d will be rec or de d i n t he e C R F.  
8. 2. 2. [ADDRESS_116503] or y a n d C o n c o mit a nt M e di c ati o n s / Tr e at m e nt s  
In v esti gat or staff will as k s u bjects if t here ha ve b ee n a n y c ha n g es i n t heir healt h, c o nc o mita nt 
me dicati o ns a n d n o n -dr u g treat me nts; f e male s u bj ects of c hil d -beari n g p ote ntial will  self -re p ort 
pre g na nc y st at us. All c ha n ges will be d oc u me nte d i n t he e C R F.  
S p o nta ne o usl y re p ort e d A Es a n d a n y A Es elicite d d u ri n g q uesti o ni n g a b o ut c ha n ges i n healt h 
or b y as ki n g s u bjects t o res p o n d t o n o n -lea di n g q uesti o ns (s uc h as ‘ h o w d o y o u feel?’) will 
rec or de d i n t he e C R F .  
A Es a n d/ or c ha n ges i n me dicati o ns/treat me nts i de ntifie d d uri n g re vie w of t he diar y will be 
rec or de d i n t he e C R F.   
8. 2. 2. [ADDRESS_116504] s a b o ut a d here nce t o t he  re q uire me nts of t he pr ot oc ol; 
a n y de viati o ns fr o m st u d y re q uire me nts will be rec or de d i n t he eC R F.  S u bject c o nti n ua nce will 
be c o nfir me d.  
8. 2. 2. [ADDRESS_116505] will 
i n de pe n de ntl y ( wit h o ut s u per visi o n) c o m plete  a har d c o p y of t he D H E Q -4 8  (s o urce ), Secti o n 1 
Q uesti o ns 7 -9 o nl y  a n d Secti o n 2 all q uesti o ns  (see A p pe n di x  1 5. 2). S u bject res p o nses will be 
later tra nscri be d i nt o t he e C R F.   
8. 2. 2. [ADDRESS_116506] u d y Assess me nts  (Secti o n 9). T o facilitate s u bj ect fl o w, s o urce d oc u me nts ca n be use d t o 
rec or d cli nical data  f or later tra nscri pti o n i nt o t he eC R F . 
• O S T e xa mi nati o n  
• Cli nic al assess me nt of t actile se nsiti vit y (t actile t hres h ol d ( g); m a xi m u m f orce 80 g) : 
Assess  t he t w o ‘ Test Te et h’ o nl y . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116507] arti n g t he ev a p or ative ( air) se nsitivity assess me nts.  
• Cli nic al assess me nt of e v a p or ati ve ( air) s e nsiti vit y ( Sc hiff se nsiti vit y sc ore):   
- First  assess t he t w o ‘ Test  Teet h’ . 
- S u bject will c o m plete t he f o ur L M Ss ( I nte nsity, D ur ati o n, T oler a bility & 
Descri pti o n ) f or eac h ‘ Test T o ot h’ i m me di atel y after t h e Sc hiff se nsiti vit y sc ore 
f or t hat t o ot h is rec or de d.  
- W he n Sc hiff se nsiti vit y s c ores h a ve bee n rec or de d, a n d L M Ss c o m plete d, f or b ot h 
‘ Test Teet h’ , t he n  assess Sc hiff se nsiti vit y sc ore f or a n y re mai ni n g ‘Eli gi ble Teet h ’, 
as i de ntifie d at Scree ni n g  (d o n ot re -ass ess  t he t w o ‘ Test Teet h’) . 
‘ Eli gi ble Teet h’ = Te et h wit h n o de ntiti o n excl usi o ns w hic h met E A R, M GI a n d m o bility i ncl usi o n 
criteri a, wit h a Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d a Scree ni n g  Sc hiff se nsitivity sc ore ≥ 2.  
N ote: L M Ss s h o ul d n ot  be c o m plete d f or t he re m ai ni n g  ‘Eli gi ble Teet h ’. 
Tra nscri pti o n of data fr o m s o urce d oc u me nts i nt o t he e C R F m ust be c o m plete d wit hi n [ADDRESS_116508]’s t o ot h b r us h. If it is  da ma g e d, 
a ne w t o ot h br us h s h o ul d be pr o vi de d; s u p pl y of a re place me nt t o ot h br us h will  be d oc u me nte d 
i n t he e C R F.  Eac h s u bje ct  will be pr o vi de d wit h a ne w diar y.  
Dis pe nsi n g staff will re -descri be t he t o ot h paste usa ge i nstr ucti o ns t o eac h s u bj ect  (re mi n di n g 
t he m t o c o ver t he f ull br us h hea d wit h a ri b b o n of t o ot h paste a n d use t he ti mer eac h ti me t he y 
br us h ) a n d t he n s u per vise eac h s u bj ect c o m pleti n g a n o n -site br us hi n g  wit h t heir all ocate d 
i n vesti gati o nal t o ot h paste a n d rec or di n g t h is  use  i n t heir diar y.  
Dis pe nsi n g staff will as k s u bjects ra n d o mize d t o t h e Test T o ot h paste t o i n dicate t he l oc ati o n of 
t heir t w o ‘ Test Teet h’  i n t he  m o ut h  (bef ore  t he y start br us hi n g)  a n d co nfir m  t he s u bject br us h es  
t hese  teet h first , pri or t o br us hi n g t heir e ntire de ntiti o n . 
A n y de viati o n fr o m t h e re q uire d pr o d uct us a ge i nstr ucti o ns will be ca pt ure d as a pr ot oc ol 
de viati o n  i n t he e C R F  a n d t he s u bject will be re -i nstr ucte d i n  t he c orrect dir ecti o ns f or us e.  
Co m pleti o n of eac h  s u per vise d o n -site br us hi n g will be d oc u me nte d i n t he e C R F.  
S p o nta ne o usl y re p orte d A Es a n d a n y A Es elicite d b y as ki n g t he s u bject t o res p o n d t o n o n -
lea di n g q uesti o ns (s uc h as ‘ h o w d o y o u feel?’) o n c o m pleti o n of t he s u per vise d br us hi n g will 
be rec or de d i n t he e C R F.  
Dis pe nsi n g staff will re mi n d  s u bjects  t o n ote a n y c ha n ges i n t heir healt h , me dicati o ns or 
treat me nts i n t he diar y  (or re p ort s uc h c ha n ges t o t he i n vesti gat or  staff  bet wee n visits  usi n g t he 
c o ntact n u m bers p r o vi de d or  i nf or m staff  at t heir ne xt visit , if preferre d) a n d t o bri n g t heir 
i n vesti gati o nal t o ot h paste , t o ot h br us h a n d c o m plete d diar y  t o t he ir  ne xt st u d y visit . 
Ra n d o mize d s u bjects will als o be re -i nstr ucte d i n t he Lifest yle G ui deli nes  (Secti o n 5. 5 ) a n d 
C o nc o mita nt Me dicati o ns/ Treat me nts  (Secti o n 6. 8 ) re q uire m e nts  of t he st u d y .  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 1  of 1 1 3  8. 2. 3  Vi sit 4 / D a y 5 6  ( ± 3 d a y s)  
T he f oll o wi n g pr oce d ures a n d assess me nts will be c o m plete d  b y t he i n vesti gat or, t he cli nical 
e xa mi ner (s) or a s uita bl y q ualifie d/e x perie nce d a n d trai ne d desi g nee . W here practicall y 
feasi ble , t he  pr oce d ures a n d assess me nts s h o ul d be c o m plete d i n t he or der liste d bel o w . All data 
c ollect e d will be rec or de d i n t he e C R F.  
8. 2. 3. [ADDRESS_116509] or y a n d C o n c o mit a nt M e di c ati o n s / Tr e at m e nt s  
In v esti gat or staff will as k s u bjects if t here ha ve b ee n a n y c ha n g es i n t heir healt h, c o nc o mita nt 
me dicati o ns a n d n o n -dr u g treat me nts; f e male s u bj ects of c hil d-beari n g p ote ntial will  self -re p ort 
pre g na nc y st at us. All c ha n ges will be d oc u me nte d i n t he e C R F.  
S p o nta ne o usl y re p ort e d A Es a n d a n y A Es elicite d d uri n g q uesti o ni n g a b o ut c ha n ges i n healt h 
or b y as ki n g s u bjects t o res p o n d t o n o n -lea di n g q uesti o ns (s uc h a s ‘ h o w d o y o u feel?’) will 
rec or de d i n t he e C R F .  
A Es a n d/ or c ha n ges i n me dicati o ns/treat me nts i de ntifie d d uri n g re vie w of t he diar y will be 
rec or de d i n t he e C R F.   
8. 2. 3. [ADDRESS_116510] s a b o ut a d here nce t o t he  re q uire me nts of t he pr ot oc ol; 
a n y de viati o ns fr o m st u d y re q uire me nts will be rec or de d i n t he eC R F.  
8. 2. 3. [ADDRESS_116511] -R e p ort e d O ut c o m e s  
Pri or t o c o m me nci n g t he O S T/ O H T  e xa mi nati o ns a n d D H assess me nts, eac h s u bject will 
i n de pe n de ntl y ( wit h o ut s u per visi o n) c o m pl ete  a har d c o p y of t he D H E Q -4 8  (s o urce ), Secti o n 1 
Q uesti o ns 7 -9 o nl y,  a n d Secti o n 2 all q uesti o ns  (see A p pe n di x  1 5. 2). S u bje ct res p o nses will be 
later tra nscri be d i nt o t he e C R F.   
8. 2. 3. [ADDRESS_116512] u d y Assess me nts  (Secti o n 9). T o facilitate s u bj ect fl o w, s o urce d oc u me nts ca n be use d t o 
rec or d cl i nical data  f or later tra nscri pti o n i nt o t he eC R F . 
• O S T e xa mi nati o n  
• O H T e xa mi nati o n  
• Cli nic al assess me nt of t actile se nsiti vit y (t actile t hres h ol d ( g); m a xi m u m f orce 8 0 g):  
Assess  t he t w o ‘ Test Te et h’ o nl y . 
E ns ure at le ast a [ADDRESS_116513] arti n g t he ev a p or ative ( air) se nsitivity assess me nts.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 2  of 1 1 3  • Cli nic al assess me nt of e v a p or ati ve ( air) s e nsiti vit y ( Sc hiff se nsiti vit y sc ore):   
- First  assess t he t w o ‘ Test Teet h’.  
- S u bject will c o m plete t he f o ur L M Ss ( I nte nsity, D ur ati o n, T oler a bility & 
Descri pti o n ) f or eac h ‘ Test T o ot h’ i m me di atel y after t h e Sc hiff se nsiti vit y sc ore 
f or t hat t o ot h is rec or de d.  
- W he n Sc hiff se nsiti vit y s c ores h a ve bee n re c or de d, a n d L M Ss c o m plete d, f or b ot h 
‘ Test Teet h’, t he n  assess Sc hiff se nsiti vit y sc ore f or a n y re mai ni n g ‘Eli gi ble Teet h’ , 
as i de ntifie d at Scree ni n g ( d o n ot re -ass ess t he t w o ‘ Test Teet h’).  
‘ Eli gi ble Teet h’ = Teet h wit h n o de ntiti o n excl usi o ns w hic h met E A R, M GI a n d m o bility i ncl usi o n 
criteri a, wit h a Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d a Scree ni n g  Sc hiff se nsitivity sc ore ≥ 2.  
N ote: L M Ss s h o ul d n ot  be c o m plete d f or t he re m ai ni n g  ‘Eli gi ble Teet h’ . 
After  t he cli nical e xa mi nati o ns/assess me nts ha ve bee n  c o m plete d, s u bjects  will c o m plete a 
Satisfacti o n wit h Treat me nt N R S a n d descri be (free te xt) w h y t he y ga ve t heir rati n g (Secti o n 
9. 3. 4).  
Tra nscri pti o n of data fr o m s o urce d oc u me nts i nt o t he e C R F m ust be c o m plete d wit hi n [ADDRESS_116514] u d y pr oce d ures (i.e., e ve n i f t h e y are  disc o nti n ue d earl y  at a n y p o i nt d uri n g t he 
st u d y ). If t he s u bject is disc o nti n ue d earl y, t he pri mar y reas o n f or wit h dra wal s h o ul d be 
rec or de d o n t he St u d y C o ncl usi o n pa ge.  F or s u bjects w h o atte n d all sc he d ule d st u d y visits, t he 
St u d y C o ncl usi o n pa ge of t he e C R F will be c o m pl ete d at V isit 4.  
I n v esti gat or s taff will i nstr uct  eac h  s u bject t o i nf or m t he site if t he y e x p eri e nce a n y c ha n ge i n 
healt h , me dicati o ns or treat me nts i n t he [ADDRESS_116515] u d y, t he s p o ns or’s me dical m o nit or ( or desi g nate d re prese ntati ve) s h o ul d  be n otifie d . T he 
s u bject ma y be as ke d t o ret ur n t o t he i n vesti gat or site f or a f oll o w -u p visit t o e ns ure a n y iss ue 
is res ol ve d or dee me d n ot cli nicall y si g nifica nt.  
8. [ADDRESS_116516] t he y ret ur n t o t he site f or a d diti o nal f oll o w -
u p visits (fi nal safet y assess me nts). At t he discreti o n of t he i n vesti gat or or me dicall y q ualifie d 
desi g nee , a d diti o nal oral e xa mi nati o ns ma y be carrie d o ut at s uc h visits . 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116517].  W he n a pr ot oc ol -r e q uire d 
e xa mi nati o n or assess me nt ca n n ot be perf or me d, t he i n vesti gat or or desi g ne e will d oc u me nt t he 
reas o n f or t h e misse d pr oce d ure  as a pr ot oc ol de viati o n a n d a n y c orrecti ve a n d pre v e ntati ve 
acti o ns t he y ha ve  ta ke n t o e ns ure t he  re q uir e d pr oce d ure s are  ad here d t o as s o o n as p ossi ble. 
T he sp o ns or s h o ul d  be i nf or me d of a n y  misse d e x a mi nati o ns  or assess me nts i n a ti mel y ma n ner.  
9. 1  S cr e e ni n g E x a mi n ati o n s/ D H A s s e s s m e nt s  
Scree ni n g e xa mi nati o ns a n d assess me nts will be perf or me d b y a p pr o priatel y trai ne d a n d 
e x perie n ce d cli nical e x a mi ners /staff  at t he ti mes a n d i n t he or der d efi ne d i n t he St u d y 
Pr oce d ures  s ecti o n of t his pr ot oc ol  (Secti o n 9).  
T he eli gi bilit y  of eac h t o ot h will be assesse d  a gai nst t he pr ot oc ol i ncl usi o n/e xcl usi o n criteria 
(Secti o ns 5. 2  a n d 5. 3 ) a n d rec or de d i n t he eC R F.  If , i n t he o pi [INVESTIGATOR_9384] o n of t he cli nical e x a mi ner , t h e  
val ue/ sc ore f or  a partic ular  t o ot h/ area of gi n gi va  lies  b et wee n t w o v al ues /descri pti o ns , a 
c o nser vati ve a p pr oac h s h o ul d be a d o pte d,  a n d t he m ore c o ns er vati ve val ue/ sc ore rec or de d . T he 
sa me a p pr oac h s h o ul d be a p plie d t hr o u g h o ut t he st u d y t o e ns ure c o nsiste nc y of assess me nt  at 
all ti me p oi nts.  
9. 1. 1  Er o si o n , A br a si o n a n d R e c e s si o n ( E A R)  
T he faci al s urfaces of all i ncis or, ca ni ne a n d pre -m olar teet h (Fi g ur e 9-1) t hat d o n ot prese nt 
a n y of t he ge neral de ntiti o n e xcl usi o n criteria, or s pecific de ntiti o n e xcl usi o n criteria , f or 
‘Eli gi ble Teet h’  will be e xa mi ne d f or si g ns of faci al/ cer vical E A R (A d d y, 2 0 0 0 ). 
 
Fi g ur e 9-1 D e nt al N o m e n cl at ur e (De m pse y, 2 0 0 1 ) 
9. 1. 2  M o difi e d Gi n gi v al I n d e x ( M GI)  
T he M GI is a n o n -i n vasi ve vis ual assess me nt  of gi n gi val healt h  (L o be n e, 1 9 8 6 ). M GI will be 
assesse d f or i n cis or, ca ni ne a n d pre -m olar te et h (Fi g ure 9-1) e x hi biti n g n o ne of t he de ntiti o n 
e xcl usi o ns a n d prese nti n g wit h facial/cer vical E A R. M GI s h o ul d be sc ore d f or t he facial gi n gi va 
directl y a djace nt t o t he area of e x p os e d de nti n (i.e., t he test area  o nl y ).  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 4  of 1 1 3  ‘Eli gi ble Teet h ’ will h a ve a M GI of zer o ( 0) directl y a dj ace nt t o t he a re a of e x p ose d de nti n . 
Sc ore  Descri pti o n  
0 A bse nce of i nfla m mati o n  
1 Mil d i nfla m mati o n; sli g ht c ha n ge i n c ol o ur, little c ha n ge i n c ol o ur; little c ha n ge i n 
te xt ure of a n y p orti o n of t he mar gi nal or pa pi[INVESTIGATOR_5778] y gi n gi val u nit.  
2 Mil d i nfla m mati o n; criteria as a b o ve b ut i n v ol vi n g t he e ntire mar gi nal or pa pi[INVESTIGATOR_104894] n gi val u nit.  
3 M o derate i nfla m mati o n; glazi n g, re d ness, oe de ma, a n d/ or h y pertr o p h y of t he mar gi nal 
or pa pi[INVESTIGATOR_5778] y gi n gi val u nit.  
4 Se vere i nfla m mati o n; mar ke d re d ness, oe de ma a n d/ or h y pertr o p h y of t he mar gi nal or 
pa pi[INVESTIGATOR_5778] y gi n gi val u nit, s p o nta ne o us blee di n g, c o n gesti o n, or ulcerati o n.  
9. 1. 3  Cli ni c al  M o bilit y  
Cli nical m o bilit y will be assesse d f or i n cis or, ca ni ne a n d pre -m olar t eet h (Fi g ure 9-1) e x hi biti n g 
n o ne of t he de ntiti o n e xcl usi o ns, wit h facial/cer vical E A R a n d a M GI = [ADDRESS_116518] 
area o nl y , usi n g a m o difi cati o n of t he Miller I n d e x (Laster, 1 9 7 5 ).  
‘Eli gi ble Teet h ’ will h a ve cli nic al  m o bilit y = 0.  
Sc ore  Descri pti o n  
0 N o m o ve me nt or m o bilit y of t he cr o w n of t he t o ot h < 0. 2 m m i n a h oriz o ntal directi o n  
1 M o bilit y of t he cr o w n of t he t o ot h 0. 2 - 1 m m i n a h oriz o ntal directi o n  
2 M o bilit y of t he cr o w n of t he t o ot h e xcee di n g 1 m m i n a h oriz o ntal directi o n  
3 M o bilit y of t he cr o w n of t he t o ot h i n a vertical directi o n as well.  
9. 1. 4  S cr e e ni n g T a ctil e S e n siti vit y  A s s e s s m e nt  
T he tactile se nsiti vit y of i ncis or, ca ni ne a n d pre -m olar teet h (Fi g ur e  9-1) e x hi biti n g n o ne of t he 
de ntiti o n e xcl usi o ns, a n d meeti n g t he E A R, M GI a n d cli nical m o bilit y  criteria, will be assesse d 
usi n g a c o nsta nt press ure pr o be ( Yea ple pr o be (P ols o n, 1 9 8 0 )). T he pr o be ti p will be place d 
per pe n dic ular t o t he faci al s urface of t he t o ot h  a n d dra w n sl o wl y acr oss t h e  e x p ose d de nti n t o 
e ns ure a p plicati o n of t he sti m ul us acr oss t he p ote ntiall y ‘se nsiti ve’ area .  
After eac h a p plicati o n  of t he tactile sti m ul us , t he s u bject will be as ke d t o i n dicate w het h er t he y 
e x perie n ce d a n y pai n or disc o mf ort. T he e xa mi ner will tell t h e s u bject t o o nl y  res p o n d ‘ y es ’ if 
t he y fe el  P AI N or DI S C O M F O R T w he n t he pr o be is  a p plie d t o t heir t o ot h. ‘ Y es ’ a n d  ‘ n o’ are 
t he o nl y acce pta bl e a ns w ers.  T he s u bject ma y res p o n d ‘yes ’ if t he y feel press ure . T he e x a mi ner 
will re mi n d t he m, if  nee de d, t hat t he y will feel press ure eac h ti me t he pr o be is i n c o ntact wit h 
t he t o ot h b ut t he y s h o ul d o nl y res p o n d ‘yes ’ if t h e y feel pai n or disc o mf ort.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 5  of 1 1 3  T he gra m setti n g w hic h elicits t w o c o nsec uti ve ‘ yes’ res p o nses will be rec or de d as t he tactile 
t hres h ol d ( g) f or t h at t o ot h . At Scree ni n g, t he u p per f orce setti n g will be 2 0 g.  
• To be dee me d  ‘eli gi ble ’ f or B aseli ne D H  assess me nt , a t o ot h  m ust h a ve a Scree ni n g 
t actile t hres h ol d ≤ 2 0 g.  
• If n o se nsiti vit y is o bser ve d  at t he u p per f orce s etti n g, Scree ni n g t actile t hres h ol d 
will be rec or de d as > [ADDRESS_116519] fails t o gi ve a defi nite a ns wer, t he e xa mi ner  will  re -pr o m pt t he m t o pr o vi de a 
res p o nse ( ‘yes ’ or ‘n o ’). If t he ir  u ncert ai nt y c o nti n ues, t his s h o ul d be rec or de d  in t he s o urce 
d oc u me nt . If t he s u bject c o nti n ues t o be u ns ure, or t he e xa mi ner is u ns ure of t he relia bilit y of 
t heir res p o nse, t he e xa mi ner ma y o pt t o re -pr o be at t he s a me f orce setti n g (i n dicate d t o t h e 
scri be b y a n o n -ver bal si g nal, e. g., a ha n d g est ure) or m o v e t o t he ne xt f or ce setti n g ( 1 0 g 
i ncreas e). If t he e xa mi ner c o nsi ders t he s u bject ’s ‘ yes’  res p o nse ma y b e bet wee n gra m setti n gs , 
a c o nser vati ve a p pr oac h s h o ul d al wa ys b e a d o pte d, a n d t he l o wer ( m ore ‘se v ere’) ta ctile 
t hres h ol d ( g) rec or de d.  
T he e xa mi ner will ge nerall y ma ke  t he f orce setti n g a dj ust me nts ( t his ca n als o be d o ne  b y a n 
assista nt  or t he scri be) ; t he scri be will rec or d t he micr o -a m pera g e setti n g a n d s u bject’s 
res p o nses  i n t he s o urce d oc u me nt . 
C ali br ati o n of t he Ye a ple Pr o be:  
T he Y ea ple pr o be will be cali brate d b y  a n a p pr o pri atel y trai ne d me m ber of t he i n vesti gat or  st aff 
(t y pi[INVESTIGATOR_1306] y t he cli nical e x a mi ner , t heir assista nt  or scri be) b ef ore use o n eac h da y s u bjects are 
assesse d. T he micr oa m p setti n gs ma y var y fr o m da y t o da y ( partl y d ue t o batter y p o wer 
c o ns u m pti o n), b ut t he differe nce s h o ul d n ot b e si g nifica nt. T h us, pre vi o us pr o be setti n gs ca n 
be use d  as a g ui d e. Cali brati o n s h o ul d start at t he l o west micr oa m p setti n g a n d t he n i ncrease.   
Eit her cali brati o n met h o d descri be d b el o w is acce pta ble.  
• Met h o d 1 (‘ W ater C u p’):  T he Yea pl e pr o be is fi xe d t o a cla m p attac he d t o a ri n g sta n d 
s o t hat t he pr o be ti p is  vertical. A s mall p a per c u p attac he d wit h c ott o n t hrea d is bala nce d 
o ver t he e n d of t he Yea pl e pr o be, wit h o ut t he pr o be tri p pi n g. T he pr o be dial is set t o t he 
micr oa m p setti n g a n d w at er is fe d i nt o t he p a per c u p usi n g a dr o p per u ntil t he pr o be 
tri ps. T he gra m setti n g is rec or de d,  a n d t he Yea ple pr o be reset t o t he ne xt micr oa m p 
val ue. T he pr oce d ure is r e peate d u ntil data h as bee n c ollecte d t o m or e t ha n 8 0 g.  
• Met h o d 2:  T he Yea ple pr o be is fi xe d t o a cla m p attac he d t o a ri n g sta n d s o t hat t he t o p 
is per pe n di c ular t o t he p a n of a n o ha us di al -o-gra m ® bala nce or e q ui v ale nt. T he pr o be 
ti p is p ositi o ne d t o j ust t o uc h t he p a n w h e n t he b ala nce is set at zer o gra ms. T he pr o be 
dial is set t o t h e micr oa m p setti n g a n d t h e gra m  setti n g is i ncreas e d o n t he b ala nce u ntil 
the pr o be tri ps. T he gra m setti n g is rec or de d,  a n d t he Yea ple pr o be reset t o t he ne xt 
micr oa m p val ue.  
T he data are pl otte d, a n d t he p oi nts c o n necte d wit h li ne se g me nts i n or der t o i nter p olate t he 
micr o -a m p val ues e q ui vale nt t o 1 0, 2 0, 3 0, 4 0, 5 0, 6 0, 7 0 a n d  8 0 g. T his cali brati o n s h o ul d be 
re peat e d t hr ee ti mes a n d t he mea n  of t h e t hr ee us e d f or t h at  da y’s setti n gs. T he setti n gs will b e 
rec or de d on t he Y ea ple pr o be cali brati o n rec or d (al o n g wit h t he pr o be’s serial n u m ber) w hic h 
will ser ve as t he f orce s etti n g g ui de f or t hat da y’s e xa mi nati o ns.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 6  of 1 1 3  9. 1. 5  S cr e e ni n g E v a p or ati v e (Air ) S e n siti vit y  A s s e s s m e nt  
Eva p orati ve (air ) se nsiti vit y will be assesse d o n t h e facial s urfaces of i ncis or, ca ni n e a n d pre -
m olar teet h (Fi g ur e 9-1) w hic h e x hi bit n o ne of t h e de ntiti o n e xcl usi o ns, m eet t he E A R, M GI, 
cli nical m o bilit y criteria a n d ha ve a Scree ni n g tactile t hres h ol d ≤ 2 0 g . E va p orati ve (air) 
assess me nt s will start  a mi ni m u m of 5 mi n utes after t he tactile assess me nts ha ve c o m plete d  
(t o ot h rec o ver y ti me) .  
T he assess me nt will be ma de b y directi n g a 1-sec o n d a p plicati o n of air fr o m a sta n dar d de ntal 
s yri n ge hel d p er pe n dic ular  t o t he t o ot h s urface, a p pr o xi matel y [ADDRESS_116520] res p o nse t o t he sti m ul us will be e val uate d usi n g t he Sc hiff se nsiti vit y scale ( Sc hiff, 
1 9 9 4 ). T his is a n e xa mi ner -bas e d i n de x, sc ore d i m me diatel y f oll o wi n g a d mi nistrati o n of t he 
e va p orati ve (air) sti m ul us. T he scale f oc uses o n a c o m bi nati o n of s pecific, o bser va ble, p h ysical, 
be ha vi oral  a n d v er bal res p o nses fr o m t he s u bject, w hi c h ma y facilitate discri mi nati o n.  
Sc ore  Descri pti o n  
[ADDRESS_116521] res p o n ds t o sti m ul us, c o nsi ders sti m ul us t o be pai nf ul, a n d re q uests 
disc o nti n uati o n of t he sti m ul us  
• T o be dee me d ‘eli gi ble’ f or B aseli ne  D H assess me nt s, a t o ot h m ust h a ve a Scree ni n g 
t actile t hres h ol d ≤ 2 0 g  a n d a Scree ni n g Sc hiff se nsiti vit y sc ore ≥ 2 .  
• Teet h wit h a Scree ni n g Sc hiff se nsiti vit y sc ore < 2 will be dis q u alifie d fr o m f urt her 
testi n g.  
9. 2  D H Effi c a c y A s s e s s m e nt s  
T he f oll o wi n g D H effi cac y ass ess me nts will be perf or m e d b y a p pr o priatel y trai ne d a n d 
e x perie n ce d cli nical e x a mi ners /staff , at t h e ti mes a n d i n t he or der defi ne d i n t he St u d y 
Pr oce d ures  s ecti o n of t his pr ot oc ol  (Secti o n 8).  
If , i n t he o pi [INVESTIGATOR_9384] o n of t he cli nical e xa mi ner , t he val u e/ sc ore f or a partic ul ar t o ot h is bet wee n t w o 
val ues/ descri pti o ns , a c o nser vati ve a p pr oac h s h o ul d be a d o pte d,  a n d t he m ore c o nser vati ve 
val ue/ sc ore rec or de d . T h e sa me a p pr oac h s h o ul d be a p plie d t hr o u g h o ut t he st u d y t o e ns ure 
c o nsiste nc y of ass ess me nt  at all ti me p oi nts.  
9. 2. 1  D e nti n e H y p er s e n siti vit y E x p eri e n c e Q u e sti o n n air e ( D H E Q -4 8 ) 
T he D H E Q -4 8  is a c o n diti o n -s pecific meas ur e of O Hr Q o L i n relati o n t o D H ( B oi k o, 2 0 1 0 ) t hat 
has bee n pre vi o usl y vali date d i n l o n git u di nal st u dies a n d s h o w n t o be res p o nsi ve t o treat me nt 
(Ba ker, 2 0 1 4 ). T he  D H E Q t otal sc ore ca n be br o ke n d o w n i nt o 5 se para te ‘d o mai n ’ sc ores t o 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 7  of 1 1 3  pr o vi de  a m ore gra n ular u n dersta n di n g of t he  s pecific areas of i m pr o ve me nt s u bjects  e x perie n ce 
i n t heir O Hr Q O L.  
• Restricti o ns : Deri ve d fr o m partici pa nt  res p o nses t o Secti o n 2, Q 1 -4 (‘ t he w ays i n w hic h 
a ny se ns ati o ns i n y o ur teet h affect y o u i n y o ur d aily life ’).   
• A d a pt ati o n : Deri ve d fr o m partici pa nt  res p o nses t o Secti o n 2, Q 5-16 (‘ t he w ays i n 
w hic h t he se ns ati o ns i n y o ur teet h h ave f orce d y o u t o c h a n ge t hi n gs i n y o ur d aily life ’; 
‘t hi n gs y o u d o i n y o ur d aily life t o av oi d ex perie nc i n g t he se ns ati o ns i n y o ur teet h ’).  
• S oci al I m p act : Deri ve d fr o m partici pa nt  res p o ns es t o Secti o n 2, Q 1 7-2 1  (‘ t he w ay t h e 
se ns ati o ns affect y o u w he n y o u are wit h ot her pe o ple or i n cert ai n sit u ati o ns ’).  
• E m oti o n al I m p act : Deri ve d fr o m partici pa nt  res p o nses t o Secti o n 2, Q 2 2 -2 9  (‘ t he w ay 
t he se ns ati o ns i n y o ur teet h m ake y o u fe el ’).  
• I de ntit y : Deri ve d fr o m p artici pa nt  res p o ns es t o Secti o n 2, Q 3 0 -3 4  (‘ w h at t h e se ns ati o ns 
i n y o ur teet h me a n f or y o u ’).  
T he  D H E Q als o pr o vi des s pecific i nf or mati o n o n h o w m uc h t he se nsati o ns i n t he partici pa nt ’s 
teet h affect t heir life o v erall:  
• Gl o b al Or al He alt h : Deri ve d fr o m partici p a nt  res p o nse t o Secti o n 2, Q 3 5  (‘ r ate t he 
he alt h of y o ur m o ut h, teet h a n d g u ms ’).  
• Effect o n  Life O ver all : Deri ve d fr o m partici p a nt  res p o nses t o Secti o n 2, Q 3 6 -3 9  
(i m pact of D H o n o v erall Q o L).  
S u bjects will i n de pe n de ntl y ( u ns u per vise d) c o m pl ete a  har d c o p y of t he D H E Q -4 8  (A p pe n di x 
15. 2 ) at Bas eli ne ( Visit 2), D a y 2 8  (Visit 3) a n d Da y 5 6  (Visit 4), pri or t o a n y  cli nical 
e xa mi nati o ns a n d assess me nts . 
• B aseli ne : Co m plete Secti o n 1 a n d Secti o n 2 (i.e., all q uesti o ns  i n b ot h secti o ns) .  
• D a y 2 8 & D a y 5 6 : Co m plete Secti o n [ADDRESS_116522] io n s 7-9 o nl y,  a n d  Secti o n 2 all q uesti o ns.  
9. 2. 2  T a ctil e S e n siti vit y A s s e s s m e nt s 
Tactile  se nsiti vit y will be assesse d at Baseli ne ( Visit 2), Da y 2 8 ( Visit 3) a n d Da y 5 6 ( Visit 4) . 
T he tactile sti m ul us will be a d mi nistere d, a n d s u bj ect res p o nse rec or de d, as descri be d i n Secti o n 
9. 1. 4 . T he gra m setti n g w hic h elici ts t w o c o nsec uti ve ‘ yes’ res p o ns es will be rec or de d as t h e 
tactile t hres h ol d ( g).  
• B aseli ne : Assess t he tactile se nsiti vit y of all teet h w hic h e x hi bit n o ne of t he de ntiti o n 
e xcl usi o ns a n d meet t he E A R, M GI a n d cli nical m o bilit y criteria , wit h a Scree ni n g 
tactile t hres h ol d of ≤ 2 0 g a n d a Scree ni n g Sc hiff se nsiti vit y sc ore ≥ 2  (i.e., t he ‘eli gi ble 
teet h’ i de ntifie d at Scree ni n g) .  
The u p per f orce setti n g will be 2 0 g; if n o se nsiti vit y is f o u n d at t he u p per setti n g, rec or d 
tactile t hres h ol d as > 2 0 g.  
• D a y 2 8 & D a y 5 6 : Assess t he tactile se nsiti vit y of t he t w o ‘ Test Teet h’  o nl y  (i.e., t he 
t w o teet h selecte d b y t he cli nical e xa mi ner at Baseli ne,  as descri be d i n Secti o n 8. 2. 1. 5 ). 
T he u p per f orce setti n g will be 8 0 g; if n o se nsiti vit y is f o u n d at t he u p per setti n g, rec or d 
tactile t hres h ol d as > 8 0 g.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 8  of 1 1 3  9. 2. 3  E v a p or ati v e ( Air) S e n siti vit y A s s e s s m e nt s 
E va p orati ve (air) se nsiti vit y will be assesse d at Baseli ne ( Visit 2), D a y 2 8 ( Visit 3) a n d D a y 5 6 
( Visit 4) . T he e v a p orati v e (air) sti m ul us will be a d mi nister e d, a n d s u bject res p o nse rec or de d  
( Sc hiff Se nsiti vit y Sc ore) , as  d escri be d i n Secti o n 9. 1. 5 . E va p orati ve (air) assess me nt s will start  
a mi ni m u m of 5 mi n utes after t he t actile assess me nts ha ve c o m plete d  (t o ot h rec o ver y ti me).  
• B aseli ne :  
- First  assess  e v a p orati ve (air) se nsiti vit y f or all ‘ Eli gi ble Teet h ’ i de ntifie d at 
Scree ni n g  wit h a Baseli n e  tactile t hres h ol d of ≤ 2 0 g . 
- T he n  assess  e va p orati v e (air) se nsiti vit y f or t he  re mai ni n g ‘Eli gi ble Teet h ’ 
i de ntifie d at Scree ni n g  wit h a Baseli ne  tactile t hres h ol d of > 2 0 g .  
• D a ys 2 8 & 5 6 :  
- First  assess  e va p orati ve (air) se nsiti vit y f or t he t w o ‘ Test Teet h’  (i. e., t he t w o teet h 
selecte d b y t he cli nical e xa mi ner at Baseli ne, as d escri be d i n Secti o n 8. 2. 1. 5 ).  
- T he n  assess e va p orati ve (air) se nsiti vit y f or all re mai ni n g ‘Eli gi ble Teet h ’ 
i de ntifie d at Scree ni n g . Do n ot  re -assess t he t w o ‘ Test Teet h’ . 
‘ Eli gi ble Teet h’ = Teet h wit h n o de ntiti o n excl usi o ns w hic h me et  E A R, M GI a n d m o bility i ncl usi o n criteri a, 
a n d h a ve  a Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d a Scree ni n g  Sc hiff se nsitivity sc ore ≥ 2.  
Sc ore  Descri pti o n  
[ADDRESS_116523] res p o n ds t o sti m ul us, c o nsi ders sti m ul us t o be pai nf ul, a n d re q uests 
disc o nti n uati o n of t he sti m ul us  
 
9. 2. 4  L a b ell e d M a g nit u d e S c al e s  ( L M S s)  
S u bjects will rate t he (i) i nte nsity , (ii) d ur ati o n  a n d (iii) t oler a bility  of t heir res p o nse t o t h e  
e va p orati ve (air) sti m ul us  a n d (i v) descri be  t heir res p o nse , usi n g f o ur 1 0 0 -milli metre ( m m) 
L M Ss ( A p pe n di x 1 5.3), at Baseli ne ( Visit 2), Da y 2 8 ( Visit 3) a n d Da y 5 6 ( Visit 4) .  
L M Ss s h o ul d  be c o m plete d i m me di atel y  after  t he cli nical e xa mi ner has rec or de d t he Sc hiff 
se nsiti vit y sc ore f or a gi ve n  t o ot h . T o a v oi d bias, t he s u bject s h o ul d be u na ware of t he 
e xa mi ner’s sc ore a n d t h e cli nical e xa mi ner s h o ul d n ot ha ve visi bilit y of t he s u bject’s L M S 
res p o nses.  
• B aseli ne : C o m plete f o ur L M Ss f or eac h t o ot h wit h a Baseli ne  tactile t hres h ol d of ≤ 2 0 g  
a n d a Baseli ne  Sc hiff se nsiti vit y sc ore ≥ 2 . 
• D a ys 2 8 & 5 6 : C o m plete f o ur L M Ss f or eac h  ‘ Test T o o t h’ (i.e., t he t w o teet h selecte d 
b y t he cli nical  e xa mi ner at Baseli ne , as des cri be d i n Secti o n 8. 2. 1. 5 ).  
St u d y staff will meas ure t he dista nce  t o t he s u bj ect’s mar k  (‘ X’)  fr o m left t o ri g ht al o n g t he 1 0 0 
m m li ne a n d rec or d t his val ue (i n m m) i n t he e C R F  f or eac h L M S c o m plet e d .  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 5 9  of 1 1 3  N ote:  S u bjects will  c o m plete t he L M S trai ni n g e xercise (A p pe n di x 1 5.4) at Scree ni n g  ( Visit 1), 
bef ore t he ir  cli nical e xa mi nati o ns/ D H assess me nts.  A n y s u bject w h o, i n t he o pi [INVESTIGATOR_9384] o n of t he 
i n vesti gat or or desi g ne e , is u na ble t o pr o vi de a p pr o priate res p o nses t o t he L M S trai ni n g 
q uesti o ns, will be e xcl u d e d fr o m p artici pati o n i n t he st u d y  (Secti o n 5. 3 E xcl usi o n Criter i o n 2 7).  
9. [ADDRESS_116524] u d y Pr oce d ures  secti o n of t his pr ot oc ol  (Secti o n  8).   
9. 3. 1  Or al S oft Ti s s u e ( O S T) E x a mi n ati o n  
T he  O S T e xa mi nati o n will be acc o m plis he d b y direct vis ual o bser vati o n a n d pal pati o n , usi n g 
retracti o n ai ds as a p pr o priate , a n d will i ncl u de e xa mi nati o n of t he la bial m uc osa (i ncl u d i n g 
li ps), b uccal m uc osa, m uc o gi n gi val f ol ds, gi n gi val m uc osa, har d p alate, s oft palate, t o nsillar 
area, p h ar y n geal area, t o n g ue, s u bli n g ual area, s u b ma n di b ular area a n d s ali var y gla n ds.  
T he res ults of t he e x a mi nati o n will be rec or de d i n t he eC R F as eit he r ‘n or mal ’ or ‘a b n or m al ’; 
details of a n y a b n or malities  will be d oc u me nte d i n t he e C R F . A n y o bser vati o n t hat c ha n ges 
fr o m  ‘n or mal ’ t o  ‘a b n or mal ’, or w orse ns, fr o m  t he O S T e xa mi nati o n c o m plete d at S cree ni n g  
will  be rec or de d as a n A E.  
9. 3. 2  Or al H ar d Ti s s u e ( O H T) E x a mi n ati o n  
T he O H T e x a mi nati o n will be acc o m plis he d b y direct vis ual o bser vati o n , usi n g retracti o n ai ds 
as a p pr o priate , a n d will i de ntif y  e na mel irre g ularities, t o ot h fract ur es, gr ossl y cari o us 
lesi o ns/ gr oss deca y, defecti ve/f a ult y rest orati o ns ( b ot h direc t a n d  i n direct rest or ati o ns , 
i ncl u di n g fi xe d/  re m o va ble  pr ost heses), n o n -cari o us t o ot h s urface l oss (a brasi o n, attriti o n, 
a bfracti o n a n d er osi o n), a n y ot her h ar d tiss u e irre g ularities (e. g. , h y p o - a n d h y per -
mi nerali zati o n , decalcificati o n) a n d si g nifica nt t o ot h stai ni n g .  
O bser vati o ns will b e liste d as ‘a bse nt ’ or ‘ p res e nt ’; c o n diti o ns n ote d as ‘pres e nt ’ will b e 
descri be d  i n t he e C R F . A n y o bser vati o n t hat c ha n g es fr o m ‘a bse nt ’ t o  ‘ p rese nt ’ or w orse ns fr o m 
t he O H T e xa mi nati o n c o m plete d at S cree ni n g  will  be rec or de d as a n A E.  
T he pres e nce of a n y i m pla nts, fi xe d or re m o v a ble de nt ures, fi xe d or re m o va ble ort h o d o ntic 
braces/ b a n ds, fi xe d ort h o d o ntic retai ners, f ull cr o w ns or ve neers will be rec or de d, al o n g wit h 
e vi de nce of gr oss i ntra -oral ne glect or t he nee d f or e xte nsi ve de nt al t hera p y.  
T he O H T e x a mi nati o n will als o be  use d t o ass ess t he s u bject’s de ntiti o n a gai nst t he ge neral a n d 
s pecific d e ntiti o n e xcl usi o ns descri be d i n Secti o n 5. 3  (E xcl usi o n Criteria 2 2, 2 3, 2 4, 2 5, 2 6a -g).  
9. 3. [ADDRESS_116525] u d y t o ot h pastes are c o ntra -i n dicat e d f or pre g na n c y or breastf ee di n g 
(t heir use w o ul d n ot be e x pecte d t o ca use h ar m t o t he m ot her, t he f oet us or a ba b y) ; t he U S 
c o m mercial pr o d ucts  (t he Accli matizati o n a n d Refere n ce To ot h pastes)  d o n ot  carr y  pre g na nc y 
war ni n g s o n t he la b elli n g (e. g., i nstr ucti o ns t o s pea k t o a d oct or b ef ore use if pre g na nt) ; t he Test 
T o ot h paste will n ot carr y a pre g na n c y war ni n g w he n mar ket e d i n t he U S . T h us , pre g na nc y 
test i n g  of  fe male s u bjects is n ot re q uire d pri or t o t heir e nr ol me nt . 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 0  of 1 1 3  Fe male s u bjects will pr o vi de ver bal c o nfir mati o n of pre g na n c y stat us at Scree ni n g ( Visit 1) a n d 
at eac h s u bse q ue nt st u d y visit ; t his will be rec or de d i n t he  e C R F. T he y will be i nstr ucte d t o 
i nf or m t he i n vesti gat or  staff i m me diatel y s h o ul d t he y fi n d o ut t he y are pre g na nt  at a n y p oi nt 
d uri n g t he st u d y.   
Fe male s u bjects w h o are pre g na nt or i nte n di n g t o bec o me pre g n a nt d uri n g t he st u d y (self -
re p orte d) will be e xcl u de d  (t he  rati o nale f or e x cl usi o n is pr o vi de d i n  Secti o n 4. 2 ). 
9. 3. [ADDRESS_116526] u d y ( Visit 4), s u bjects will be as ke d t o rate t heir le v el of satisfacti o n wit h 
t heir all ocate d i n vesti gati o nal t o ot h p aste usi n g a N u meric Rati n g Scale ( N R S).  
T he N R S is a n [ADDRESS_116527]’s satisfacti o n wit h t he pr o d uct’s 
o verall ma na g e me nt of t heir D H. T he scale ra n ges fr o m 0 (c o m pletel y dissatisfie d) t o 1 0 
(c o m pletel y satisfie d), wit h  hi g her s c ores i n dicati v e of greater satisfacti o n ( va n Berc kel, 2 0 1 7 ): 
see e xa m ple b el o w .  
S u bjects will be as ke d t o rec or d t he n u meric v al u e o n t he se g me nte d s cale t hat best descri bes 
t heir le vel of satisfacti o n after 8 w ee ks t wic e d ail y use a n d i n dicate w h y t he y sele cte d a 
partic ular s c ore i n a ns wer t o t he q uesti o n ‘ Pleas e gi ve m ore det ails o n w h y y o u are satisfie d or 
dissatisfie d wit h t he pr o d uct’ (free te xt res p o nse).  
 
E x a m ple N R S - N ot t o Sc ale  
[ADDRESS_116528] u d y  partici pati o n.  
1 0. 1  D efi niti o n of a n A d v er s e E v e nt ( A E)  
A n A E is a n y u nt o war d me dical occ urre nce i n a cli nical st u d y s u bject, te m p orall y ass ociate d 
wit h t he use of a st u d y pr o d uct i ncl u di n g a n accli matizati o n  pr o d uct ( or me dical d e vice), 
w het her or n ot c o nsi dere d relate d t o t he st u d y pr o d uct, i ncl u di n g a n accli matizati o n  pr o d uct ( or 
me dical de vice).  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 1  of 1 1 3  Note : A n A E ca n t h eref o re be a n y u nfa v ora ble a n d u ni nte n de d si g n (i ncl u di n g a n a b n or mal 
la b orat or y fi n di n g), s y m pt o m, or disease ( ne w or e xacer bate d) te m p orall y ass ociate d wit h t he 
use of a st u d y pr o d uct i n cl u di n g a n accli matizati o n  pr o d uct ( or me dical de vice).  
E ve nts Meeti n g  t he A E Defi niti o n:   
• A n y a b n or mal la b orat or y test res ults ( he mat ol o g y, cli nical c he mistr y  or uri nal ysis) or 
ot her safet y assess m e nts (e. g. , electr o car di o gra m , ra di ol o gical s ca ns, vital si g n 
meas ure me nts), i ncl u di n g t h ose t hat w ors e n fr o m Baseli ne, c o nsi dere d cli nicall y 
si g nifica nt i n t he me dical a n d scie ntific j u d g me nt of t he i n vesti gat or (i.e., n ot relate d t o 
pr o gressi o n of u n derl yi n g disease).  
N ote:  A n y O S T o bser vati o n t hat c h a n ges fr o m ‘ n or mal’ t o ‘a b n or mal’, or w orse ns, fr o m t he O S T 
e x a mi nati o n c o m plete d at Scree ni n g s h o ul d be rec or de d as a n A E’ irres pecti ve of cli nical si g nifica n ce.  
• E xacer bati o n  of a c hr o nic or i nter mitte nt pre -e xisti n g c o n diti o n i ncl u di n g eit her a n 
i ncreas e i n fre q u e nc y a n d/ or i nte nsit y of t he c o n diti o n.  
• Ne w c o n diti o ns detecte d  or dia g n ose d aft er st u d y pr o d uct a d mi nistrati o n e ve n t h o u g h it 
ma y ha ve bee n pres e nt b ef ore t h e start of t he st u d y.  
• Si g ns, s y m pt o ms, or t he cli nical se q uela e of a s us pecte d dr u g -dr u g i nteracti o n.  
• Si g ns, s y m pt o ms, or t he cli nical se q uelae of a s us pe cte d o v er d os e of eit her st u d y pr o d uct 
or a c o n c o mita nt me dicati o n. O ver d ose p er s e will n ot be re p orte d as a n A E/ S A E u nless 
it is a n i nte nti o nal o v er d ose ta ke n wit h p ossi bl e s uici dal/self -h ar mi n g i nte nt. S uc h 
o ver d oses s h o ul d be re p orte d re g ar dless of s e q uela e.  
• ‘Lac k of efficac y ’ or ‘fail ure of e x pecte d p har m ac ol o gical acti o n ’ per se will n ot be 
re p orte d as a n A E. S u c h i nsta nces will be ca pt ure d i n t he efficac y assess me nts. 
H o we ver, t he si g ns, s y m pt o ms a n d/ or cli nical se q uelae res ulti n g fr o m lac k of effic ac y 
will be re p orte d as a n A E if t he y f ulfill t he defi niti o n of a n A E.  
E ve nts N O T  meeti n g t he A E defi niti o n:  
• A n y cli nicall y si g nifica nt a b n or mal la b orat or y fi n di n gs (if a p plica ble) or ot her a b n or mal 
safet y assess me nts w hic h are ass ociat e d wit h t he u n derl yi n g dise ase, u nless j u d ge d b y 
t he i n vesti gat or t o be m ore se vere t ha n e x pect e d f or t he s u bject’s c o n diti o n.  
• T he diseas e/ dis or der bei n g st u die d or e x pecte d pr o gressi o n, si g ns, or s y m pt o ms of t he 
disease/ dis or der b ei n g st u die d, u nless m ore se v ere t ha n e x pecte d f or t he s u bject’s 
c o n diti o n.  
• A me dical or s ur gical pr oce d ure (e. g. , e n d osc o p y, a p pe n dect o m y) is n ot a n  A E. T he 
c o n diti o n t hat lea ds t o t he pr oce d ure is a n A E ( e. g.,  a p pe n dicitis).  
• Sit uati o ns w here a n u nt o war d me dical occ urre nce di d n ot o cc ur (s o cial a n d/ or 
c o n ve nie nce a d missi o n t o a h os pi[INVESTIGATOR_307]).  
• A ntici pate d da y -t o -da y fl uct uati o ns of pre -e xisti n g disease(s) or c o n diti o n(s) pres e nt or 
detecte d at t he start of t h e st u d y t hat d o n ot w orse n.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 2  of 1 1 3  1 0. 2  D efi niti o n of a S eri o u s A d v er s e E v e nt ( S A E)  
A seri o us ad v erse eve nt ( S A E) is a p artic ular cate g or y of A E  w h ere t he a d verse o utc o me is 
seri o us. If a n e v e nt is n ot a n A E per defi niti o n a b o ve, t he n it ca n n ot be a n S A E , e ve n if seri o us 
c o n diti o ns are met (e. g. , h os pi[INVESTIGATOR_1314] o n f or si g ns/s y m pt o ms of t he disease u n der st u d y , d eat h 
d ue t o pr o gressi o n of dis ease).  
A seri o us a d verse e v e nt is a n y u nt o war d me dic al occ urre nce at a n y d ose t h at:  
• Res ults i n de at h  
• Is life -t hre ate ni n g   
- T he ter m 'life -t hreate ni n g' i n t he defi niti o n of 'seri o us' refers t o a n e ve nt i n w hic h 
t he s u bject wa s at ris k of deat h at t he ti me of t he e ve nt. It d oes n ot refer t o a n e ve nt, 
w hic h h y p ot heticall y mi g ht ha ve ca us e d deat h, if it were m or e se vere . 
• Re q uires i n p atie nt h os pit aliz ati o n or pr ol o n g ati o n of e xisti n g h os pit aliz ati o n   
- I n g e neral, h os pi[INVESTIGATOR_1314] o n si g nifies t hat t he s u bject has bee n detai ne d ( us uall y 
i n v ol vi n g at least a n o ver ni g ht sta y) at t he h os pi[INVESTIGATOR_6879] e mer ge n c y w ar d f or 
o bser vati o n a n d/ or treat me nt t hat w o ul d n ot ha ve bee n a p pr o priat e i n t he 
p h ysicia n’s office or o ut patie nt setti n g. C o m plicati o ns  t hat occ ur d uri n g 
h os pi[INVESTIGATOR_1314] o n are A Es. If a c o m plicati o n pr ol o n gs h os pi[INVESTIGATOR_1314] o n or f ulfills a n y 
ot her seri o us criteria, t he e ve nt is s eri o us. W he n i n d o u bt as t o w het her 
‘h os pi[INVESTIGATOR_1314] o n ’ occ urre d, or was necessar y, t he A E s h o ul d be c o nsi dere d seri o us.  
- H os pi[INVESTIGATOR_1314] o n f or electi ve treat me nt of a pre -e xisti n g c o n diti o n t hat di d n ot w orse n 
fr o m Baseli ne is n ot c o nsi dere d a n A E.  
• Res ults i n persiste nt or si g nific a nt dis a bilit y/i nc a p acit y  
- T he ter m disa bilit y mea ns a s u bsta ntial disr u pti o n of a pers o n’s a b ilit y t o c o n d uct 
n or mal life f u ncti o ns.  
- T his defi niti o n is n ot i nte n de d t o i ncl u de e x perie nces of relati vel y mi n or me dical 
si g nifica nce s uc h as u nc o m plicate d hea d ac h e, na usea, v o miti n g, diarr hea, 
i nfl ue nza, a n d acci de ntal tra u ma (e. g. , s prai ne d a n kle) w hic h ma y i nterfere wit h or 
pre ve nt e v er y da y life f u ncti o ns b ut d o n ot c o nstit ute a s u bsta ntial disr u pti o n . 
• Res ults i n c o n ge nit al a n o m al y/ birt h defect  
• Ot her sit u ati o ns:  
- Me dical or s cie ntific j u d g me nt s h o ul d be e xercise d i n deci di n g w het h er S A E 
re p orti n g is a p p r o priate i n ot her sit uati o ns s uc h as i m p orta nt me dical e v e nts t hat 
ma y n ot be i m me diatel y life -t hreate ni n g or res ult i n deat h or h os pi[INVESTIGATOR_27967] o n b ut 
ma y je o par di ze t he s u bj ect or ma y re q uire me dical or s ur gical i nter ve nti o n t o 
pre ve nt o n e of t he ot her o utc o mes liste d i n t he a b o ve d efi niti o n. T hese e ve nts 
s h o ul d us uall y be c o nsi dere d seri o us.  
E xa m ples of s uc h e ve nts i ncl u de i n vasi ve or mali g na nt ca ncers, i nte nsi ve tr eat me nt 
i n a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d yscrasias or 
c o n v ul si o ns t hat d o n ot res ult i n h os pi[INVESTIGATOR_1314] o n, or de vel o p me nt of dr u g 
de pe n de n c y or dr u g a b us e.  
N ote:  Classificati o n of a n A E as ‘seri o us’ is base d o n t he o utc o me of t he e ve nt a n d is a fact or 
i n deter mi ni n g re p orti n g re q uire me nts.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116529] u d y b y t he c o m pleti o n (si g nat ure) of t he I C F u ntil [ADDRESS_116530] ( or t he last st u d y pr oce d ure).  
Me dical occ urre nces t hat be ga n bef ore o btai ni n g i nf or me d c o nse nt will be rec or de d i n t he 
Me dical Hist or y/ C urre nt Me dical C o n diti o ns  secti o n of t he eC R F , n ot t he A E secti o n . 
Details rec or de d b y t he s u bject in a diar y or si milar d oc u me nt t h at meet t h e defi niti o n of a n A E 
m ust be disc usse d wit h t he s u bjects a n d tra ns cri b e d i n t o  t he A E secti o n of t he eC R F.  
All S A Es will be rec or de d a n d re p orte d t o t he s p o ns or or d esi g nee i m me dia tel y , a n d u n der n o 
circ u msta nce s h o ul d t his e xcee d [ADDRESS_116531] u d y s u bjects  a n d t h ose elicite d b y as ki n g s u bjects  t o res p o n d 
t o n o n -lea di n g q uesti o ns ( s uc h as ‘ h o w d o y o u fee l?’)  will be assess e d , rec or de d i n t he eC R F  
a n d re p ort e d , as a p pr o pri ate . 
Eac h A E is t o be ass esse d t o deter mi ne if it meets t he criteria f or a S A E. If a n S A E occ urs, 
e x pe dite d re p orti n g will f oll o w l ocal a n d i nter nati o nal re g ulati o ns, as a p pr o priate.  
W he n a n A E o cc urs, it is t he res p o nsi bilit y of t he i n vesti gat or or t heir  me dicall y q ualifie d 
desi g nee t o re vie w all d o c u me ntati o n (e. g. , h os pi[INVESTIGATOR_75512] o gress n otes,  la b orat or y a n d dia g n ostics 
re p orts) relate d t o t he e ve nt.  T he i n v esti gat or or st u d y  staff will t he n rec or d all rele va nt 
i nf or mati o n rel ati n g t o t h e  e v e nt  i n t he A E secti o n of t he eC R F . I n a d diti o n, all details relati n g 
t o a n S A E will be rec or de d o n t he pa per S A E for m pr o vi de d.  
It is n ot  acce pta ble f or t he i n vesti gat or or t heir me dicall y q ualifie d desi g nee t o se n d p h ot oc o pi[INVESTIGATOR_66494] a s u bject’s me dical rec or ds t o t he s p o ns or i n lie u of c o m pleti o n of t he A E secti o n of t he 
eC R F / pa per S A E f or m.  T here m a y be i nsta n ces w he n c o pi[INVESTIGATOR_1309] m e dical rec or ds f or certai n 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116532] 
n u m ber, will be re dacte d o n t he c o pi[INVESTIGATOR_1309] t he me dical rec or ds pri or t o s u b missi o n t o t he s p o ns or . 
T he i n vesti gat or or t heir me dicall y q ualifie d desi g nee will atte m pt t o esta blis h a dia g n osis base d 
o n si g ns, s y m pt o ms a n d/ or ot her cli nical i nf or mati o n  relate d t o t he e ve nt . T he dia g n osis will be 
t he d oc u me nte d as t he A E/ S A E , w here k n o w n , a n d n ot t he i n di vi d ual si g ns/s y m pt o ms (e. g. , 
u p per res pir at or y tract i nfecti o n  or  seas o nal aller g y , n ot  ‘r u n n y n ose ’).  
1 0. 4. 1  R e p orti n g a n A E  
A Es will be re p orte d b y t he  i n vesti gat or , t heir me dicall y q ualifie d desi g ne e  or site staff  i n t he 
A E secti o n of t he eC R F .  The pa per f or m use d f or c ollecti o n of S A E i nf or mati o n is n ot t he sa me 
as t he A E s ecti o n of t he eC R F . A Es / S A Es  s h o ul d be re p orte d usi n g c o ncise me di cal 
ter mi n ol o g y.  W here t he s a me dat a are c ollecte d, t h e A E secti o n of t he eC R F a n d t he S A E f or m 
m ust be c o m plete d i n a c o nsiste nt ma n ner  (e. g., t h e sa me A E ter m s h o ul d be use d f or  b ot h ).   
1 0. 4. 2  R e p orti n g a n S A E  
I n a d diti o n t o rec or di n g t he details of eac h SA E i n t he A E secti o n of t he eC R F , a n S A E f or m 
s h o ul d be c o m plete d, as f ull y as p ossi ble. Har d c o pi[INVESTIGATOR_1309] t he ‘ pa p er’ S A E f or m will be pr o vi de d 
i n t he i n vesti gat or site  file. Ori gi nal , c o m plete d  S A E f or ms will be  retai ne d i n t he i n vesti gat or 
site  file.  
It is esse ntial t o rec or d  t h e f oll o wi n g i nf or mati o n  f or eac h S A E :  
• Pr ot oc ol a n d s u bject i de ntifiers  
• S u bject de m o gra p h y  
• Descri pti o n of e v e nt wit h dia g n osis , if a vaila ble  
• I n v esti gat or o pi [INVESTIGATOR_9384] o n of relati o ns hi p t o st u d y pr o d uct ( or st u d y pr oce d ure)  
• Criteri o n f or seri o us ness.  
T he f oll o wi n g are desir a ble a n d are of partic ul ar rele v a nce f or i n vesti gat or a n d s p o ns or  
assess me nt of t he S A E re p ort:  
• Date of o nset of SA E  
• Date SA E st o p pe d, if rele va nt  
• St u d y pr o d uct start date  
• St u d y pr o d uct e n d date , if rele v a nt  
• Acti o n ta ke n i n relati o n t o st u d y pr o d uct  
• O utc o me , if k n o w n  
T he S A E f or m, c o m plete d as f ull y as p ossi ble, m ust be sca n n e d a n d e -mail e d t o t he s p o ns or’s 
Case Ma na ge me nt Gr o u p  mail b o x ( , wit h t he a p pr o priate 
s p o ns or St u d y Ma na ger  i n c o p y , wit h t he st u d y n u m ber a n d s u bject n u m ber i n t he s u bject li ne 
of t he e mail i m me di atel y  after site st aff  le ar n of t he e ve nt , a n d  u n der n o circ u mst a nce s 
s h o ul d t his e xcee d [ADDRESS_116533] a nce s h o ul d t his e xcee d 2 4 h o urs 
of it bei n g a v ail a ble .  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI P P D 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 5  of 1 1 3  T he i nitial re p ort will be f oll o we d u p wit h m ore  i nf or mati o n as rele va nt, or as re q ueste d b y t he  
s p o ns or’s St u d y Ma na ger . T he s p o ns or’s St u d y Ma na ger  will be res p o nsi ble f or f or war di n g t he 
S A E f or m t o ot her s p o ns or  pers o n nel as a p pr o pri ate.  
[ADDRESS_116534] u d y a n d will assi g n it t o o ne of t he f oll o wi n g cate g ories:  
• Mil d:   A n e ve nt t hat is easil y t olerate d b y t he s u bject, ca usi n g mi ni mal disc o mf ort a n d 
n ot i n terferi n g wit h e ver y da y acti vities.  
• M o der ate:   A n e ve nt t hat is s ufficie ntl y disc o mf orti n g t o i nterfere wit h n or mal 
e ver y da y acti vities  
• Se vere:   A n e ve nt t hat pre ve nts n or mal e v er y da y acti vities.  
Note : A n A E assess e d as ‘se vere ’ s h o ul d n ot be c o nf use d wit h a n S A E. ‘Se vere ’ is a cate g or y 
utilize d f or rati n g t he i nte nsit y of a n e v e nt . B ot h n o n -seri o us A Es a n d S A Es ca n b e assess e d as 
se vere , e. g., a hea dac he ma y be se vere ( si g nifica ntl y i nterferes wit h t he s u bject's us ual f u ncti o n) 
b ut w o ul d n ot be classifie d as seri o us u nless it met o ne of t he criteria f or S A Es liste d i n Secti o n 
10. 2 . A n e ve nt is defi ne d as ‘seri o us’ w he n it meets at least o ne  of t he pre -defi ne d o utc o mes  
descri be d i n t he d efi niti o n of a n S A E  (Secti o n 1 0. 2 ), n ot  w he n  it is rate d as ‘se vere ’. 
1 0. 5. 2  A s s e s s m e nt of C a u s alit y  
F or eac h A E ( n o n -seri o us  a n d seri o us ), t he i n vesti gat or  or t heir me dicall y q ualifie d desi g nee  
m ust  pr o vi de a n assess me nt of ca usalit y in t he A E secti o n of t he eC R F a n d o n t he S A E f or m 
(as a p pr o priat e, s u bject t o classificati o n of t he A E). Ca usalit y is o ne of t he criteria use d t o  
deter mi n e re g ulat or y re p orti n g re q uire me nts.  
A ‘reas o na bl e p ossi bilit y ’ of a relati o ns hi p c o n v e ys t here are facts  (e vi de n ce ) a n d/ or ar g u me nts 
t o s u g gest a ca usa l rel ati o ns hi p, rat her t ha n a relati o ns hi p ca n n ot be r ule d o ut. Ge nerall y, t h e 
facts (e vi de n ce) or ar g u m e nts t o s u g gest a ca usal relati o ns hi p s h o ul d be pr o vi de d  i n t he A E / S A E  
re p ort . 
T he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  will use cli nical j u d g me nt t o deter mi ne 
ca usalit y  a n d will als o c o ns ult t he I n vesti gat or Br oc h ure (I B), Safet y State me nt a n d/ or Pr o d uct 
I nf or mati o n, as a p pr o priate , w he n ma ki n g  t heir  assess me nt.  Alter nati v e ca uses, s uc h as 
u n derl yi n g disease(s), c o nc o mita nt t hera p y , ot her r is k fact ors a n d t h e te m p oral relati o ns hi p of 
t he e ve nt t o st u d y pr o d uct use will be c o nsi dere d a n d i n vesti gate d.  
W here a p plica ble, t he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  m ust d oc u me nt i n t he 
me dical n otes t h e y ha v e  re vie we d t he A E/ S A E a n d p r o vi de d a n ass ess me nt of ca usalit y.  
T here ma y be sit uati o ns , w he n a n S A E has occ urre d, w here t h e i n vesti gat or or t h eir me dicall y 
q ualifie d desi g nee  has mi ni mal i nf or mati o n t o i ncl u de i n t he i nitial  S A E  re p ort. H o we ver, it is 
ver y i m p ort a nt t h at t he i n vesti g at or or t heir m e dic all y q u alifie d desi g nee al w a ys m a ke s 
a n assess me nt of c a us alit y f or e ver y e v e nt pri or t o i niti al tr a ns missi o n of t he S A E d at a t o  
t he s p o ns or . T he i n vesti gat or ma y c ha n ge t heir  o pi [INVESTIGATOR_9384] o n of ca u salit y , i n li g ht of f oll o w -u p 
i nf or mati o n , a n d se n d a n S A E f oll o w -u p re p ort wit h a n  u p date d ca usalit y assess me nt.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 6  of 1 1 3  1 0. 6  F oll o w -u p of A E s a n d S A E s   
After t he i nitial A E/ S A E re p ort, t he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  is re q uire d 
t o pr oacti vel y  f oll o w u p wit h eac h s u bject a n d pr o vi de f urt her i nf or mati o n o n t he s u bject’s 
c o n diti o n , as a vaila ble.  
All A Es ( n o n -seri o us  a n d seri o us ) s h o ul d  be f oll o we d u ntil res ol uti o n, u ntil t he c o n diti o n 
sta bilizes, u ntil t he e ve nt is ot her wise e x plai ne d or u ntil t h e s u bject is l ost t o f oll o w -u p.   
T he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  is o bli gate d t o perf or m or arra n ge f or t he 
c o n d uct of  s u p ple me ntal meas ure me nts a n d/ or e val uati o ns as ma y b e i n dicate d (or as re q uest e d 
b y t he s p o ns or ) t o el uci date as  f ull y as p ossi ble t he nat ure a n d/ or ca usalit y of t he A E / S A E . 
T h ese  ma y i ncl u de a d diti o nal la b orat or y tests or i n vesti gati o ns, hist o pat h ol o gical e xa mi nati o ns, 
or c o ns ultati o n wit h ot her healt hcare pr ofessi o nals.  
Ne w or u p date d i nf or mati o n will be rec or de d in t he A E secti o n of t he eC R F a n d o n t he S A E 
f or m ( as a p pr o priate, s u bject t o classificati o n of t he A E) . T h e i n vesti gat or or t heir me dicall y 
q ualifie d desi g nee  will s u b mit a n y u p date d S A E data t o t he s p o ns or  wit hi n [ADDRESS_116535] pr o m ptl y n otif y t he s p o ns or  b y e maili n g t he 
i nf or mati o n  t o  t he s p o ns or’s Case  Ma na g e me nt  Gr o u p  mail b o x 
( , wit h t he a p pr o priate s p o ns or  St u d y Ma na ger  i n c o p y . 
T he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  will s u b mit a n y u p date d S A E data t o t he 
s p o ns or  wit hi n t he desi g nate d re p orti n g ti me fra mes.  
[ADDRESS_116536] a w al D u e t o a n A d v er s e E v e nt  
Wit h dra wal d ue t o A Es s h o ul d be disti n g uis he d fr o m wit h dra wal d ue t o ot her ca us es, acc or di n g 
t o t he defi niti o n of a n A E pr o vi de d  (Secti o n 1 0. 1 ) a n d rec or de d in t he A E s ecti o n of t he eC R F .  
W he n a s u bject wit h dra ws d ue t o  a n S A E, t he S A E m ust be re p orte d i n  acc or da nce wit h t he 
re p orti n g re q uir e me nts d efi ne d  i n t his pr ot oc ol . 
[ADDRESS_116537] be pre pare d f or s us pecte d u ne x p ecte d seri o us a d verse reacti o ns 
( S U S A R) acc or di n g t o l ocal re g ulat or y re q uire m e nts a n d s p o ns or p olic y , a n d f or war de d t o t he 
i n vesti gat or , as a p pr o pri ate . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI P P D 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 7  of 1 1 3  If t he  i n vesti gat or recei ves a n i n vesti gat or safet y re p ort descri bi n g a S A E or ot her s pecific safet y 
i nf or mati o n (e. g. , a  s u m mar y or listi n g of S A E s)  fr o m t he s p o ns or , t he y  will re vie w it , file  it  
wit h ot her safet y i nf or m ati o n (e. g., t he I B)  i n t he i n vesti gat or site  file a n d n otif y t he I R B, if 
a p pr o priate , acc or di n g t o l ocal re q uir e me nts.  
[ADDRESS_116538] u d y fr o m t he date/ti me of si g ni n g t he  i nf or me d c o nse nt u ntil [ADDRESS_116539].  
1 0. 9. 2  A cti o n t o b e T a k e n if Pr e g n a n c y O c c ur s  
T he i n vesti gat or or t heir me dicall y q ualifie d desi g nee  will rec or d pre g na n c y i nf or mati o n o n t h e 
a p pr o priate f or m sca n a n d e -mail it t o t he Case Ma n a ge me nt Gr o u p mail b o x 
( , wit h t he a p pr o priate s p o ns or  St u d y Ma na ger  i n c o p y . 
Ori gi nal c o m plete d pre g na nc y i nf or mati o n f or ms will be retai ne d i n t he i n vesti gat or site file.  
T he fe male s u bject will be f oll o we d t o deter mi ne t he o utc o me of t he pre g na nc y.  I nf or m ati o n 
o n t he stat us of t he m ot her a n d i nf a nt/ ne o nate (i ncl u di n g c o nc o mita nt me dicati o ns ta ke n b y t he 
m ot her d uri n g pre g na n c y) will be f or war de d b y t he i n vesti gat or  or t heir me dicall y q ualifie d 
desi g nee  t o  t he s p o ns or’s Case  Ma na ge me nt  Gr o u p mail b o x 
( ), wit h t he a p pr o priate s p o ns or  St u d y Ma na ger  i n c o p y . 
Ge nerall y, f oll o w -u p will be f or n o l o n ger t ha n 6 t o 8 wee ks f oll o wi n g t he esti mate d d eli ver y 
date. Ter mi nati o n of pre g na nc y will be re p orte d.  
W hile pre g na n c y itself  is n ot c o nsi dere d t o be a n A E, a b n or mal pre g na n c y o utc o mes (e. g. , 
s p o nta ne o us a b orti o n, fet al deat h, still birt h, c o n ge nital a n o malies, ect o pic pre g na nc y) are, a n d 
s h o ul d be rec or de d as a n S A E.  
A n y fe male s u bject w h o bec o mes pre g na nt w hile partici pati n g wi ll be wit h dra w n.    
[ADDRESS_116540] u d y; t he me dical d e vice i n 
t his st u d y is  t he ma n u al t o ot h br us h ( Oral B Se nsi -Soft , U S  mar ket)  use d t o a p pl y t he st u d y 
t o ot h pastes .  
The i n vesti gat or a n d t he s p o ns or will c o m pl y wit h l ocal me dical de vice re p orti n g re q uire me nts.  
1 0. 1 0. 1  D efi niti o n of a n I n ci d e nt  
A me dical de vic e i nci de nt is a n y malf u n cti o n or deteri or ati o n i n t he c haracteristics a n d/ or 
perf or ma n ce of a d e vice as well as a n y i na de q uac y i n t he la beli n g or t he i nstr ucti o ns f or use 
w hic h, directl y or i n directl y, mi g ht lea d t o or mi g ht ha ve le d t o t he deat h of a s u bject/ user/ ot her 
pers o n or t o a seri o us det eri orati o n i n t heir  state of healt h.  
N ot all i nci de nts lea d t o deat h or seri o us deteri or at i o n i n healt h. T he n o n -occ urre nce of s uc h a 
res ult mi g ht ha ve bee n d ue t o ot her f ort u nat e cir c u msta nces or t o t he i nter ve nti o n of healt hcare 
pers o n nel.  
It is s ufficie nt t hat  an i n ci de nt  ass ociate d  wit h a de vice ha p p e ne d a n d  the i nci de nt  was s uc h 
t hat, if it occ urre d a gai n, mi g ht lea d t o deat h or a s eri o us deteri or ati o n i n he alt h.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI P P D 
P P D 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 8  of 1 1 3  A seri o us deteri orati o n i n state of healt h ca n i ncl u de a n y of t he f oll o wi n g:  
• Life -t hreate ni n g ill ness  
• Per ma ne nt i m pair me nt of b o d y f u ncti o n or per ma n e nt da ma ge t o b o d y str uct ure  
• C o n diti o n necessitati n g me dical or s ur gic al i nter ve nti o n t o pre ve nt o ne of t he a b o ve  
• Fetal distress, f etal deat h, or a n y c o n ge nital a b n or malit y or birt h defects  
E x a m ples of i nci de nts:  
• A s u bject, user, care gi ver, or healt hcare pr ofessi o nal is i nj ure d as a res ult of a me dical 
de vice fail ure or its mis use.  
• A s u bject’s st u d y treat me nt is i nterr u pte d or c o m pr o mise d b y a me dical de vi ce fail ure.  
• A mis dia g n osis d ue t o me dical de vice fail ure lea ds t o i na p pr o priate treat me nt.  
• A s u b ject’s healt h deteri orates d ue t o me dic al de vice fail ure.  
[ADDRESS_116541]'s 
me dical rec or ds, if i n acc or da nce wit h t he i n vesti gat or's n or mal cli nic al practice, a n d o n t he 
a p pr o priate I nci d e nt Re p ort For m.  I n a d diti o n, f or i nci de nts f ulfilli n g t he defi niti o n of a n A E 
( n o n -seri o us  a n d s eri o us ), t he A E secti o n of t he eC R F /S A E f or m will be c o m plete d a n d re p orte d 
as per t he A E /S A E re p orti n g s ecti o ns  a b o ve . 
T he I nci de nt Re p ort F or m will be c o m plete d as t h or o u g hl y as p ossi ble a n d si g ne d b y t he 
i n vesti gat or bef ore tra ns mittal t o t he s p o ns or .  It is ver y i m p orta nt t hat t he i n vesti gat or descri bes 
a n y c orrecti ve or re me di al acti o ns ta ke n t o pr e ve nt rec urre nce of t he i nci de nt.  
T he c o m plet e d I n ci de nt Re p ort F or m s h o ul d be sca n ne d a n d e maile d t o  t he s p o ns or’s Case 
Ma na ge me nt Gr o u p  mail b o x ), wit h t he a p pr o priate s p o ns or  
St u d y Ma na ger  i n c o p y , wit h t he st u d y n u m ber a n d s u bject n u m ber i n t he s u bject li ne of t he 
e mail i m me di atel y after site staff  lear n of t he e ve nt  a n d u n der n o circ u mst a nce s s h o ul d t his 
e xcee d [ADDRESS_116542] t he pr oce d ure f or  re p ort i n g  a n S A E.  T he ori gi nal 
c o m plete d I nci de nt Re p ort F or m will be ret ai ne d i n t he i n vesti gat or si te  file.  
T he i nitial me dical de vice i nci de nt re p ort will be f oll o we d u p wit h m ore i nf or mati o n as rele va nt, 
or as re q u este d b y t he s p o ns or’s st u d y ma na ger.  
T he i n vesti gat or will f oll o w t he f oll o wi n g directi o ns re gar di n g t h e re p orti n g of a de vi ce fail ure 
( m alf u ncti o n):  
• N otif y t he s p o ns or  i m me diatel y ( as  descri be d a b o ve).  
• Sc he d ule t he s u bject t o ret ur n t o site pr o m ptl y t o ret ur n t he faile d de vic e.  
• Rec or d a n y i nci de nts in t he eC R F a n d o n t he I nci d e nt Re p ort F or m (as des cri be d a b o ve ). 
• F or a n y i nci d e nt/ malf u ncti o n occ urri n g wit h a me dical de vic e (i ncl u di n g t h ose t hat are 
part of c o m bi nati o n pr o d ucts) s u p plie d b y t he s p o ns or , r et ur n t he faile d d e vice t o t he 
s p o ns or as s o o n as p ossi ble, i ncl u di n g d oc u me ntati o n of t he details of t he fail ure . 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI P P D 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 6 9  of 1 1 3  • F or a n y i nci d e nt /malf u ncti o n  occ urri n g wit h a me dical de vic e  (i ncl u di n g t h ose t hat are 
part of c o m bi nati o n pr o d ucts)  s u p plie d b y t he in vesti gat or site, re p ort t he i nci de nt t o t he 
de vice ma n ufact ur er  a n d f oll o w t he ma n ufact urer i nstr ucti o n s f or t he ret ur n  of t he faile d 
de vice  ( w hilst ke e pi n g t he s p o ns or  i nf or me d).  
[ADDRESS_116543] u d y.  
T he i n vesti gat or is res p o nsi ble f or e ns uri n g t hat f oll o w -u p i ncl u des a n y s u p ple me ntal 
i n vesti gati o ns as i n dicate d t o el uci date t he nat ur e a n d/ or ca us alit y of t he i nci de nt.  
Ne w or u p date d i nf or mati o n w ill be rec or de d o n t h e ori gi nall y c o m plete d I n ci de nt Re p ort f or m , 
wit h all c ha n ges si g ne d a n d date d b y t he i n vesti gat or.  
[ADDRESS_116544] d ata will be e ntere d 
i nt o a n electr o ni c C R F (e C R F), usi n g a vali date d s yste m. Data relati n g t o S A Es, pre g na nc y a n d 
i nci de nts will als o be c ollecte d o n pa p er f or ms . 
S u bjects will c o m plete pa per c o p ies  of t he D H E Q -4 8  (s o urce) , t he L M Ss  (s o urce) a n d  t he 
Treat me nt Satisfacti o n N R S (s o urce) ; to facilitate s u bject fl o w, p a per f or ms (s o urce) ma y  als o 
be use d t o rec or d cli ni cal  data f or later tra ns cri pti o n i nt o t he eC R F . T ra nscri pti o n of 
D H E Q / L M S / N R S  res p o nses a n d cli nical d ata i nt o t he e C R F m ust be c o m plete d wit hi n [ADDRESS_116545] N u m b er.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116546] be c o m plete d a n d si g ne d b y t he 
in vesti gat or ( or a ut h orize d desi g ne e) t o certif y t hat t he dat a are c o m plete a n d c orrect.  T h e 
i n vesti gat or m ust mai ntai n acc urate d oc u me ntati o n (s o urce d ata) t o  s u p p ort t he i nf or mati o n 
e ntere d i n t he C R F.  
Ma na ge me nt of cli nical data will be perf or me d i n acc or da nc e wit h T hir d Part y B D M Ve n d or 
a p plica ble sta n dar ds a n d data clea ni n g pr oce d ures , wit h o versi g ht b y t he s p o ns or  t o e ns ure data  
i nte grit y  (e. g.,  t o re m o ve err ors a n d i nc o nsiste ncies i n t he data ).  
T o pr otect t he pri vac y of st u d y s u bjects, n o Pers o nal I nf or ma ti o n ( PI) , i ncl u di n g s u bject na me , 
i nitials a n d  birt h date , is t o be rec or de d i n t he C R F or as part of q u er y te xt.  
All C R F pa ges s h o ul d be c o m plete d d uri n g a s u bject assess me nt w he n t he C R F is  t he  desi g nate d 
s o urce.  Data rec or de d else w here s h o ul d be tra nscri be d fr o m t he s o urce d oc u me nt  i nt o t he C R F 
wit hi n [ADDRESS_116547] u d y perf or m a nce.  
Cha n ges a n d  c o rrecti o ns t o data will be perf or me d i n t he Electr o nic Data Ca pt ure ( E D C) S yste m  
w hic h  will i ncl u de a rati o nale f or t he c ha n g e  or c orrecti o n . T h e E D C s yste m has a n a u dit trail 
t o  pr o vi de a c o m plete rec or d of t he c h a n ges a n d c orrecti o ns e n d orse d b y t h e in ves ti gat or.  
A Es  will be c o de d usi n g Me dical Dicti o nar y f or Re g ulat or y A cti vities ( Me d D R A) , a n d 
c o nc o mita nt me dicati o n t er ms (if a p plica ble) usi n g a n i nter nal vali date d m e dicati o n dicti o nar y  
( W H O Dr u g) .   
1 1. 2. 1  D at a Q u eri e s  
Pr o gra m me d e dit c hec ks will be ge nerate d a ut o maticall y as t he data are bei n g e ntere d i nt o t he 
s yste m. Re p orts a n d listi n gs o n t he C R F data will als o be r u n, i n a d diti o n t o t he q ueries alrea d y 
pr o gra m me d a n d ge nerat e d b y t he s yste m, t o raise ma n ual q ueries as nee de d f or i n vesti gat or 
site clarificat i o n or c orrecti o n. T he Cli nical Dicti o nar y De v el o p me nt a n d Ma na ge me nt Gr o u p 
will raise q ueries as nee de d o n safet y data t o c o de t he ter ms ( A Es a n d Dr u gs or c o nc o mita nt 
me dicati o n) a p pr o priatel y.  
T he st u d y m o nit or will perf or m o n g oi n g re vie w of t he C R Fs , in acc or da nce wit h t he m o nit ori n g 
pla n, t o c o nfir m t hat data e ntere d i nt o t he C R F b y a ut h orize d i n vesti gat or site pers o n nel are 
acc urate, c o m plet e, a n d verifia ble fr o m s o urce d oc u me nts; t hat t he safet y a n d ri g hts of 
partici pa nts are bei n g pr otecte d; a n d t ha t t he st u d y is bei n g c o n d ucte d i n acc or da n ce wit h t he 
c urre ntl y a p pr o ve d pr ot oc ol a n d a n y ot her st u d y a gree me nts, I C H G C P a n d all a p plica bl e 
re g ulat or y re q uire me nts.  
Queries g e nerate d i n t h e E D C S yste m will a ut o maticall y be se nt t o t h e i n vesti gat or site , 
ena bli n g err ors t o be a d dresse d i n parallel wit h Data Ma na g e me nt re vie w. T he st u d y m o nit or 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116548] re p orte d o utc o mes will be rec or de d i n p a per -base d  diar ies  a n d  i n q uesti o n naire s 
( D H E Q -4 8 ,  L M Ss  a n d N R S ) f or later tra nscri pti o n i n t o t he e C R F .   
So urce d oc u me nts rec or di n g s u bject -re p orte d  o utc o me s will  be re vie we d b y t he i n ves ti gat or 
staff a n d t he st u d y m o nit or t o  e ns ure t he data , a n d  a n y p ote ntial A Es or c o nc o mita nt me dicati o ns 
re p orte d in t hese d o c u me nts , are acc uratel y tra nscri be d i n t o t he eC R F.    
S u bject re p orte d o utc o mes classe d as s o urce data will be retai ne d b y t he i n vesti gat or ; 
tr ue/certifie d c o pi[INVESTIGATOR_66488] y be se nt t o t he s p o ns or or a t hir d -part y ve n d or , as re q uire d.  T o pr otect 
s u bject  pri vac y , n o PI  (i ncl u di n g s u bject na me , i nitials or birt h date ) is t o be rec or de d in a n y 
s u bject re p orte d o utc o me s o urce d oc u me nt t hat will  be f or war de d t o t he s p o ns or or a t hir d -part y 
ve n d or . 
[ADDRESS_116549] (a p pr o xi matel y 5 5  s u bjects per treat me nt 
gr o u p ) t o e ns ur e a p pr o xi matel y [ADDRESS_116550] u d y (a p pr o xi matel y 5 0  s u bjects  per 
treat me nt gr o u p ), all o wi n g f or a p pr o xi matel y 1 0 % dr o p o ut s. 
T he st u d y will be s ufficie ntl y p o were d t o de m o nstrate statistical s u peri orit y of t he Test 
T o ot h paste c o m pare d t o t he Refere nce T o ot h paste ( ne gati ve  c o ntr ol)  f or t he c ha n ge fr o m 
Baseli ne i n t he Sc hiff se nsiti vit y sc ore  ( pri mar y o bjecti ve)  a n d tactile t hres h ol d ( ke y s ec o n dar y 
o bjecti ve) after 5 6 d a ys ( 8 w ee ks ) treat me nt . A sa m ple siz e of [ADDRESS_116551] 9 0 % p o wer t o detect a mea n differe n ce of 0. 4  u nits ( S D = 
0. 6) i n c ha n g e fr o m Bas eli ne i n Sc hiff se nsiti vit y sc ore after [ADDRESS_116552] wit h a 5 % si g nifica nce le vel.  T he sa m ple size calc ulati o n was perf or me d usi n g 
P A S S s oft ware versi o n [ADDRESS_116553] u dies of si milar 
desi g n a n d d urati o n e val uati n g 0. 4 5 4 % S n F 2 t o ot h pastes (Cli nical St u dies  2 0 5 7 9 4 , 2 0 8 1 5 3  a n d  
2 1 6 9 5 4 : s p o ns or data hel d o n file, a vaila ble o n re q uest ).  
[ADDRESS_116554] recei ve d.  
T he pri mar y p o p ulati o n f or t he assess me nt of efficac y will be  a m o difie d  i nte nti o n -t o -treat 
(mI T T) p o p ulati o n. T h e mI T T  p o p ul ati o n will c o m prise  all ra n d o mize d s u bjects w h o recei v e at 
least o ne d ose of i n vesti gati o nal pr o d uct  a n d c o m plete  at least o ne -p ost Baseli ne D H effi cac y 
assess me nt . T his p o p ulati o n will be base d o n t he i n vesti gati o nal pr o d uct t he s u bject was 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116555] s w h o re cei ve a ra n d o mizati o n n u m ber will be c o nsi dere d  
ra n d o mize d.  
T he P er -Pr ot oc ol ( P P)  p o p ulati o n will c o m prise  all  s u bjects i n t he mI T T p o p ulati o n w h o ha ve 
at least o ne D H effic ac y assess me nt c o nsi dere d t o be u naffecte d b y p r ot oc ol de viati o ns . 
1 2. 2. 2  E x cl u si o n s of D a t a fr o m A n al y si s  
E xcl usi o n of data fr o m a n y  of t he pla n ne d a nal yses will be a gree d d uri n g Bli n de d Data Re vie w 
( B D R) , pri or t o data bas e l oc k. T he  reas o n (s) f or e xcl usi o n of a s u bject fr o m a n a n al ysis 
p o p ulati o n or s pecifi c dat a fr o m a n a n al ysis will be d oc u me nte d  a n d, if a p plica ble, liste d  i n t he 
Cli nical St u d y Re p ort ( C S R) . 
A P P a nal ysis will be perf or me d f or  t he pri mar y e n d p oi nt if ≥ 1 0 % s u bjects i n t he mI T T 
p o p ulati o n are e xcl u de d fr o m t he P P p o p ulati o n. Efficac y data det er mi ne d  t o ha ve bee n 
p ote ntiall y i m pacte d b y a pr ot oc ol de vi ati o n will be e xcl u de d fr o m t he P P a nal ysis.  T h e 
decisi o n s as t o w het h er  or n ot  a pr ot oc ol d e viati o n i m pacts effi cac y data  a n d w het her t o p erf or m 
a P P a nal ysis will be ma de d uri n g  B D R , pri or t o data base l oc k.   
[ADDRESS_116556] atistical a nal yses; t he detail of t h e pr o p ose d statistical 
a nal yses will be d oc u me nte d  i n t he  Statistical A nal ysis Pla n (SA P), t o be writte n f oll o wi n g 
fi nali zati o n of t he pr ot oc ol a n d pri or t o st u d y u n bli n di n g.  
T he mI T T p o p ulati o n will be use d f or all  effic ac y a nal yses.   
All p -val ues prese nt e d will be t w o -si de d a n d assess e d  at t h e 5 % si g nifica nce l e vel . A s e q ue ntial 
testi n g strate g y will be use d t o a dj ust f or t he c o m paris o ns bet wee n t he Test a n d Refere nce 
T o o t h pastes i n c ha n g e fr o m Baseli ne i n Sc hiff se nsiti vit y sc ore a n d tactile t hres h ol d ( g) at eac h 
assess me nt ti me p oi nt . 
At eac h ti me  p oi nt, c ha n g e fr o m Baseli ne i n ta ctile t hres h ol d ( g)  will o nl y be assesse d f or 
c o nfir mat or y e vi de nce if t he c ha n g e fr o m Baseli ne i n Sc hiff s e nsiti vit y sc ore ac hie ves a 
statisticall y si g nifica nt greater re d u cti o n f or t he Test T o ot h paste c o m pare d t o t he  Refere n ce 
T o ot h p aste ( ne gati ve c o ntr ol) . T his strate g y will be gi n at Da y [ADDRESS_116557] T o ot h paste c o m pare d t o t he  Refere nce 
T o ot h paste ( ne gati ve c o ntr ol) f or b ot h Sc hiff se nsiti vit y sc ore a n d tactile t hres h ol d ( g) . T here 
will be n o f urt her a dj ust me nts f or m ulti plicit y f or t he ot her sec o n d ar y e n d p oi nt s ( D H E Q -4 8).  
S u m mar y statistics ( mea n, me dia n, S E, S D, mi ni m u m, ma xi m u m) will be prese nt e d f or eac h  
Sc hiff se nsiti vit y sc ore a n d tactile t hr es h ol d ( g) o ut c o me varia ble at eac h ass ess me nt ti me p oi nt. 
Ra w mea ns ( ± S E) of Sc hiff s e nsiti vit y sc ore  a n d  tactile t hr es h ol d ( g) at eac h assess me nt 
ti me p oi nt will be pl ot te d b y treat me nt gr o u p.  
T he res ults fr o m eac h Mi xe d M o del wit h Re p eate d Meas ures ( M M R M) will be ta b ulate d, 
prese nti n g t he f oll o wi n g i nf or mati o n, i n a d diti o n t o t he res ults s pecifie d f or t he pri mar y a n d 
sec o n dar y a nal yses b el o w: least s q uare mea n c h a n ge fr o m Bas eli ne f or eac h i n vesti gati o nal 
pr o d uct at Da ys 2 8 a n d 5 6 ( base d o n t he o bser ve d stratificati o n mar gi ns f or t h ose M M R M wit h 
a ter m f or ra n d o mize d str ata) a n d use d t o test f or a n y c ha n ge fr o m Baseli ne, wit h t w o -si de d p -
val ues a n d 9 5 % CIs.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116558] u d y is t he c ha n ge fr o m Baseli ne i n Sc hiff se nsiti vit y sc ore at 
Da y 5 6 ( Wee k 8); t he  pri mar y h y p ot hesis test will be t he c o m paris o n bet wee n t he Test 
T o ot h paste a n d t he  Refere nce T o ot h past e ( ne g ati ve c o ntr ol ) i n t he  mI T T p o p ulati o n.  
Sc hiff se nsiti vit y sc ore will be deri ve d as t he me a n sc ore  f or  t he t w o  ‘ Test Teet h’  (select e d at 
Baseli ne). C ha n ge fr o m Baseli ne will be deri v e d f or eac h  i n di vi d ual t o ot h first bef ore 
calc ulati n g me a n c h a n g e f or t he t w o  ‘ Test Teet h’  w here c ha n ge fr o m Baseli ne i n Sc hiff 
se nsiti vit y sc ore at Da y X is defi ne d as [( Sc hiff se nsiti vit y sc ore at Da y X) mi n us ( Bas eli ne 
Sc hiff se nsiti vit y sc ore)] . 
C ha n ge fr o m Basel i ne i n Sc hiff se nsiti vit y sc ore at Da y 5 6 will be a nal yse d usi n g a Mi xe d 
M o del wit h Re peat e d Meas ur es ( M M R M) wit h i n vesti gati o nal  pr o d uct, visit a n d 
[i n vesti gati o nal pr o d uct x visit] i nteracti o n as fi xe d effects, a n d Baseli ne Sc hiff se nsiti vit y sc ore 
as a c o variate. S u bject will be i ncl u de d as a re peate d m eas ur e wit h u nstr uct ure d c o varia nce 
matri x. Ke n w ar d R o gers de grees  of free d o m a p pr oac h will be a p plie d  (K e n war d, 1 9 9 7 ). T he 
differe n ce bet w ee n t he least s q uare mea n c ha n ge s fr o m Baseli ne  f or t he Test T o ot h paste 
c o m pare d t o R efere nce T o ot h paste ( ne g ati ve c o ntr ol) at Da y 5 6  fr o m t he M M R M wi ll be 
prese nte d , al o n g wit h  t he t w o -si de d p -val ue a n d 9 5 % CIs . 
T he ass u m pti o n s of n or malit y  a n d h o m o ge neit y of varia nce i n t he  M M R M will be i n vesti gate d. 
I n case of vi olati o n of t hese ass u m pti o ns, a s uita ble n o n -para metric test (a dj uste d f or t h e 
ra n d o mizati o n  stratifi cati o n) will be perf or me d t o assess t he c ha n g e fr o m B aseli ne c o m paris o n 
(Test T o ot h paste vs.  Refere nce T o ot h paste  at D a y 5 6 ); t he res ults will be pr o vi de d t o s u p p ort 
t he M M R M res ults . 
1 2. 3. 2  S e c o n d ar y  E n d p oi nt  A n al y s e s  
T actile T hres h ol d  at D a y 5 6 : 
Tactile t hres h ol d ( g) will be deri ve d as t he mea n val ue f or  t he t w o  ‘ Test Teet h’  (s elect e d at 
Baseli ne). C ha n ge fr o m Baseli ne will be deri v e d f or eac h  i n di vi d ual t o ot h first bef ore 
calc ulati n g me a n c h a n g e f or t he t w o  ‘ Test Teet h’  w here c ha n ge fr o m Baseli ne i n tactil e 
t hres h ol d ( g) at Da y X is defi ne d as [(tactile t hres h ol d at Da y X) m i n us ( Baseli ne tactile 
t hres h ol d)] . 
T his k e y sec o n dar y e n d p oi nt, c ha n ge fr o m Bas eli ne i n tactile t hres h ol d ( g) at Da y 5 6 , will b e 
a nal yse d usi n g t he sa me M M R M as t he pri mar y e n d p oi nt b ut wit h Baseli ne tactile t hres h ol d  ( g)  
as a c o v ariate  (rat her t ha n Baseli ne Sc hiff se nsiti vit y sc ore ). I n a d diti o n, t he ma xi m u m Baseli ne 
Sc hiff se nsiti vit y sc ore of t he t w o  ‘ Test Teet h’ ( 2 or 3) will be fitte d as a fi xe d effect. T he 
differe n ce bet w ee n t he least s q uare mea n  c ha n ge s fr o m Baseli ne  f or t he Test T o ot h paste 
c o m pare d t o R efere nce T o ot h paste ( ne g ati ve c o ntr ol) at Da y 5 6 fr o m t he M M R M will be 
prese nte d, al o n g wit h t he t w o -si de d p -val ue a n d 9 5 % CIs.  
T actile T hres h ol d / Sc hiff Se nsiti vit y Sc ore  at D a y 2 8 : 
T he ot her sec o n dar y e n d p oi nts : 
• Cha n ge  fr o m Baseli ne i n Sc hiff se nsiti vit y sc ore at Da y 2 8  
• C ha n ge  fr o m Baseli ne i n tactile t hres h ol d ( g) at Da y 2 8  
will be  a nal y se d usi n g t he sa me M M R M m o dels descri be d a b o v e  f or Sc hiff se nsiti vit y sc ore 
a n d tactile t hres h ol d ( g), res pecti vel y.  Differe nces bet we e n t he le ast s q uare mea n c ha n g e s fr o m 
Baseli ne  i n Sc hiff se nsiti vit y sc ore a n d tactile t hres h ol d ( g) will be prese nte d f or t he T est 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 7 4  of 1 1 3  T o ot h paste c o m pare d t o Refere n ce T o ot h paste ( ne gati ve c o ntr ol) at Da y  2 8  fr o m t heir 
res pecti ve M M R Ms,  al o n g wit h t w o -si de d p -val u es a n d 9 5 %  CIs .  
T he ass u m pti o n s of n or malit y a n d h o m o ge neit y of varia nce i n eac h  M M R M will be 
i n vesti gate d. I n case of vi olati o n of t hese ass u m pti o ns, a s uita ble n o n -para metric test (a dj uste d 
f or t he ra n d o mi zati o n stratificati o n  val ue ) will be perf or me d t o assess c ha n ge fr o m Baseli ne  
c o m paris o ns ( T est T o ot h paste vs.  Refere nce T o ot h paste at Da y  5 6  a n d  Da y 2 8 , as a p p r o priate ); 
t he res ults will be pr o vi de d t o s u p p ort t he M M R M res ults .  
D H E Q -4 8 : 
Cha n ge fr o m Baseli ne will be calc ulate d  at Da y 2 8 a n d Da y 5 6  f or all  D H E Q e n d p oi nts .  
• Secti o n  [ADDRESS_116559]  o n Ever y da y Life: Q 7, Q 8 & Q9 (se parate sc ores)  
• Secti o n 2  
- D H E Q T otal Sc ore (s u m of Q 1 -3 4)  
- D H E Q Restricti o ns D o m ai n sc ore (s u m of Q 1 -4)  
- D H E Q A da pt ati o n D o mai n sc ore (s u m of Q 5 -1 6)  
- D H E Q S ocial I m pa ct D o mai n sc ore (s u m of Q 1 7 -2 1)  
- D H E Q E m oti o nal I m pact D o mai n sc ore (s u m of Q 2 2 -2 9)  
- D H E Q I de ntit y D o mai n sc ore (s u m of Q 3 0 -3 4)  
- D H E Q Gl o bal Oral Healt h ( Q 3 5)  
- D H E Q  Effect o n  Lif e Ov erall (s u m of Q 3 6 -Q3 9)  
C ha n ge fr o m Baseli ne will be calc ulate d at t he s u bject -le vel first t he n mea n c ha n ge fr o m 
Baseli ne will be calc ulat e d f or eac h D H E Q e n d p oi nt acr oss all s u bjects.  
Cha n ge fr o m Baseli ne f or  eac h D H E Q  e n d p oi nt liste d a b o ve will be a nal yze d usi n g a M M R M 
wit h ti me p oi nt a n d ma xi m u m Baseli ne Sc hiff se nsiti vit y sc ore of t h e t w o ‘ Test Teet h’  ( 2 or 3) 
as fi xe d effect s, a n d t he res pecti ve Baseli ne D H E Q sc ore as c o vari ate . S u bject  will be i ncl u de d 
as a re peate d meas ur e wit h u nstr uct ure d c o varia nce matri x. Ke n w ar d -R o gers de grees of 
free d o m will be a p plie d. T he esti mate s of t he a dj uste d mea n ( S E) c h a n ge fr o m Baseli ne will be 
prese nte d al o n g wit h 9 5 % C Is f or eac h treat me nt gr o u p . 
F or eac h  D H E Q e n d p oi nt  liste d a b o ve , a n d eac h i n di vi d ual D H E Q q uesti o n, t he val ue  at eac h 
ti me p oi nt ( Baseli ne , Da y 2 8 a n d Da y 5 6 ) a n d t h e c orres p o n di n g c h a n ge fr o m Baseli ne will be 
s u m marize d des cri pti vel y  f or eac h tr eat me nt gr o u p . Ra w mea ns ( ± S E) f or eac h D H E Q 
e n d p oi nt, a n d t he i n di vi d ual D H E Q q uesti o ns,  at eac h assess me nt ti me p oi nt will be pl otte d b y 
treat me nt gr o u p.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116560] or at or y  A n al y s e s  
N u m ber of ‘Se nsiti ve Teet h ’: 
T he n u m ber of teet h se nsiti ve t o a n e va p orati ve (air) sti m ul us i n t he p o ol of ‘ Eli gi ble Teet h’ 
i de ntifie d at Scree ni n g will be m o nit ore d acr oss t he st u d y peri o d. F or t his p ur p ose, a ‘ Se nsiti ve 
T o ot h’ will be defi ne d as ha vi n g a Sc hiff se nsiti vit y sc ore  ≥ 2.  
‘ Eli gi ble Teet h’ = Teet h wit h n o de ntiti o n excl usi o ns w hic h meet E A R, M GI a n d m o bility i ncl usi o n criteri a, a n d 
h ave a Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d  a Scree ni n g  Sc hiff se nsitivity sc ore ≥ 2.  
T he n u m ber of ‘ Se nsiti ve Teet h’  (i.e., t he n u m ber of ‘ Eli gi ble Teet h’  wit h Sc hiff se nsiti vit y 
sc ore ≥ 2) will be calc ulate d at Scree ni n g, Bas eli ne, Da y 2 8 a n d Da y 5 6 .  
• At Scree ni n g, t he n u m ber of ‘ Se nsiti ve Teet h’ will be e q u al t o t he n u m b er of  ‘Eli gi ble 
Teet h ’ (as descri be d i n Secti o n 8. 1. 5 ).  
‘ Eli gi ble Teet h’ = Teet h wit h Scree ni n g  t actile t hres h ol d ≤ 2 0 g a n d Scree ni n g  Sc hiff se nsitivity 
sc ore  ≥ 2.  
• At Baseli ne, Da y 2 8 a n d Da y 5 6, all  ‘Eli gi ble Teet h ’ will be teste d f or e va p orati ve (air) 
se nsiti vit y . T he n u m ber of ‘ Se nsiti ve Teet h’ will be t he n u m ber of ‘Eli gi ble Teet h ’ wit h 
a Sc hiff se nsiti vit y sc ore ≥ 2  at t hat visit . 
Su m mar y statistics ( m ea n, me dia n, S E, S D, mi ni m u m, ma xi m u m ) will be pres e nte d at eac h 
assess me nt ti me p oi nt f or eac h treat me nt gr o u p . F or eac h s u bject, t he Sc hiff se nsiti vit y sc ore of 
eac h ‘eli gi ble t o ot h’ at eac h ti me p oi nt  will be liste d  b y  treat me nt gr o u p.  Mea n ( ± S E) n u m ber 
of ‘ Se nsiti ve Teet h’ will be pl otte d b y treat me nt gr o u p  
L a belle d M a g nit u de Sc ales ( L M Ss) : 
Cha n ge fr o m Baseli ne will be calc ulate d  at Da y  2 8 a n d Da y 5 6 f or eac h  L M S  e n d p oi nt.  
• I nte nsity  
• D ur ati o n  
• T oler a bility  
• Descri pti o n  
L M S data will be a nal yse d  f or t he t w o ‘ Test Teet h’ o nl y . C ha n ge fr o m Baseli ne will be deri ve d 
f or eac h ‘ Test T o ot h ’ first bef ore calc ul ati n g mea n c ha n g e f or t he t w o ‘ Test Teet h’  f or eac h 
s u bject.  
C ha n ge fr o m Baseli ne f or eac h L M S e n d p oi nt liste d a b o ve will be a nal yze d usi n g a M M R M 
wit h ti me p oi nt a n d ma xi m u m Baseli ne Sc hiff se nsiti vit y sc ore of t he t w o test teet h ( 2 or 3) as 
fi xe d effect s, t he res pecti ve Baseli ne L M S  val u e  as a c o v ariate a n d s u bjec t as a re peate d 
meas ure  wit h u nstr uct ur e d c o vari a nce m atri x. K e n war d -R o gers de grees of free d o m will be 
a p plie d. T he esti mate s of t he a dj uste d mea n ( S E) c ha n ge fr o m Bas eli ne will be prese nt e d al o n g 
wit h 9 5 % C Is f or eac h tr eat me nt gr o u p . 
F or eac h  L M S  e n d p oi n t liste d a b o ve, t h e v al ue  (i n m m)  at eac h ti me p oi nt ( Baseli ne, Da y 2 8 
a n d Da y 5 6 ) a n d t he c orres p o n di n g c h a n ge fr o m Baseli ne (i n m m) will be s u m marize d 
descri pti vel y  f or eac h tr eat me nt gr o u p . Ra w me a ns ( ± S E) f or eac h L M S  e n d p oi nt, at eac h 
assess me nt ti me p oi nt , will be pl otte d b y treat me nt gr o u p.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 7 6  of 1 1 3  D H E Q -4 8 a n d L a belle d M a g nit u de Sc ales ( L M Ss) Rel ati o ns hi p : 
T he rel ati o ns hi p bet wee n s u bject res p o ns es t o t he D H E Q -4 8  a n d t h e f o ur L M S s will be 
i n vesti gate d . F or eac h D H E Q d o mai n  ( Restricti o ns, A da ptati o n, S ocial I m pa ct, E m oti o nal 
I m pa ct, I de ntit y) , eac h  L M S e n d p oi nt (I nte nsit y, D urati o n, T olera bilit y, Descri pti o n)  will be 
pl otte d a gai nst d o mai n sc ore at eac h ass ess me nt ti me p oi nt ( Baseli ne, 2 8 a n d 5 6 da ys). A matri x 
of c orrelati o n pl ots will be pres e nte d f or eac h d o mai n.  S pear ma n’s c orrel ati o n c oefficie nt will 
be calc ulate d al o n g wit h t he ass ociate d p -val ue a n d prese nte d wit h its res pecti ve c orrelati o n 
pl ot.  
Sc hiff Se nsiti vit y Sc ore a n d L a belle d M a g nit u de Sc ales ( L M Ss) Rel ati o ns hi p : 
T he rel ati o ns hi p bet wee n Sc hiff se nsiti vit y sc ore a n d t he f o ur L M Ss will be i n vesti gate d. Sc hiff 
se nsiti vit y sc ore ( mea n sc ore of  t he t w o ‘ Test Teet h’)  a n d t he f o ur L M S e n d p oi nts ( I nte nsity, 
D ur ati o n, T oler a bility, Descri pti o n ) will be pl otte d at eac h assess me nt ti m e p oi nt ( Baseli ne, 2 8 
a n d 5 6 da ys) i n a matri x of c orrelati o n pl ots. S pear ma n’s c orrel ati o n c oeffi cie nt will be 
calc ulate d al o n g wit h t he ass o ciate d p -v al ue a n d prese nte d wit h its res pecti ve c orrelati o n pl ot.  
S atisf acti o n wit h Tre at me nt N R S  
A s u m mar y  of t he n u m b er of s u bjects re p orti n g at eac h le v el of t he N R S a n d t he c u m ulati ve 
n u m ber of s u bjects re p orti n g at eac h l e vel or hi g h er at D a y 5 6 ( Wee k 8) will be prese nte d , a n d 
t he  N R S sc ore at D a y 5 6 ( Wee k 8) will be s u m marize d descri pti vel y , b y treat me nt gr o u p .  
S u bject free t e xt c o m me nts will be liste d  b y treat me nt gr o u p . 
[ADDRESS_116561] 
recei v e d. A Es will be re g ar de d as ‘treat me nt e mer ge nt’ if t he y o cc ur o n or after t h e first use of 
i n vesti gati o nal pr o d uct at Baseli ne ( Visit 2).  I n t he e ve nt o f a missi n g start date, a n  A E will be 
ass u me d t o be ‘treat me nt e mer g e nt’ u nless t he e n d date is pri or t o starti n g tr eat me nt . I n  cas e of 
misall ocati o n, c o m pare d t o t he ra n d o mizati o n  sc he d ule, T E A Es will be ass ociate d wit h t h e 
m ost rece nt st u d y i n vesti gati o n al recei ve d.  
Eac h A E will b e cate g orize d as oral or n o n -oral b y t he i n vesti gat or or me dicall y q ualifie d 
desi g nee. All will be re vie we d b y t he C R S  a n d c o de d usi n g t he Me d D R A  pri or t o data base l oc k 
a n d u n bli n di n g .  
A listi n g of all A Es will b e pres e nte d f or all s u bjects i n t he Safet y p o p ulati o n wit h t he f oll o wi n g 
A E s u m maries ( n u m ber of disti nct A Es a n d fre q ue nc y/ pr o p orti o n of s u bjects affect e d) 
prese nte d b y  tr eat me nt  gr o u p  a n d o verall :  
• T E A Es   
• T E A Es  b y S yste m Or ga n Class ( S O C) a n d Preferre d Ter m ( P T)  
• T E A Es  b y Oral/ N o n -Oral a n d P T  
• Treat me nt e mer ge nt treat me nt relate d A Es b y Oral/ N o n -Oral a n d P T  
• Treat me nt  e mer ge nt treat me nt relate d seri o us A Es b y  S O C  a n d P T  
Se parate listi n gs will be prese nte d f or:  
• Dea t hs, S A Es a n d a n y A Es lea di n g t o pr o d uct or st u d y disc o nti n uati o n.  
• O S T fi n di n gs ( wit h a s u m mar y of a b n or malities b y visit)  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 7 7  of 1 1 3  • O H T  fi n di n gs  ( wit h a s u m mar y of c ha n g es b y visit)  
• E x p os ure  t o st u d y pr o d u ct  (Secti o n 1 2.3. 6. 1 .) 
Me dical de vi ce i n ci de nts will be liste d; if t here are n o i nci de nts, a n ull listi n g will be pr o d uce d.  
W hile n o s pecific ris ks or a ntici pate d a d vers e d e vice effects are e x p ect e d fr o m use of t he 
me dical de vice ( ma n u al t o ot h br us h) pr o vi de d , a n y me dical de vice i nci de nts re p orte d d uri n g t he 
c o n d uct of t his st u d y will be assesse d t o e v al uate t he safet y of t h e de vic e . 
[ADDRESS_116562] eri sti c s  
De m o gra p hic a n d Baseli ne c haracteristics will be s u m mari ze d b y treat me nt gr o u p f or t he Safet y 
a n d mI T T p o p ulati o ns  (a n d f or t he P P p o p ulati o n , if a P P a nal ysis is perf or m e d ) usi n g 
descri pti ve statistics . 
Cate g orical v aria bles (s uc h as s e x , race , et h ni cit y  a n d Baseli ne Sc hiff se nsiti vit y sc ore 
stratificati o n val ue ) will be s u m mari ze d b y t he n u m ber a n d p erce nta ge of s u bjects wit h eac h 
rele va nt c h aracteristic i n eac h treat me nt  gr o u p. C o nti n u o us varia bles s uc h as (a ge) will be 
s u m mari ze d b y mea n, S D , me dia n, mi ni m u m a n d ma xi m u m val ues i n eac h treat me nt  gr o u p . 
[ADDRESS_116563] use ( n u m ber of br us hi n gs) will be liste d a n d 
s u m marize d f or t he mI T T p o p ulati o n at eac h visit, a n d c u m ulati vel y f or t he e ntire  treat me nt 
peri o d (f or m ost s u bjects t h is will be a p pr o xi matel y 8 wee ks) b y tr eat me nt  gr o u p.  
N u m ber of e x p ecte d br us hi n gs =  2 × Nu m ber of da ys bet w ee n Visit  [ADDRESS_116564] ual br us hi n gs      =  (N u m ber of e x pecte d br us hi n gs ) – ( N u m ber of miss e d  
br us hi n gs ) + ( N u m ber of a d diti o nal b r us hi n gs ) 
% C o m pli a nce at ‘ Visit X’ =   ( N u m ber of act ual br us hi n gs pri or t o Visit  X)     x 1 0 0  
(Nu m ber of e x pect e d br us hi n gs  pri or t o Visit X ) 
1 2. 3. 6. 2  Pri or a n d C o n c o mit a nt M e di c ati o n s  
Pri or me dicati o ns / n o n -dr u g t hera pi[INVESTIGATOR_014]  a n d  c o n c o mita nt me dicati o ns /si g nifica nt n o n -dr u g 
t hera pi[INVESTIGATOR_104895] k e n d uri n g t he st u d y will be liste d f or t he Safet y p o p ulati o n . 
[ADDRESS_116565] o p o ut s a n d Mi s si n g D at a  
M M R M a nal yses acc o u nt f or missi n g data usi n g  ‘a missi n g at ra n d o m ’ ass u m pti o n, i.e., t here 
is a s yste matic relati o ns hi p bet wee n t he pr o pe nsit y f or  missi n g val ues a n d t he o bser ve d data, 
b ut n ot t he missi n g data.  
U n der s uc h ass u m pti o ns, M M R M is s h o w n t o pr o vi de u n biase d esti mates of t he treat me nt effect 
w hilst a nal ysis of o nl y c o m plete cases usi n g a n a l ysis of c o v aria nce ( A N C O V A)  is  bias e d 
(As h bec k,  2 0 1 6 ; Bar o n, 2 0 0 8 ).  
S uc h c o m plete case a nal ysis re q uires a ‘ missi n g c o m pletel y at ra n d o m’ ass u m pti o n t o re mai n 
u n biase d a n d t his is u nli kel y t o h ol d, i.e.,  t he fact t hat t he data are missi n g is i n de pe n de nt of t he 
o bser ve d a n d u n o bs er ve d data .  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116566] wit h si milar n o n -missi n g res ults at ot her 
ti me p oi nts ( Baseli ne a n d t he ot her p ost -Baseli ne  assess me nt visit s).  
[ADDRESS_116567] u d y . 
1 3  S T U D Y G O V E R N A N C E C O N SI D E R A TI O N S  
1 3. 1  Q u alit y C o ntr ol  
I n acc or da nce wit h a p plica ble re g ulati o ns  (i ncl u di n g G C P ) a n d s p o ns or  pr oce d ures, t he s p o ns or  
or desi g nee (i.e. , t hir d -p art y ve n d or) m o nit ors will c o ntact t he i n vesti gat or site pri or t o t he start 
of t he st u d y t o re vie w t he pr ot oc ol, st u d y re q uire me nts  a n d  site  res p o nsi bilities t o satisf y 
re g ulat or y, et hical a n d s p o ns or  re q uire m e nts  wit h t he st u d y  staff .  
W he n re vie w i n g data c ollecti o n pr oce d ures, t he disc ussi o n will i ncl u de i de ntificati o n, 
a gree m e nt a n d d oc u me ntati o n of data ite ms f or w hic h t he eC R F will ser ve as t he s o ur ce 
d oc u me nt.  
T he s p o ns or  or desi g ne e will m o nit or t he st u d y a n d site acti vit y t o verif y t hat:  
• Dat a are a ut he ntic, acc urate, a n d c o m plete.  
• T he s afet y a n d ri g hts of s u bjects are b ei n g pr otect e d.  
• T he s t u d y is c o n d ucte d i n acc or da n ce wit h t he c urre ntl y a p pr o ve d pr ot oc ol , a n y ot her 
st u d y a gree me nts, G C P a n d all a p plica ble re g ulat or y re q uire m e nts.  
T he e xte n t a n d nat ur e of m o nit ori n g will be descri be d i n a writte n m o nit ori n g pla n hel d o n file 
b y t he s p o ns or . T he i n vesti gat or ( or desi g nee) a grees t o all o w t he m o nit or direct access t o all 
rele va nt d o c u me nts a n d a grees t o c o -o perate wit h t he m o nit or t o e ns ure t h at a n y pr o ble ms 
detecte d d uri n g  t hes e m o nit ori n g visits are res ol ve d.  
[ADDRESS_116568] a q ualit y ass ura n ce assess me nt a n d/ or a u dit of t he i n vesti gat or site r ec or ds ; re g ul at or y 
a ge ncies ma y c o n d u ct a re g ulat or y i ns pe cti o n at a n y ti me d uri n g or aft er c o m pleti o n of t he 
st u d y.  
I n t he e v e nt of a n assess me nt, a u dit or i ns pe cti o n, t he i n vesti gat or m ust a gree t o gra nt a d vis ors, 
a u dit ors a n d i ns pe ct ors direct access t o  all rele v a nt d oc u me nts a n d t o all ocat e t heir ti me a n d t h e 
ti me of t heir staff t o disc uss t he c o n d uct of t he st u d y, a n y fi n di n gs/rele va nt iss ues a n d t o 
i m ple me nt a n y c orrecti ve a n d/ or pre v e ntati ve acti o ns t o a d dress a n y fi n di n gs/iss ues i de ntifie d.  
T he i n ve sti gat or will n otif y t he s p o ns or  or its a ge nts i m me diatel y of a n y re g ulat or y i ns pecti o n 
n otificati o n i n relati o n t o t he st u d y. F urt her m ore, t he i n vesti gat or will c o o perat e wit h t he 
s p o ns or  or its a g e nts t o pre pare t he i n vesti gat or site f or t he i ns pecti o n a n d will all o w t he s p o ns or  
or its a ge nt, w he n e ver feasi ble, t o b e prese nt d uri n g t he i ns pe cti o n. T h e i n vesti gat or will 
pr o m ptl y s u p pl y c o pi[INVESTIGATOR_1309] t he i ns pecti o n fi n di n g s t o t he s p o ns or  or its a ge nt. Bef ore res p o ns e 
s u b missi o n t o t he re g ulat or y a ut h orit y, t he i n vesti gat or will pr o vi de t he s p o ns or  or its a ge nts 
wit h o p p ort u nit y t o re vie w a n d c o m me nt o n res p o nses t o a n y s uc h fi n di n gs.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 7 9  of 1 1 3  T he s p o ns or will be a vail a ble t o hel p t he i n vesti gat or pre pare f or a n i ns pecti o n.  
1 3. 3  R e g ul at or y a n d Et hi c a l C o n si d er ati o n s  
1 3. 3. 1  I n stit uti o n al R e vi e w B o ar d  (I R B)   
It is t he res p o nsi bilit y of t he i n vesti gat or t o ha v e pr os pecti ve a p pr o val of t he st u d y pr ot o c ol, 
pr ot oc ol a me n d me nts, t h e I C F , t h e I B  a n d/ or safet y state me nt (i ncl u di n g a n y u p dates) , a n d ot her 
rele va nt d o c u me nts  (e. g. , recr uit me nt a d vertise m e nts , diaries) , as  a p plica bl e, fr o m t he I R B.  All 
c orres p o n d e nce wit h t he I R B s h o ul d be ret ai ne d i n t he i n v esti gat or site file. C o pi[INVESTIGATOR_1309] I R B 
a p pr o vals s h o ul d be f or war de d t o t he s p o ns or  pri or t o t he i nitiati o n of t he st u d y, a n d 
s u bse q ue ntl y f or a n y pr ot oc ol  a me n d me nt s. 
T he o nl y circ u msta n ce i n w hic h a n a me n d me nt ma y be i nitiate d pri or t o I R B a p pr o val is w here 
t he c ha n g e is n ecess ar y t o eli mi nate a p p are nt i m me diate hazar ds t o t he s u bjects.  I n t hat e v e nt, 
t he i n vesti gat or  m ust n otif y t he I R B a n d t he s p o ns or  i n writi n g i m me diatel y after 
i m ple me ntati o n.  
[ADDRESS_116569] u d y will be c o n d u cte d i n acc or da n ce wit h t he pr ot oc ol a n d a p plica ble l ocal re g ul at or y 
re q uire me nts  a n d la ws , as well as t he ge neral pri nci p les set f ort h i n t he I nter nati o nal Et hical 
G ui deli nes f or Bi o me dical Researc h I n v ol vi n g H u ma n S u bjects ( C o u ncil f or I nter nati o nal 
Or ga nizati o ns of Me di cal Scie nces 2 0 0 2), I nt er nati o nal Et hical G ui deli nes f or Healt h -Rel ate d 
Researc h I n v ol vi n g H u ma ns ( C o u nci l f or I nter nati o nal Or ga ni zati o ns of Me dical Scie nces, 
2 0 1 6) , G ui deli nes  f or G C P ( I C H T o pic E 6 ( R 2) G ui deli ne f or G o o d Cli nical Practice, N o v 
2 0 1 6 ), a n d t he Declarati o n of Helsi n ki ( W orl d Me dical Ass ociati o n, 6 4t h Ge neral Asse m bl y, 
F ortale za 2 0 1 3 ). I n a d di ti o n, t he st u d y will be c o n d ucte d i n acc or da n ce wit h a p plica ble me dical 
de vice  re g ulati o n s. 
[ADDRESS_116570]’s n u merical c o de t o t heir  act ual i de ntit y. I n case of data tra nsf er, t he 
s p o ns or will mai ntai n hi g h sta n dar ds of c o nfi de nti alit y a n d pr otecti o n of s u bjects’ pers o n al data 
c o nsiste nt wit h a p plica ble pri vac y la ws.  
I nf or me d c o nse nt d oc u me nts m ust be i n c o m plia n ce wit h I C H G C P , l ocal re g ulat or y 
re q uire me nts (i ncl u di n g a p plica ble l ocal me dical de vice re g ulati o ns) a n d le gal re q uire me nts  
(i ncl u di n g a p plica ble pri vac y la ws ). All  d oc u m e nts use d d uri n g t he i nf or me d c o nse nt pr ocess 
m ust be re vie we d a n d a p pr o ve d b y t he s p o ns or, a p pr o ve d b y t he I R B bef ore use, a n d a vaila bl e 
f or i ns pecti o n.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116571]'s i nf or me d c o ns e nt si g ne d d oc u me nt (s) . 
[ADDRESS_116572] R e cr ui t m e nt  
A d vertis i n g materials  a p pr o ve d b y t he I R B a n d t he i n vesti gat or ’s  data base ma y be use d t o 
recr uit  st u d y s u bject s.   Use of a n I R B  a p pr o ve d  pre -scree ni n g q uesti o n nair e t o assess ge neral 
s uita bilit y  (basic s u bject c haracteristics ) f or t h e st u d y is  per mi tte d . T his  ge neric q uesti o n nair e 
ma y be use d as a p h o ne s cri pt a n d/ or t o re vi e w i nter nal data b ases t o i de ntif y p ote ntial s u bjects.   
T he s p o ns or will ha ve a n o p p ort u nit y t o re vie w a n d a p pr o ve t he c o nt e nt of a n y recr uit me nt 
materials bef ore s uc h m aterials are s u b mitte d f or I R B re vie w a n d  use d  t o i de ntif y  p ote ntial 
st u d y s u bjects .  
[ADDRESS_116573] u dies.  
I n t he e ve nt of a n y pr o hi biti o n or restricti o n i m p ose d (i.e., cli nical h ol d) b y a n a p plica bl e 
c o m pete nt a ut h orit y i n a n y area of t he w orl d, or if t he i n vesti gat or is a ware of a n y ne w 
i nf or mati o n t hat mi g ht i nfl ue nce t he e val uati o n of t he be n efits a n d ris ks of t he i n vesti gati o nal 
pr o d uct (s) , t he s p o ns or s h o ul d be i nf or me d i m me diatel y.  
I n a d diti o n, t he i n vesti gat or will  i nf or m t he s p o ns or i m me diatel y of a n y ur ge nt safet y me as ures 
ta ke n b y t he i n vesti gat or t o pr otect t he st u d y s u bjects a gai nst a n y i m me diate hazar d, a n d of a n y 
seri o us breac hes of t his pr ot oc ol or of I C H G C P t hat t he i n vesti gat or bec o m es a ware of.  
[ADDRESS_116574] u d y s u bjects, as a p pr o priate.   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116575] u d y rec or ds (e x ce pt f or 
t h ose re q uire d b y l oc al re g ulati o ns t o be mai ntai ne d else w here) i n a s afe a n d sec ure l o cati o n.   
Rec or ds ( i n vesti gat or site file) m ust be mai ntai ne d i n s uc h a wa y t o all o w eas y a n d ti mel y 
retrie val w h e n nee d e d (e. g. , f or s p o ns or a u dit or re g ulat or y i ns pecti o n) a n d m ust be a vaila ble 
f or re vie w i n c o nj u ncti o n wit h assess me nt of t he facilit y, s u p p orti n g s yste ms a n d rele va nt 
i n vesti gat or site staff.  
W here per mitte d b y l ocal la ws/re g ulati o ns or i nstit uti o nal p olic y, s o me or all of t hes e rec or ds 
ca n be mai ntai ne d i n a f or mat ot her t ha n har d c o p y (e. g. , micr ofic h e, sca n ne d, ele ctr o nic); 
h o we ver, ca uti o n n ee ds t o be e x ercise d bef ore s u c h acti o n is ta ke n. T he i n v esti gat or m ust e ns ure 
t hat all re pr o d ucti o ns are le gi ble , are a tr u e a n d acc ura te c o p y of t he ori gi nal a n d meet 
accessi bilit y a n d retri e v al sta n dar ds, i ncl u di n g re -ge n erati on of  a h ar d c o p y, if re q uire d.  
F urt her m ore, t he i n v esti gat or m ust e ns ure t here is a n acce pta bl e bac k -u p of t hese re pr o d ucti o ns 
a n d t hat a n acce pta bl e q u alit y c o n tr ol pr ocess e xists f or ma ki n g t hese re pr o d ucti o ns.  
T he i n vesti gat or m ust ass ure t he s u bject’s a n o n y mit y will be mai ntai ne d. In C R Fs or ot her 
d oc u me nts s u b mitte d t o t he s p o ns or , s u bjects s h o ul d n ot be i de ntifie d b y t heir na mes or i nitials, 
b ut b y a n i de nti ficati o n c o de. T he i n vesti gat or s h o ul d kee p a se parate l o g of s u bjects’ c o des, 
na mes a n d a d dresses.  D oc u me nts n ot f or s u b missi o n t o t he s p o ns or ( e. g. , s u bject si g ne d  c o nse nt 
f or ms ) s h o ul d be mai ntai ne d b y t he i n vesti gat or i n strict c o nfi de nce.  
Rec or ds a n d  d oc u me nts, i ncl u di n g si g ne d I C F s, p ertai ni n g t o t he c o n d uct of t his st u d y m ust b e 
retai ne d b y t he i n vesti gat or as per t he si g ne d c o ntract ual a gree me nt, fr o m t he iss ue of t he fi nal 
C S R or e q ui vale nt s u m mar y,  u nless l ocal re g ulati o ns or i nstit uti o nal p olici es re q uire a l o n ger 
rete nti o n peri o d. T he mi ni m u m rete nti o n ti me will meet t he strictest sta n dar d a p plica ble t o t hat 
i n vesti gat or site f or t h is  st u d y, as dictate d b y a n y i nstit uti o nal re q uire me nts or l oc al la ws or 
re g ulati o ns, s p o ns or sta n dar ds/ pr oce d ures,  a n d/ or i nstit uti o nal re q uire me nts.   
N o st u d y d oc u me nt s h o ul d be d estr o ye d wit h o ut a pri or writte n a gree me nt b et wee n t he s p o ns or  
a n d t he i n vesti gat or. T h e i n vesti gat or m ust n otif y t he s p o ns or  of a n y c ha n ges i n t he arc hi val 
arra n g e me nts i ncl u di n g, b ut n ot li mite d t o, arc hi val at a n off -site facilit y or tra nsf er of 
o w ners hi p of t he rec or ds i n t he e ve nt t he i n vesti gat or is n o l o n ger ass ociate d wit h t he 
i n vesti gat or site.  
[ADDRESS_116576] all partici pati n g s u bjects  a n d s h o ul d ass ur e 
a p pr o priate t hera p y/f oll o w -u p f or t he s u bjects.  As directe d b y t he s p o ns or , all st u d y materials 
m ust be c ollecte d a n d all C R Fs  c o m plete d t o t he greatest e xte nt p ossi ble. W here re q uire d b y 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 2  of 1 1 3  t he a p plica ble re g ulat or y re q uire me nts, t he s p o n s or  s h o ul d i nf or m t he re g ul at or y a ut h orit y(ies) 
a n d t he i n vesti gat or s h o ul d pr o m ptl y i nf or m t he I R B a n d pr o vi d e t he I R B a det aile d writte n 
e x pla nati o n f or  t he t er mi nati o n or s us pe nsi o n.  
If t he I R B ter mi nates or s us pe n ds its a p pr o val/fa v ora ble o pi [INVESTIGATOR_9384] o n of the st u d y , t he i n vesti gat or 
s h o ul d pr o m ptl y n otif y t he s p o ns or a n d pr o vi de t he s p o ns or  wit h a detaile d writte n e x pla nati o n 
f or  t he ter mi nati o n or s us pe nsi o n.  
U p o n c o m pleti o n or pre mat ure disc o nti n uati o n of t he st u d y, t he s p o ns or’s m o nit or will c o n d uct 
site cl os ure acti vities wit h t he i n vesti gat or a n d  site staff, as a p pr o priat e, i n acc or da nce wit h 
a p plica ble re g ulati o ns , i ncl u di n g G C P a n d s p o ns or  Sta n dar d O perati n g Pr oce d ures.  
1 4  R E F E R E N C E S  
[A bsi  E G, A d d y M, A d a ms D ( 1 9 8 7)] D e nti ne h y perse nsiti vit y: A st u d y of t he p ate nc y of 
de nti nal t u b ules i n se nsiti ve a n d n o n -se nsiti ve cer vical de nti ne. J Cli n Peri o d o nt ol 1 9 8 7; 1 4( 5): 
2 8 0 -2 8 4.  
[A d d y  M, M ostafa P, A bsi E , et al.,  e dit ors ( 1 9 8 5)]  Cer vical de nti n h y perse nsiti vit y: Eti ol o g y 
a n d ma na g e me nt wit h partic ular refere n ce t o de ntifrices. Pr ocee di n gs of S y m p osi u m o n 
H y perse nsiti ve De nti n: Ori gi n a n d Ma na ge m e nt 1 9 8 5: U ni versit y of Mic hi ga n.  
[A d d y  M, M ostafa  P, Ne wc o m be  R G ( 1 9 8 7)] De nti ne h y pers e nsiti vit y: t he distri b uti o n of 
recessi o n, se nsiti vit y a n d pla q ue. J De nt 1 9 8 7; 1 5( 6): 2 4 2 -2 4 8.  
[A d d y  M. ( 2 0 0 0)] D e nti ne h y perse nsiti vit y: defi niti o n, pre v ale nce, distri b uti o n a n d 
aeti ol o g y.  T o ot h wear a n d se nsiti vit y: Cli nical a d va nces i n rest orati ve de ntistr y.  L o n d o n: 
Marti n D u nitz  2 0 0 0: 2 3 9 -2 4 8.  
[A d d y , M ( 2 0 0 2)] De nti ne h y perse nsiti vit y : Ne w pers pecti ves o n a n ol d pr o ble m. I nt D e nt J 
2 0 0 2; 5 2: 3 6 7 -3 7 5.  
[A g h az a de h  Z, Be hr o ozia n A, N ajafi H , et al. ( 2 0 1 9 )]  C o m paris o n of gi n gi val a n d de ntal 
i n dices i n lactati n g a n d n o n -lactati n g m ot hers d uri n g first 6 m o nt h after deli ver y. Pes q ui Bras 
O d o nt o pe diatria Clí n I nt e gr 2 0 1 9; 1 9:  e 4 5 8 6 . 
[A mi ni  P, Kl u k o ws ka M, E use bi o R, et al. ( 2 0 1 9)] A nti -Se nsiti vit y Efficac y of Bi oa vaila bl e 
Sta n n o us Fl u ori de De ntifrice vs. Ne g ati ve C o nt r ol ( A bstract # 2 3 2 2). I A D R. Va nc o u v er, 
Ca na da.  
[As h bec k  E L, Bell M L. ( 2 0 1 6)] Si n gle ti me p oi nt c o m paris o ns i n l o n git u di nal ra n d o mize d 
c o ntr olle d trials: p o wer a n d bias i n t he prese nce of missi n g data. B M C Me d Res Met h o d ol 2 0 1 6; 
1 6: 4 3.  
[B a d a d he  S, Ga n gar de G, et al. ( 2 0 2 3)] I m pa ct of a nti -se nsiti vit y t o ot h paste o n oral healt h. 
W orl d J P har m Res 2 0 2 3; 1 2( 7): 1 0 4 3 -1 0 6 0.   
[B ae  J H, Ki m Y K, M y u n g S K ( 2 0 1 5)] Dese nsitizi n g t o ot h paste vers us place b o f or d e nti n 
h y perse nsiti vit y: A s yste matic re vie w a n d m et a -a nal ysis. J Cli n Peri o d o nt ol 2 0 1 5; 4 2( 2): 1 3 1 -
1 4 1.  
[B a ker  S R, Gi bs o n BJ, S ufi F, et al. ( 2 0 1 4)] T he de nti n h y perse nsiti vit y e x perie nce 
q uesti o n naire ( D H E Q): A l o n git u di nal vali dati o n st u d y. J Cli n Peri o d o nt ol 2 0 1 4; 4 1: 5 2 -5 9. 
d oi: 1 0. 1 0 1 6/ B 9 7 8 0 -1 2 -8 0 1 6 3 1 -2. 0 0 0 0 9 -9.  
[B ar o n  G, Ra va u d P, Sa ms o n A, et al. ( 2 0 0 8)] Missi n g data i n ra n d o mize d c o ntr olle d trials of 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 3  of 1 1 3  r he u mat oi d art hritis wit h ra di o gra p hic o utc o m es: A si m ulati o n st u d y. Art hritis R he u m -Art hritis 
Care Res 2 0 0 8; 5 9: 2 5 -3 1.  
[B art ol d  P M. ( 2 0 0 6)] De nti n al h y perse nsiti vit y: a re vie w. A ust D e nt J 2 0 0 6; 5 1( 3): 2 1 2 -2 1 8.  
[B aş ar a n  S, Celi k C. ( 2 0 1 8)] T ur kis h a d a ptati o n of de nti n h y p erse nsiti vit y e x perie nce 
q uesti o n naire ( D H E Q). C o m m u nit y De nt Healt h 2 0 1 8; 3 5( 1): 4 7 -5 1.  
[B oi k o  O V, Ba ker S R, Gi bs o n BJ, et al. ( 2 0 1 0)]  C o nstr ucti o n a n d vali dati o n of t he q ualit y of 
life meas ure f or de nti n h y perse nsiti vit y ( D H E Q). J o ur nal of cli nical peri o d o nt ol o g y. 2 0 1 0; 
3 7( 1 1): 9 7 3 -98 0.  
[Br ä n nstr ö m  M ( 1 9 6 3)] A h y dr o d y na mic mec ha nis m i n t he tra ns m issi o n of pai n pr o d uci n g 
sti m uli t hr o u g h t he de nti n. I n: A n ders o n DJ: Se ns or y mec ha nis m i n d e nti n. O xf or d, Per ga m m o n 
Press, 1 9 6 3; 7 3 -7 9.  
[B ur nett  G R, Wills o n RJ, L ucas R A . ( 2 0 1 3) ] I n vitr o st u dies i n vesti gati n g t he de nti n t u b ule  
occl usi o n pr o perties of a n e x peri me ntal a n h y dr o us sta n n o us fl u ori de de ntifrice. A m  J D e nt; 2 6  
( S pI[INVESTIGATOR_104896] A): 1 0 A -1 4 A.  
[C a n a di a n A d vis or y B o ar d o n De nti n H y perse nsiti vit y  ( 2 0 0 3)]  Ca na di a n A d vis or y B oar d 
o n De nti n H y perse nsiti vit y, C o nse ns us -base d rec o m me n dati o ns f or t he dia g n osis a n d 
ma n a ge me nt of d e nti n h y perse nsiti vit y. J Ca n De nt Ass oc 2 0 0 3; 6 9: 2 2 1 -2 2 6.  
[C h a k nis  P, Pa na ga k os F S, De Vizi o W, et al. ( 2 0 1 1)] Assess me nt of h y pers e nsiti vit y re d ucti o n 
of a de ntifric e c o ntai ni n g 0. 3 % tricl osa n, 2. 0 % P V M/ M A c o p ol y mer, 0. 2 4 3 % Na F a n d 
s peciall y -desi g ne d silica as c o m pare d t o a de ntifrice c o ntai ni n g 0. 4 5 4 % sta n n o us fl u ori d e, 
s o di u m he xa meta p h os p hate a n d zi nc lact ate a n d t o a de ntifrice c o ntai ni n g 0. 2 4 3 % Na F o n 
de nti n h y perse nsiti vit y re d ucti o n: A n [ADDRESS_116577] u d y. A m J De nt; 2 4( A): 1 4 -2 0.  
[C o x  C F, W hite K C, Ra m us D L, et al. ( 1 9 9 2)] Re parati ve de nti n: fact ors affecti n g its 
de p ositi o n. Q ui ntesse nce I nt 1 9 9 2; 2 3: 2 5 7 -2 7 0.  
[Creet h  J, Gall o b J, S ufi F, et al. ( 2 0 1 9 [a])] Ra n d o mise d cli nical st u dies i n vesti gati n g 
i m me diate a n d s h ort -ter m efficac y of a n occl u di n g t o ot h paste i n pr o vi di n g de nti ne 
h y perse nsiti vit y relief. B M C Oral Healt h  2 0 1 9; 1 9: 9 8.  
[Creet h  J, M acl ur e R, Se o n g J, et al. ( 2 0 1 9 [b])] T hree ra n d o mize d st u dies of de nti ne 
h y perse nsiti vit y re d ucti o n after s h ort‐ter m S n F 2 t o ot h paste use J Cl i n Peri o d o nt ol  2 0 1 9; 4 6: 
1 1 0 5 -1 1 1 5.  
[Creet h  J E, B ur nett G R. ( 2 0 2 1)] Effi cac y of a n E x peri me ntal O ccl usi o n Tec h n ol o g y 
T o ot h paste i n t he Relief of De nti nal H y perse nsiti vit y: A n 8 -wee k Ra n d o mise d C o ntr olle d Trial. 
Oral Healt h & Pre ve nti ve De ntistr y 2 0 2 1; 1 9( 1 ): 1 9 5 -2 0 2.  
[Cu n h a -Cr uz  J, Wata ha J C, Heat o n LJ, et al. ( 2 0 1 3)] T he pre v ale nce of de nti n h y perse nsiti vit y 
i n ge neral de ntal practices i n t he n ort h west U nite d States. J A m De nt Ass oc 2 0 1 3; 1 4 4( 3): 2 8 8 -
2 9 6.  
[D a b a b ne h  R H, K h o uri A T, A d d y M . ( 1 9 9 9)]  D e nti ne h y perse nsiti vit y - a n e ni g ma? A re vie w 
of ter mi n ol o g y, mec ha nis ms, aeti ol o g y a n d ma na ge me nt. Br De nt J 1 9 9 9;  1 8 7( 1 1):  6 0 6 -1 1 . 
Disc ussi o n 6 0 3. D OI:  1 0. 1 0 3 8/sj. b dj. 4 8 0 0 3 4 5. P MI D: 1 6 1 6 3 2 8 1.   
[D a y  T, Ei n wa g J, Her ma n n J, et al. ( 2 0 1 0)] A cli nical asse ss me nt of t he efficac y of a sta n n o us 
c o ntai ni n g s o di u m fl u ori de de ntifrice o n de nti nal h y perse nsiti vit y. J C o nte m p De nt Pract 2 0 1 0; 
1 1( 1): E 0 0 1 -E 8.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 4  of 1 1 3  [De m pse y  PJ, T o w nse n d G C. ( 2 0 0 1)]  G e netic a n d e n vir o n me ntal c o ntri b uti o ns t o variati o n i n 
h u ma n t o ot h size. Here dit y 2 0 0 1;  8 6( 6):  6 8 5.  
[D oci m o  R, M o ntesa ni L, Mat ur o P, et al. ( 2 0 0 9)] C o m pari n g t he Efficac y i n Re d uci n g De nti n 
H y perse nsiti vit y of a N e w T o ot h paste C o ntai ni n g 8. 0 % Ar gi ni ne, Calci u m Car b o nate, a n d 1 4 5 0 
p p m Fl u ori de t o a C o m mercial Se nsiti ve T o ot h pas te C o ntai ni n g 2 % P otassi u m I o n: A n Ei g ht -
Wee k Cli nical St u d y i n R o me, Ital y . J Cli n De nt 2 0 0 9; 2 0( 1) ( S pec Iss): 1 7 -2 2.  
[D o u gl as -de -Oli veir a  D W , Vit or G P , Sil veira J O,  et al. ( 2 0 1 8)] Effect of de nti n 
h y perse nsiti vit y treat me nt o n oral h ealt h relate d q u alit y of life – A s yste matic re vi e w a n d meta -
a nal ysis. J De nt 2 0 1 8; 7 1: 1 -8.  
[D’ S o uz a  R N, Bac h ma n T, Ba u m gar d ner K R, et al.  (1 9 9 5) ] C haracterizati o n of cell ular 
res p o nses i n v ol ve d i n re p arati ve de nti n o ge n esis i n rat m olars. J De nt Res 1 9 9 5; 7 4: 7 0 2 -7 0 9.  
[D u  M, Jia n g H, Tai B, et al. ( 2 0 1 1)] De -se nsitizi n g effect of a sta n n o us c o ntai ni n g s o di u m 
fl u ori de n o vel de ntifri ce ( A bstract # 2 8 2 6). I A D R  2 0 1 1 , Sa n Die g o, Calif or nia.  
[E arl  J S, La n gf or d R M ( 2 0 1 3)] P h ysical a n d c he mical c haracterizati o n of t he s urface la yers 
f or me d o n d e nti n f oll o wi n g treat me nt wit h a n e x peri me ntal a n h y dr o us sta n n o us fl u ori d e 
de ntifrice. A m J D e nt 2 0 1 3; 2 6 ( S pI[INVESTIGATOR_104896] A): 1 9 A -2 4 A.  
[Elli n gse n  J E, R olla G. ( 1 9 8 7)] Treat me nt of de nti n wit h sta n n o us fl u ori de –S E M a n d electr o n 
micr o pr o be st u d y. E ur o p ea n J Oral Sci 1 9 8 7; 9 5( 4): 2 8 1 -2 8 6.  
[E xter k ate  R A M. ( 2 0 2 2)] W hat is t he f u ncti o ni n g of ti n i n sta n n o us fl u ori de? Ne d erla n ds 
tij dsc hrift v o or ta n d heel k u n de 2 0 2 2; 1 2 9( 5): 2 1 9 -2 2 2.  
[Fisc her  C, Fisc her R G, We n n ber g A. ( 1 9 9 2)]  Pre vale nce a n d distri b uti o n of cer vical de nti ne 
h y perse nsiti vit y i n a p o p ulati o n i n Ri o de Ja neir o, Brazil J De nt 1 9 9 2 ; 2 0 : 2 7 2 -2 7 6.  
[Fl y n n  J, Gall o wa y R, Orc har ds o n R.  ( 1 9 8 5)]  T he i nci de nce of “ h y p erse nsiti ve” teet h i n t he 
West of Sc otla n d. J De nt 1 9 8 5 ; 1 3 : 2 3 0 -2 3 6.  
[G a gliese  L, Weiz blit N, Ellis W, et al . ( 2 0 0 5)]  T he me as ure me nt of p ost o perati ve pai n: a 
c o m paris o n of i nte nsit y scales i n y o u n ger a n d ol der s ur gical patie nts. Pai n 2 0 0 5; 1 1 7( 3): 4 1 2 -
4 2 0.  
[G all o b  J, S ufi F, A mi ni P, et al. ( 2 0 1 7)] A ra n d o mise d e x pl orat or y cli nical e v al uati o n of 
de ntifrices us e d as c o ntr ols i n de nti nal h y perse nsiti vit y st u dies. J o ur nal of d e ntistr y; 6 4: 8 0 -8 7.  
[Gerl ac h  R W, Sa g el P ( 2 0 1 7)] C o nc urre nt  Se nsiti vit y a n d Gi n gi vitis Effects of S n F 2/ H 2O2 
H y gie ne: I ncl usi ve Met a -A nal ysis ( A bstract # 3 0 4 2). I A D R 2 0 1 7 Sa n Fra n cisc o, Calif or nia.  
[Gi bs o n  BJ, B oi k o O V, Ba ker S R, et al. ( 2 0 1 5) ] T he e v er y da y i m pact of de nti n  se nsiti vit y: 
Pers o nal a n d f u n cti o nal as pects.  De nti n  Hy perse nsiti vit y: Else vier; 2 0 1 5. p. 8 9 -1 0 7.  
[Gill a m  D G, Aris A, B ul ma n J S, et al. (2 0 0 2 )] D e nti ne h y perse nsiti vit y i n s u bjects recr uite d 
f or cli nical trials: cli nical e val uati o n, pre val e nce a n d i ntra -oral distri b uti o n . J Oral Re ha b 2 0 0 2 ; 
2 9 : 2 2 6 -2 3 1 . 
[G ysi  A ( 1 9 0 0)]  A n atte m pt t o e x plai n t he se nsiti ve ness of de nti ne. Br D e nt J  1 9 0 0;  4 3:  8 6 5 -
8 6 8.  
[H all  C, Mas o n S, C o o ke J. ( 2 0 1 7)] E x pl orat or y ra n d o mise d c o ntr olle d cli nical st u d y t o 
e val uate t he c o m parati v e effic ac y of t w o occl u di n g t o ot h pastes  – a 5 % calci u m s o di u m 
p h os p h osilicate t o ot h paste a n d a n 8 % ar gi ni ne/c al ci u m car b o nat e t o ot h paste  – f or t he l o n ger -
ter m relief of de nti ne h y p erse nsiti vit y. J De nt 2 0 1 7 ; 6 0 : 3 6 -4 2.  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 5  of 1 1 3  [H aze n  S, V ol pe A, Ki n g W ( 1 9 6 8)] C o m parati ve dese nsitizi n g effect of d e ntifrices c o nt ai ni n g 
s o di u m m o n ofl u or o p h os p hate, sta n n o us fl u ori de, a n d f or mali n. Peri o d o ntics  1 9 6 8 ; 6( 5): 2 3 0 - 
2 3 2.   
[He  T, Bar ker M L, Bies br oc k A, et al. ( 2 0 1 4 [a] )] A ra n d o mize d c o ntr olle d cli nical trial t o as sess 
t he dese nsitizi n g effect of a sta n n o us fl u ori de d e ntifrice. A m J D e nt; 2 7( 2): 1 0 6 -11 0.  
[He  T, Bar ker M L, Bies br oc k A R, et al. ( 2 0 1 4 [ b] )] A Cli nical St u d y t o Assess t he Effect of a 
Sta bilize d Sta n n o us Fl u ori de De ntifrice o n H y perse nsiti vit y Relati ve t o a Mar kete d S o di u m 
Fl u ori de/ Tricl osa n C o ntr ol. J Cli n De nt 2 0 1 4; 2 5( 2): 1 3 -1 8.   
[He  S, Wa n g J.  ( 2 0 1 5 [a] )]  De v el o p me nt of t he c hi nese versi o n of t he d e nti n  h y perse nsiti vit y 
e x perie n ce q uesti o n nair e.  De nti n  Hy perse nsiti vit y ; Else vier 2 0 1 5 : 1 6 5 -17 5.  
[He  Sl, Wa n g J H. ( 2 0 1 5[ b])]  Relia bilit y a n d vali dit y of t he c hi nese versi o n of t he s h ort f or m of 
t he de nti n h y perse nsiti vit y e x perie nce q uesti o n n aire ( D H E Q -1 5). Q ualit y of Life Researc h 
2 0 1 5a;  2 4( 6):  1 4 6 5 -1 4 6 9.  
[He  T, Peters J, G o yal C R, et al. ( 2 0 1 9)] Cli ni cal Dese nsitizi n g Effect of Bi oa vaila ble S n F 2 
De ntifrice ( A bstract # 2 2 1 0). I A D R 2 0 1 9 Va n c o u ver, Ca na d a.  
[He at o n  LJ, Barl o w A P, C ol d well S E. ( 2 0 1 3)] De vel o p me nt of la bel e d ma g nit u de scales f or 
t he assess me nt of pai n of de nti n h y perse nsiti vit y. J Or ofac Pa i n 2 0 1 3; 2 7( 1): 7 2 -8 1.  
[Hi nes  D, X u S, Stra nic k M, et al. ( 2 0 1 9)] Effect of a sta n n o us fl u ori de t o ot h paste o n de nti nal 
h y perse nsiti vit y: I n vitr o a n d cli nical e val u ati o n. J A m De nt Ass oc 2 0 1 9; 1 5 0( 4): S 4 7 -S 5 9.  
[H oll a n d  G R, Nar hi M N, A d d y M, et al. ( 1 9 9 7)]  G ui deli nes f or t he d esi g n a n d c o n d u ct of 
cli nical trials o n de nti ne h y perse nsiti vit y. J Cli n Peri o d o nt ol 1 9 9 7;  2 4( 1 1):  8 0 8 -1 3.  
[K a n o uté  A, N da me Die n g S, Di o p M, et al. ( 2 0 2 2)]  C he mical vs. nat ural t o ot h paste: w hic h 
f or m ulas f or w hic h pr o perties? A sc o pi n g re vi e w . J P HI A 2 0 2 2 ; 1 3 (3):  1-1 3 . htt ps:// d oi. or 
g/ 1 0. 4 0 8 1/j p hia. 2 0 2 2. 1 9 4 5.  
[Ke n w ar d  M G, R o ger J H. ( 1 9 9 7)] S mall sa m ple i nfere n ce f or fi xe d effects fr o m restricte d 
ma xi m u m li keli h o o d. Bi o metrics 1 9 9 7 ; 5 3( 3):  9 8 3 -9 9 7.   
[Ki m  J Y , et al. ( 2 0 2 1 )] Cli nical a n d In-Vitr o St u dies of Our Ne w S n F 2 T o ot h paste. 2 0 2 1 
I A D R/ A A D R/ C A D R Ge neral Sessi o n .  
[K o nr a dss o n K, Li n gstr ö m P, E mils o n C G, et al. ( 2 0 2 0)] Sta bilize d sta n n o us fl u ori d e 
de ntifrice i n relati o n t o de ntal caries, de ntal er osi o n a n d de nti n h y perse nsiti vit y: A s yste matic 
re vie w. A m J D e nt 2 0 2 0; 3 3( 2): 9 5 -1 0 5.  
[L aster  L, La u de n bac h K W, St oller N H. ( 1 9 7 5)]  A n e val uati o n of cli nical t o ot h m o bilit y 
meas ure me nts. J. Peri o d o nt ol 1 9 7 5 ; 4 6 : 6 0 3 -6 0 7.   
[Lei g ht  R, S ufi F, Gr oss R, et al. ( 2 0 0 8 )] De nti nal h y perse nsiti vit y: A [ADDRESS_116578] u d y of a n o vel 
de ntifrice deli ver y s yste m c o m pari n g differe nt br us hi n g ti mes a n d assessi n g t he efficac y f or 
har d -t o -reac h m olar teet h. J  Cli n  De nt 2 0 0 8;  1 9( 4):  1 4 7 -5 3.  
[Li n de  A, G ol d ber g M. ( 1 9 9 3)] De nti n o ge n esis. Cri t Re v Oral Bi ol Me d 1 9 9 3; 4( 5): 6 7 9 -7 2 8.  
[L o be ne  R R, Weat herf or d T, R oss N M, et al. ( 1 9 8 6)]  A m o difie d gi n gi val i n de x f or use i n 
cli nical trials. Cli n Pre v De nt 1 9 8 6 ; 8: 3-6.   
[M ac h uc a  C, Ba ker S, S ufi F, et al. ( 2 0 1 4)] Deri vati o n of a s h ort f or m of t he de nti ne 
h y perse nsiti vit y e x perie n ce q uesti o n nair e. J Cli n Peri o d o nt ol 2 0 1 4;  4 1:  4 6 -5 1.   3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 6  of 1 1 3  [M a gl oire  H, B o u vier M, J offre A. ( 1 9 9 2)] O d o nt o blast res p o nse u n der cari o us lesi o ns. Pr oc 
Fi n n De nt S oc 1 9 9 2; 8 8( S u p pl 1): 2 5 7 -2 7 4.  
[M a ki n  S A. ( 2 0 1 3)] Sta n n o us fl u ori de de ntifric es. A m J De nt 2 0 1 3 ; 2 6 S pec N o  A:  3 A – 9 A.   
[M arti ns  C C, Fir mi n o R T, Ri va JJ, et al. ( 2 0 2 0)] Dese nsitizi n g T o ot h pastes f or De nti n 
H y perse nsiti vit y: A Net w or k Meta -a nal ysis. J De nt Res 2 0 2 0; 9 9: 5 1 4 -2 2.  
[M arti ns  C C, Ri va J J, Fir mi n o R T, et al. ( 2 0 2 2)] F or m ulati o ns of dese nsitizi n g t o ot h pastes f or 
de nti n h y perse nsiti vit y: a sc o pi n g re vie w. J A p pl Oral Sci 2 0 2 2; 3 0: e 2 0 2 1 0 4 1 0. 
htt ps:// d oi. or g/ 1 0. 1 5 9 0/ 1 6 7 8 -7 7 5 7 -2 0 2 1 -0 4 1 0.  
[M art o  C, Ba ptista P A, N u nes T, et al. ( 2 0 2 0)] E val u ati o n of t h e efficac y of de nti n 
h y perse nsiti vit y treat me nts - A s yste matic re vie w a n d f oll o w -u p a nal ysis. J Oral Re ha b 2 0 2 0; 
4 6: 9 5 2 -9 0.  
[M as o n  S, Ki n gst o n R, S h ne yer L, et al . ( 2 0 1 7) ]. Cli nical st u d y t o m o nit or de nti nal 
h y perse nsiti vit y wit h e pis o dic use of  a d ese nsitisi n g de ntifrice.  B DJ  ope n  2 0 1 7;  3( 1) : 1-6.   
[M as o n  S, B ur nett G R, Patel N, et al. ( 2 0 1 9)] I m pa ct of t o ot h paste o n oral healt h -relate d q ualit y 
of life i n pe o ple wit h de nti ne h y perse nsiti vit y. B M C Oral Healt h 2 0 1 9; 1 9: 1 -1 1.  
[Miller  S, Tr u o n g T, He u R, et al. ( 1 9 9 4 )] Rece nt a d va nces i n sta n n o us fl u ori de te c h n ol o g y: 
a nti bacterial efficac y a n d mec ha nis m of acti o n t o war ds h y p erse nsiti vit y. I nt  De nt  J 1 9 9 4; 4 4  
( S u p pl. 1): 8 3 -9 8.   
[Mj ör  I A. ( 2 0 0 2)] Cli nical Ma n a ge me nt a n d Tiss ue C ha n ges Ass ociat e d wit h Wear a n d 
Tra u ma, i n P ul p -De nti n Bi ol o g y i n Rest orati ve De ntis tr y 2 0 0 2: 8 0 -8 3. I S B N: 0 -8 6 7 1 5 -4 1 2 -8.  
[Ni  L X, He T, C ha n g A, et al. ( 2 0 1 0)] T he dese nsitizi n g efficac y of a n o vel sta n n o us -c o ntai ni n g 
s o di u m fl u ori de de ntifri ce: A n 8 -wee k ra n d o mi ze d a n d c o ntr olle d cli ni cal trial. A m J D e nt 
2 0 1 0; 2 3( S pI[INVESTIGATOR_104896] B): 1 7 B -2 1 B.  
[Ni  L, He T, C ha n g J, et al. ( 2 0 1 1)] De -se nsitizi n g effect of a sta n n o us c o ntai ni n g s o di u m 
fl u ori de t o ot h paste ( A bstract # 2 8 2 5). I A D R 2 0 1 1 Sa n Die g o, Calif or nia.  
[P ar ki ns o n  C R , Wills o n  RJ ( 2 0 1 1)]  A c o m parati ve i n vitr o st u d y i n vesti gati n g t he occl usi o n 
a n d mi ne ralizati o n pr o perties of c o m merci al de ntifrices i n a f o ur -d a y de nti ne disc m o del. J. 
Cli n. De nt 2 0 1 1; 2 2( 3): 7 4 -8 1.  
[P ar ki ns o n  C, H u g hes N, Jeffer y P, et al. ( 2 0 1 3)] T he efficac y of a n e x p eri me ntal de ntifrice 
c o ntai ni n g 0. 4 5 4 % w/ w sta n n o us fl u ori de i n pr o vi di n g relief fr o m t he pai n of de nti n 
h y perse nsiti vit y: a n [ADDRESS_116579] u d y. A m J D e nt 2 0 1 3; 2 6( S pI[INVESTIGATOR_104896] A): 2 5 A -3 1 A.  
[P ar ki ns o n  C R, Jeff er y P, Mille ma n J L, et al. ( 2 0 1 5[a])] C o nfir mati o n of efficac y i n pr o vi di n g 
relief fr o m t he pai n of d e nti n h y perse nsiti vit y of a n a n h y dr o us de ntifric e c o ntai ni n g 0. 4 5 4 % 
wit h or wit h o ut sta n n o us fl u ori de i n a n 8 -wee k ra n d o mize d cli nical trial. A m J De nt; 2 8 ( 4): 
1 9 0 -1 9 6.  
[P ar ki ns o n  et al ( 2 0 1 5 [ b] )] R C Ts of Sta n n o us Fl u ori de T o ot h paste A nti micr o bial Acti vit y; 
E val uati o n of t he Pla q ue Gl yc ol ysis a n d Re gr o wt h M o del. J De nt Res 2 0 1 5; 9 4 B: A bstract # 
3 4. B S O D R Car diff, U K.  
[P as hle y  D H  (1 9 9 4 )]  De nti ne per mea bilit y  a n d its r ole i n t he pat h o bi ol o g y of de nti ne 
se nsiti vit y. Arc h  Oral Bi ol 1 9 9 4;  3 9:  S 7 3 -8 0.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 7  of 1 1 3  [Pereir a  J C, de Car val h o Sales -Peres S H, Fra n cis c o ni -d os -Ri os L F, et al. ( 2 0 1 5)] C urre nt a n d 
n o vel cli nical a p pr oac hes f or t he treat me nt of de nti n h y perse nsiti vit y. De nti ne H y pers e nsiti vit y: 
A d va nces i n Di a g n osis, Ma na ge me nt, a n d Treat me nt 2 0 1 5:  1 0 1 -3 2.  
[P oll ar d  AJ , K ha n I, D a vies M, et al. ( 2 0 2 3)] C o m parati ve effic ac y of self -a d mi nistere d 
de ntifrices f or t he ma n a g e me nt of de nti ne h y p erse nsiti vit y - A s yste matic re vie w a n d n et w or k 
meta -a nal ysis . J De nt  2 0 2 3;  1 3 0: 1 0 4 4 3 3 . 
[P ols o n  A M, Cat o n J G, Yea ple R N, et al. ( 1 9 8 0) ] Hist ol o gical deter mi nati o n of pr o be ti p 
pe netrati o n i nt o gi n gi val s ulc us of h u ma ns usi n g a n electr o nic press ure -s e nsiti ve pr o be. J Cli n  
Peri o d o nt ol  1 9 8 0 ; 7( 6): 4 7 9 -8 8 . 
[P orritt  J M, S ufi F, Ba ker S R.  ( 2 0 1 6)]  Utilisi n g dail y diaries t o e xa mi ne oral healt h e x peri e nces 
ass ociate d wit h de nti n  h y perse nsiti vit y. B M C Oral Healt h 2 0 1 6;  1 6:  1-1 1.  
[Rees  J S.  ( 2 0 0 0)]  T he pre vale nce of de nti ne h y p erse n siti vit y i n ge neral de ntal practice i n t he 
U K. J Cli n Peri o d o nt ol 2 0 0 0 ; 2 7 : 8 6 0 –8 6 5.  
[R o bi ns o n  P G.  ( 2 0 1 4)]  De nti n  h y perse nsiti vit y: De vel o pi n g a pers o n -ce ntre d a p pr oac h t o oral 
healt h . Aca d e mic Press; 2 0 1 4.  
[S a m a nt  A, Mali k C, C ha bra S, et al. ( 1 9 7 6)] Gi n gi vitis a n d peri o d o ntal disease i n pre g n a nc y. 
J Peri o d o nt ol 1 9 7 6; 4 7( 7): 4 1 5 -8.  
[Sc hiff  T, D ots o n M, C o he n S , et al. (1 9 9 4 )] Efficac y of a de ntifric e c o ntai ni n g p otassi u m 
nitrate, s ol u ble p yr o p h os p hate, P V M/ M A c o p ol y mer, a n d s o di u m fl u ori de o n de nti nal 
h y perse nsiti vit y: a t wel ve -wee k cli nical st u d y. J Cli n De nt 1 9 9 4; 5: 8 7 -9 2. P MI D: 8 5 3 4 3 8 0.  
[Sc hiff  T, Saletta L, Ba ker R, et al. ( 2 0 0 5)] Dese nsitizi n g effect of a sta bilize d sta n n o us 
fl u ori de/s o di u m he xa meta p h os p hate d e ntifric e. C o m pe n d C o nt E d De nt; 2 6( [ADDRESS_116580]. 1): 3 5 -4 0.  
[Sc hiff  T, H e T, Sa gel L, et al. ( 2 0 0 6)]  Efficac y a n d safet y of a n o vel sta bilize d sta n n o us 
fl u ori de a n d s o di u m he xa meta p h os p hate de ntifrice f or de nti nal h y pers e nsiti vit y. J C o nte m p 
De nt Pract 2 0 0 6 ; 7: 1-8.  
[Seltzer  S, Be n der I.  ( 1 9 7 5)]  T he De ntal P ul p: Bi ol o gic C o nsi derati o ns i n De ntal Pr oce d ure s, 
2n d  E diti o n, P hila del p hia, P A:  JB Li p pi [INVESTIGATOR_104897]  C o  1 9 7 5 . 
[S h ar m a  N, R o y S, Ka kar A, et al. ( 2 0 1 0)] A cli nical st u d y c o m pari n g oral f or m ulati o ns 
c o ntai ni n g 7. 5 % calci u m s o di u m p h os p h osilicate ( N o va Mi n), 5 % p otassi u m nitrate, a n d 0. 4 % 
sta n n o us fl u ori de f or t he ma na ge me nt of d e nti n h y perse nsiti vit y. J Cli n De nt; 2 1( 3): 8 8 -9 2.  
[S hi  Y, C he n H, S u n L. ( 2 0 1 2)] De nti n T u b ule Occl usi o n wit h a N o vel S n Cl 2/ Na F/ Silica 
De ntifrice ( A bstract # 1 3 5 4). A A D R A n n ual Me eti n g 2 0 1 2 Ta m pa, Fl ori da.  
[S pliet h  C H, Tac h o u A. ( 2 0 1 3)] Epi [INVESTIGATOR_32450] o g y of de nti n h y perse nsiti vit y. Cli n Oral I n v est 
2 0 1 3; 1 7: 3 -8.  
[v a n Berc kel  M M, B os ma N H, H a ge ma n M G, et al. ( 2 0 1 7)]  T he c orrelati o n bet wee n a 
n u merical rati n g scale of patie nt satisfacti o n wit h c urre nt ma na g e me nt of a n u p per e xtre mit y  
dis or der a n d a ge neral meas ure of satisf acti o n wit h t he me dical visit. Ha n d 2 0 1 7;  1 2( 2):  2 0 2 -
2 0 6.  
[Vi n a y a  K R, S h u b has hi ni N, Ses ha n H, et al. ( 2 0 1 0)] A cli nical tri al c o m pari n g a sta n n o us 
fl u ori de base d de ntifric e a n d a str o nti u m c hl ori de base d de ntifric e  i n alle viati n g de nti nal 
h y perse nsiti vit y. J I nt Oral Healt h; 2( 1): 3 7 -5 0.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 8 8  of 1 1 3  [West  N, A d d y M, Jac ks o n R, et al. ( 1 9 9 7 )] De nti ne h y pers e nsiti vit y a n d t h e place b o res p o nse: 
A c o m paris o n of t he effect of str o nti u m acetate, p otassi u m nitrate a n d fl u ori de t o ot h pastes. J  
Cli n  Peri o d o nt ol  1 9 9 7;  2 4( 4):  2 0 9 -1 5.  
[West  N X . ( 2 0 0 8) ] De nti ne h y perse nsiti vit y: pre ve nti ve a n d t h era p e utic a p pr oac hes t o 
treat me nt. Peri o d o nt ol 2 0 0 0 ; 4 8( 1) : 3 1 -4 1.  
[West  N X, Sa n z M, L ussi A, et al. (2 0 1 3) ] Pre v ale nce of de nti ne h y p erse nsiti vit y a n d st u d y of 
ass ociate d fact ors: a E ur o pea n p o p ulati o n -base d cr oss -secti o nal st u d y. J  De nt  2 0 1 3;  4 1( 1 0) : 
8 4 1 -8 5 1.  
[West  N, Se o n g J, Da vies M . ( 2 0 1 4)] D e nti ne h y perse nsiti vit y. M o n o gr Oral Sci  2 0 1 4 ; 2 5: 1 0 8 -
12 2.  
[West  N X, Se o n g J, Da vies M . ( 2 0 1 5)]  Ma n a ge me nt of de nti ne h y pers e nsiti vit y: efficac y of 
pr ofessi o nall y a n d self‐a d mi nistere d a ge nts. J Cli n Peri o d o nt ol 2 0 1 5;  4 2:  S 2 5 6 -S3 0 2.  
[West  N, Da vies M, He T, et al. ( 2 0 1 9)] Effects of bi oa vaila ble S n F 2 de ntifrice o n er osi o n a n d 
se nsiti vit y: meta -a nal ysis ( A bstract # 2 3 2 3). I A D R 2 0 1 9 Va nc o u ver, Ca na d a.  
[West  N X, He T, Z o u Y, et al. ( 2 0 2 1)] Bi oa vaila ble gl uc o nate c helate d sta n n o us fl u ori de 
t o ot h paste meta -a nal yses: Effects o n de nti ne h y perse nsiti vit y a n d e na mel er osi o n. J De nt 2 0 2 1; 
1 0 5: 1 0 3 5 6 6.  
[West  N X  ( 2 0 2 2)]  P ositi o n pa per b y Pr ofess or Nic ola West o n de nti ne h y perse nsiti vit y i n 
c hil dre n. A vaila ble o n re q uest . 
[W hite  DJ, La wless M, Fata d e A, et al. ( 2 0 0 7)] Sta n n o us fl u ori de/s o di u m he xa meta p h os p hat e 
de ntifrice i ncreases de nti n resista nce t o t u b ule e x p os ure i n vitr o. J Cli n De nt  2 0 0 7 ; 1 8( 2): 5 5 -
59.  
[Y a n g  S, Yi n g K, Wa n g F, et al. ( 2 0 1 6)] D ese nsitizi n g effect of sta n n o us fl u ori de -c o ntai ni n g 
t o ot h paste f or patie nts wit h de nti ne h y perse nsiti vit y: a meta -a nal ysis. West C hi na J  St o mat ol; 
3 4( 2): 1 5 0 -1 5 5.  
[Zsis k a  M. ( 2 0 1 2)] De nti nal t u b ule occl usi o n wit h sta n n o u s fl u ori de a n d K N O 3/ Ga ntrez 
de ntifrices. J D e nt Res; 9 1: 7 4 4.  
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116581] u d y R e p ort  
D H  D e nti n H y p er s e n siti vit y  
D H E Q  D e nti n H y p er s e n siti vit y E x p eri e n c e Q u e sti o n n air e  
E A R  Er o si o n/ A br a si o n/ Attriti o n  
e C R F  El e ctr o ni c C a s e R e p ort F or m  
E D C  El e ctr o ni c D at a C a pt ur e  
E u dr a C T  E ur o p e a n Cli ni c al Tri al s D at a b a s e  
F D A  F o o d an d Dr u g A d mi ni str ati o n (U nit e d St at e s ) 
g Gr a m  
G C P  G o o d Cli ni c al Pr a cti c e  
G D S  Gl o b al D at a S h e et  
G R A S E  G e n er all y R e c o g ni z e d a s S af e a n d Eff e cti v e  
G S K C H  Gl a x o S mit h Kli n e C o n s u m er H e alt h c ar e  
I B  I n v e sti g at or’ s Br o c h ur e  
I C F  I nf or m e d C o n s e nt F or m  
I C H  I nt er n ati o n al C o nf er e n c e on H ar m o ni s ati o n  
I N D  I n v e sti g ati o n al N e w Dr u g  
I R B  I n stit uti o n al R e vi e w B o ar d  
I R T  I nt er a cti v e R e s p o n s e T e c h n ol o g y  
L M S  L a b ell e d M a g nit u d e S c al e  
L S L V  L a st S u bj e ct L a st Vi sit  
M e d D R A  M e di c al Di cti o n ar y for R e g ul at or y A cti viti e s  
M GI  M o difi e d Gi n gi v al I n d e x  
mI T T  M o difi e d I nt e nti o n -t o -Tr e at  
ml  Millilit er  
m m  Milli m et er  
M M R M  Mi x e d M o d el wit h R e p e at e d M e a s ur e s  
M o A  M o d e of A cti o n  
N/ A  N ot A p pli c a bl e  
N R S  N u m eri c R ati n g S c al e  
O Hr Q o L  Or al H e alt h -R el at e d Q u alit y of Lif e  
O H T  Or al H ar d Ti s s u e  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116582] at e s  
V A S  Vi s u al A n al o g u e S c al e  
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 1  of 1 1 3  1 5. 2  D e nti n e H y p er s e n siti vit y E x p eri e n c e Q u e sti o n n air e (E x a m pl e 
D H E Q -4 8)  
 
S E C TI O N O N E  
 
T he f oll o wi n g q uesti o ns are a b o ut y o ur se nsiti ve teet h, a n d t he i m pact it has o n y o ur e ver y da y life.   
 
 
Fr o m n o w o n i n t his q uesti o n naire we are g oi n g t o call w hat y o u feel as ‘se ns ati o ns i n y o ur teet h’  or 
‘se ns ati o ns’ . 
   
 
            
            
       3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 2  of 1 1 3   
 
         
 
 
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116583] it has o n y o ur  e ver y da y life.  
 
 
 
 
 
     
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116584] m o nt h  t o w hat e xte nt w o ul d y o u a gree 
or disa gree wit h t he f oll o wi n g state me nts ( Please tic k o nl y o ne res p o nse f or eac h q u esti o n).    
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
  
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e 
n or  
di s a gr e e  
( 4)  Di s a gr e e 
a littl e  
( 3)  Di s a gr e e  
 
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
1) H a vi n g s e n s ati o n s i n m y t e et h 
t a k e s a l ot of t h e pl e a s ur e o ut of 
e ati n g a n d dri n ki n g.                
2) T h er e h a v e b e e n ti m e s w h e n I 
c a n’t fi ni s h m y m e al b e c a u s e of 
t h e s e n s ati o n s.                
3) It t a k e s a l o n g ti m e t o fi ni s h 
s o m e f o o d s a n d dri n k s b e c a u s e of 
s e n s ati o n s i n m y t e et h.                
4) T h er e h a v e b e e n ti m e s w h e n I 
h a v e h a d pr o bl e m s e ati n g i c e 
cr e a m b e c a u s e of t h e s e 
s e n s ati o n s.                
 
T he  f oll o wi n g q uesti o ns are a b o ut t he w a ys i n w hic h t he se ns ati o ns i n y o ur teet h  h a ve 
f orce d y o u t o c h a n ge t hi n gs i n y o ur d ail y life.  T hi n ki n g a b o ut y o urself over t he l ast m o nt h  
t o w hat e xte nt w o ul d y o u a gree or disa gree wit h t he f oll o wi n g state me nts ( Please tic k o nl y o ne 
res p o nse f or eac h q uesti o n).    
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
 
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e n or  
di s a gr e e  
( 4)  Di s a gr e e  
a littl e  
(3)  Di s a gr e e  
 
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
5) I h a v e t o c h a n g e t h e w a y I e at 
or dri n k c ert ai n t hi n g s.                
6) I h a v e t o b e c ar ef ul h o w I 
br e at h e o n a c ol d d a y.                
7) I h a v e t o l e a v e s o m e c ol d 
f o o d s or dri n k s t o w ar m u p 
b ef or e I c a n h a v e t h e m.                
8) I h a v e t o c o ol s o m e f o o d s or 
dri n k s d o w n b ef or e I c a n h a v e 
t h e m.                
9) I h a v e t o c ut u p s o m e fr uit s 
b ef or e b ei n g a bl e t o e at t h e m.                
1 0) I h a v e t o w e ar a s c arf o v er 
m y m o ut h o n c ol d d a y s.                3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116585] m o nt h  t o w hat e xte nt 
w o ul d y o u a gree or disa gree wit h t he f oll o wi n g state me nts ( Please tic k o nl y o ne res p o nse f or  
eac h q u esti o n).    
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
  
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e n or  
di s a gr e e  
( 4)  Di s a gr e e  
a littl e  
( 3)  Di s a gr e e  
 
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
1 1) I h a v e a v oi d e d v er y c ol d 
dri n k s or f o o d s.                
1 2) I h a v e a v oi d e d v er y h ot 
dri n k s or f o o d s.                
1 3) W h e n e ati n g s o m e f o o d s I 
h a v e m a d e s ur e t h e y d o n’t 
t o u c h c ert ai n t e et h.                
1 4) I h a v e c h a n g e d t h e w a y I 
br u s h m y t e et h.                
1 5) W h e n e ati n g s o m e f o o d s I 
h a v e m a d e s ur e I bit e i n s m all 
pi e c e s.                
1 6) T h er e ar e ot h er f o o d s I 
h a v e a v oi d e d.                
  
T he  f oll o wi n g q uesti o ns are a b o ut t he w a y t he se ns ati o ns affect y o u w he n y o u  are wit h ot her 
pe o ple or i n cert ai n sit u ati o ns . T hi n ki n g a b o ut y o urself over t he l ast m o nt h  t o w hat e xte nt 
w o ul d y o u a gree or disa gree wit h t he f oll o wi n g state me nts ( Please tic k o nl y o ne res p o nse f or 
eac h q u esti o n).    
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
 
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e n or  
di s a gr e e  
( 4)  Di s a gr e e  
a littl e  
( 3)  Di s a gr e e  
  
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
1 7) B e c a u s e of t h e s e n s ati o n s I 
t a k e l o n g er t h a n ot h er s t o fi ni s h 
a m e al.                
1 8) I h a v e t o b e c ar ef ul w h at I 
e at w h e n I a m wit h ot h er s 
b e c a u s e of t h e s e n s ati o n s i n 
m y t e et h.                
1 9) I hi d e t h e w a y I a m e ati n g 
w h e n I a m wit h ot h er s b e c a u s e 
of t h e s e n s ati o n s i n m y t e et h.                
2 0) I a m u n a bl e t o f ull y t a k e 
p art i n c o n v er s ati o n s b e c a u s e 
of t h e s e n s ati o n s i n m y t e et h.                3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 6  of 1 1 3  2 1) G oi n g t o t h e d e nti st i s h ar d 
f or m e b e c a u s e I k n o w it i s 
g oi n g t o b e p ai nf ul a s a r e s ult 
of s e n s ati o n s i n m y t e et h.                
 
T he f oll o wi n g q uesti o ns are a b o ut t he w a y t he se ns ati o ns i n y o ur teet h m a ke y o u  feel . 
T hi n ki n g a b o ut y o urself over t he l ast m o nt h  t o w hat e xte nt w o ul d y o u a gree or disa gree wit h 
t he f oll o wi n g state me nts ( Please tic k o nl y o ne res p o nse f or eac h q u esti o n).    
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
 
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e 
n or  
di s a gr e e  
( 4)  Di s a gr e e 
a littl e  
( 3)  Di s a gr e e  
 
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
2 2) I’ v e b e e n fr u str at e d b e c a u s e I 
c a n’t fi n d a n yt hi n g t h at d e al s wit h 
t h e s e n s ati o n s I h a v e i n m y t e et h.                
2 3) I’ v e b e e n a n xi o u s t h at 
s o m et hi n g I e at or dri n k mi g ht 
c a u s e s e n s ati o n s i n m y t e et h.                
2 4) T h e s e n s ati o n s i n m y t e et h 
h a v e b e e n irrit ati n g.                
2 5) I h a v e b e e n a n n o y e d wit h 
m y s elf b e c a u s e I di d s o m et hi n g 
t h at I k n e w c a u s e d t h e s e 
s e n s ati o n s.                
2 6) I f elt g uilt y b e c a u s e I mi g ht 
h a v e c o ntri b ut e d t o t h e s e n s ati o n s 
I a m h a vi n g wit h m y t e et h.                
2 7) T h e s e n s ati o n s i n m y t e et h 
h a v e b e e n a n n o yi n g.                
2 8) T h e s e n s ati o n s i n m y t e et h 
h a v e b e e n e m b arr a s si n g.                
2 9) I h a v e b e e n a n xi o u s b e c a u s e 
of t h e s e n s ati o n s i n m y t e et h.                
 
T he f oll o wi n g q uesti o ns are a b o ut w h at t he se ns ati o ns i n y o ur teet h me a n f or y o u.  T hi n ki n g 
a b o ut y o urself over t he l ast m o nt h  t o w hat e xte nt w o ul d y o u a gree or disa gree wit h t he 
f oll o wi n g state me nts ( ple ase tic k o nl y o ne res p o nse f or eac h q u esti o n).  
  Str o n gl y 
a gr e e  
( 7)  A gr e e  
 
( 6)  A gr e e a 
littl e  
( 5)  N eit h er 
a gr e e n or  
di s a gr e e  
( 4)  Di s a gr e e  
a littl e  
( 3)  Di s a gr e e  
 
( 2)  Str o n gl y 
di s a gr e e  
( 1)  
3 0) I fi n d it diffi c ult t o a c c e pt 
t h at I a m a p er s o n w h o h a s 
t h e s e s e n s ati o n s i n m y t e et h.                3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 7  of 1 1 3  3 1) H a vi n g t h e s e s e n s ati o n s i n 
m y t e et h m a k e s m e f e el 
diff er e nt fr o m ot h er s.                
3 2) H a vi n g t h e s e s e n s ati o n s i n 
m y t e et h m a k e s m e f e el ol d.                
3 3) H a vi n g t h e s e s e n s ati o n s i n 
m y t e et h m a k e s m e f e el 
d a m a g e d.                
3 4) H a vi n g t h e s e s e n s ati o n s i n 
m y t e et h m a k e s m e f e el s a s 
t h o u g h I a m u n h e alt h y.                
 
 
T he last fi ve q uesti o ns as k a b o ut h o w m uc h t he se ns ati o ns i n y o ur teet h affect  y o ur life 
o ver all .  
  E x c ell e nt  
( 1)  V er y  
g o o d  
( 2)  G o o d   
 ( 3)  F air  
( 4)  P o or  
( 5)  V er y p o or  
( 6)  
3 5) O v er all h o w w o ul d y o u r at e t h e 
h e alt h of y o ur m o ut h, t e et h a n d g u m s ?               
 
 
  
V er y M u c h  
( 4)  Q uit e a bit  
( 3)  S o m e w h at  
( 2)  A littl e  
( 1)   
N ot at all  
( 0)  
 
3 6) O v er all h o w m u c h d o t h e s e n s ati o n s i n 
y o ur t e et h b ot h er y o u ?             
3 7) O v er all, h o w m u c h d o t h e t hi n g s y o u 
d o t o m a n a g e t h e s e n s ati o n s b ot h er y o u ?             
3 8) O v er all, h o w m u c h d o t h e s e n s ati o n s 
i n y o ur t e et h aff e ct y o ur q u alit y of lif e ?             
3 9) O v er all, h o w m u c h d o t h e t hi n g s y o u 
d o t o m a n a g e t h e s e n s ati o n s i n y o ur t e et h 
aff e ct y o ur q u alit y of lif e ?             
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 8  of 1 1 3  1 5. 3  La b ell e d Ma g nit u d e Sc al e s : I nt e n sit y, D ur ati o n, T ol er a bilit y & 
De s cri pti o n  ( E x a m pl e L M S s ) 
 
N O T T O S C A L E  
 
 
 
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 9 9  of 1 1 3   
N O T T O S C A L E  
 
 
 
 
 
 
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 0  of 1 1 3  1 5. 4  L M S Tr ai ni n g E x er ci s e ( E x a m pl e)  
 
S T U D Y S T A F F I N S T R U C TI O N S  
S u bjects will be gi ve n a har d c o p y of t h e i nstr ucti o ns f or c o m pleti n g  t he L M S s; t he i n vesti gat or  
(or desi g ne e ) s h o ul d rea d t he ‘ S u bject I nstr u cti o ns ’ al o u d w hile t he s u bject rea ds al o n g. 
S u bjects s h o ul d  be e nc o ura ge d  t o as k q u esti o ns  if t he y are u ns ur e  a b o ut a n yt hi n g t he y rea d.   
T he s u bject will t he n c o m plete t he L M S tr ai ni n g e xercise,  a n d t he i n vesti gat or  (or desi g ne e ) 
will deter mi ne w het her t he s u bject u n dersta n ds h o w t o use t he L M S base d o n t he ir  trai ni n g 
e xercis e res p o nses  a n d t h e g ui da nce  b el o w.  
 
I nter pret ati o n of t he Li ne Sc ale Tr ai ni n g E xercise  
T he o bjecti ve of t h e trai ni n g  e xercise is N O T t o deter mi ne w het her  t he s u bject ca n pr o vi de 
s pecific  ‘c orrect’  a ns wers b ut t o deter mi ne if  t he y u n dersta n d t he c o nce pt  of L M S c o m pleti o n . 
T he f oll o wi n g ge ner al assess me nt criteria are s u g geste d .  
• Is t he s u bject placi n g t h eir mar ks o nl y o n t he ver bal descri pt ors? If s o, re mi n d t he m  t he y 
s h o ul d  use  t he e ntire scale, i ncl u di n g areas of t he li ne bet wee n d escri pt ors.  
• Is t he s u bject placi n g t heir mar ks i n t he sa me  place o n all f o ur L M Ss . If s o, e x plai n 
a gai n t hat eac h L M S  me as ure s a differe nt as p ect of t heir res p o nse  (i nte nsit y, d urati o n, 
t heir a bilit y t o t olerate  it , a n d h o w t he y w o ul d descri be it ) a n d t his li kel y pr o d uce mar ks 
i n differe nt places o n eac h scal e.  
• T he s u bject s h o ul d i n dicate t heir res p o ns e b y mar ki n g a n ‘X’ o n t he L M S . If t he y  are 
circli n g descri pt ors  or  m a ki n g u nclear mar ks, re mi n d t he m of t he c orrect w a y t o rec or d 
t heir res p o nse .  
If t he s u bject a p pear s u na ble t o c o m plete t he  L M S s (i nte nsit y, d urati o n, t olera bilit y a n d 
descri pti o n) wit h a p pr o priate res p o nses, t he i n vesti gat or  ( or d esi g nee ) s h o ul d tal k t hr o u g h t he ir  
gra di n g of t he first t w o sce nari os. If t he mar ks are ge nerall y c orrectl y or dere d b ut far fr o m t heir 
li kel y tr ue p ositi o ns, as k  t he s u bject t o ver balize w h y t he y place d t he mar ks w here  t he y di d. 
H o we ver, t he i n vesti gat or/ desi g nee s h o ul d be caref ul n ot t o press ure t he s u bject t o c ha n ge t h eir 
res p o nses. Start wit h a n ite m t he s u bject rate d  ‘w ell ’, as k a b o ut t hat , t he n c o nti n ue b y as ki n g 
a b o ut a n ite m w here t he y di d less well.  
If t he i n vesti gat or ( or desi g nee)  dee ms a s u bject  u n a ble t o pr o vi de a p pr o pri ate  res p o nses t o t he 
L M S trai ni n g  q uesti o ns, it is u nli kel y t he y will pr o vi de relia ble  L M S res p o nses f oll o wi n g 
a p plicati o n of  t he e v a p orati ve (air) sti m ul us . T he s u bject s h o ul d be wit h dra w n.   
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : [ADDRESS_116586] u d y . Eac h o ne h a s differe nt w or ds p ositi o ne d al o n g t he li ne t h at ca n 
be use d t o rate t h e  feeli n g s or se nsati o ns pe o ple ca n e x peri e nce  i n t heir m o ut hs.   
T here are n o ri g ht or w r o n g a ns wers.  
Rea d t he descri pti o n of eac h  e x a m ple  se nsati o n  or feeli n g caref ull y , t he n tr y t o re me m ber or 
ima gi ne w hat eac h o ne  feels li ke. If y o u ha v e n’t e x perie n ce d e x actl y w hat is  descri be d, tr y t o 
t hi n k of s o met hi n g si milar. As y o u t hi n k a b o ut t he  e xa m ple , t hi n k a b o ut t he w or d o n t he li ne 
t hat best descri bes w h at t hat se nsati o n feels li ke. Yo u ca n  ‘fi ne t u n e’ y o ur rati n g t o best reflect 
t hat e x peri e nce b y mar ki n g t he li ne b et wee n t hat w or d a n d t he w or d s ne xt t o it,  u p or d o w n t he 
scale.  
I N DI C A T E H O W Y O U W O U L D R A T E T H E F E E LI N G D E S C RI B E D B Y P L A CI N G A N 
‘X’ O N T H E LI N E.  
Y O U C A N  P L A C E Y O U R M A R K A N Y W H E R E  A L O N G T H E LI N E , E X A C T L Y O N A 
D E S C RI P TI V E W O R D O R B E T W E E N W O R D S.  
Ple ase t ur n t o t he ne xt p a ge f or t he fi rst e x a m ple i n t his e xercise.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 2  of 1 1 3   
Let ’s start wit h t his e xa m ple.  
T he t o uc h of a pi[INVESTIGATOR_4382] o n y o ur t o n g ue.  
Ha ve y o u e v er e x perie n ce d t his feeli n g or se nsati o n bef ore?  Yes / N o  ( Ple as e circle o ne)  
First please rate t he I N T E N SI T Y  of t his feeli n g or se nsati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 3  of 1 1 3   
Still t hi n ki n g a b o ut t he t o uc h of a pi[INVESTIGATOR_4382] o n y o ur t o n g ue , please rate t he D U R A TI O N  of t his 
feeli n g or se ns ati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
  
 
N O T T O  S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 4  of 1 1 3   
Still t hi n ki n g a b o ut t he t o uc h of a pi[INVESTIGATOR_4382] o n y o ur t o n g ue , please rat e h o w m uc h y o u are a ble t o 
T O L E R A T E  wit h t his feeli n g or se nsati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
 
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 5  of 1 1 3   
Fi nall y, still t hi n ki n g a b o ut t he t o uc h of a pi[INVESTIGATOR_4382] o n y o ur t o n g ue , please gi ve a rati n g t hat 
D E S C RI B E S  t he ki n d of feeli n g or s e nsati o n t his is.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet we e n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 6  of 1 1 3   
Let’s tr y t his e xa m ple.  
T he p ai n fr o m biti n g y o ur t o n g ue.  
Ha ve y o u e v er e x perie n ce d t his feeli n g or se nsati o n bef ore? Yes / N o  ( Ple as e circle o ne)  
First please rate t he I N T E N SI T Y  of t his feeli n g or se nsati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber , y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
 
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 7  of 1 1 3   
Still t hi n ki n g a b o ut t he p ai n fr o m biti n g y o ur t o n g ue , please rate t he D U R A TI O N  of t his 
feeli n g or se ns ati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
  
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt  p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 8  of 1 1 3   
Still t hi n ki n g a b o ut t he p ai n fr o m biti n g y o ur t o n g ue , please rate h o w m uc h y o u are a ble t o 
T O L E R A T E  wit h t his feeli n g or se nsati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u c a n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
  
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 0 9  of 1 1 3   
Fi nall y, still t hi n ki n g a b o ut t he p ai n fr o m biti n g y o ur t o n g ue , please gi ve a rati n g t hat 
D E S C RI B E S  t he ki n d of feeli n g or s e nsati o n t his is.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 1 0  of 1 1 3   
Let’s tr y o ne last e x a m ple.  
T he p ai n of a persiste nt t o ot h ac he.  
Ha ve y o u e v er e x perie n ce d t his feeli n g or se nsati o n bef ore? Yes / N o  ( Ple as e circle o ne)  
First please rate t he I N T E N SI T Y  of t his feeli n g or se nsati o n.  
Mar k  t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 1 1  of 1 1 3   
Still t hi n ki n g a b o ut t he p ai n of a persiste nt t o ot h ac he , pleas e rate t h e D U R A TI O N  of t his 
feeli n g or se ns ati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u  ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 1 2  of 1 1 3  Still t hi n ki n g a b o ut t he p ai n of a persiste nt t o ot h ac he , pleas e rate h o w m uc h y o u are a ble t o 
T O L E R A T E  wit h t his feeli n g or se nsati o n.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
Ple ase t ur n t o t he ne xt p a ge.  
  3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Hale o n   
Cli nical Pr ot oc ol    
Pr ot oc ol N u m ber : 3 0 0 1 0 4  
 
Pr o pert y of Hal e o n - C o nfi de ntial   
Ma y n ot be use d, di v ul ge d, p u blis he d or ot her wise discl ose d wit h o ut t he c o nse nt of Hale o n  
 Cli nical Pr ot oc ol Te m plate v 1 0 . 0  
Pa ge 1 1 3  of 1 1 3   
Fi nall y, still t hi n ki n g a b o ut t he p ai n of a persiste nt t o ot h ac he , pleas e gi ve a rati n g t h at 
D E S C RI B E S  t he ki n d of feeli n g or s e nsati o n t his is.  
Mar k t he scale b el o w wit h a n ‘X’ t o i n dicate t he best descri pti o n of t hat feeli n g or se nsati o n. 
Re me m ber, y o u ca n mar k a n y w here  o n t he li ne, i ncl u di n g bet wee n t he d es cri pti ve w or ds.  
 
 
N O T T O S C A L E  
 
 
Y o u h a ve fi nis he d t he tr ai ni n g  e xercise a n d are n o w re a d y t o t a ke p art i n t he m ai n p art 
of t he st u d y.  
If y o u h a ve a n y q uesti o ns a b o ut t his tr ai ni n g , ple ase as k t he me m ber of st aff tr ai ni n g y o u.   
If y o u feel t h at y o u u n derst a n d h o w t o use t hese sc ales, ple ase tell  t he  me m ber of st aff t o o .  
 
T h a n k y o u f or y o ur ti me!  
 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
C CI 
Si g nat ure Pa ge f or  3 0 0 1 0 4 T M F- 2 5 2 7 7 5 v 2. 0 
Si g nat ure Pa ge f or T M F- 2 5 2 7 7 5 v 2. 0 Reas o n f or si g ni n g: A p pr o ve d Na me: 
R ole: A p pr o ver 
Date of si g nat ure: 
G M T + 0 0 0 0 
Reas o n f or si g ni n g: A p pr o ve d Na me: 
R ole: A p pr o ver 
Date of si g nat ure: 
G M T + 0 0 0 0 
Reas o n f or si g ni n g: A p pr o ve d Na me: 
R ole: A p pr o ver 
Date of si g nat ure: 
G M T + 0 0 0 0 3 0 0 1 0 4 Pr ot oc ol  0 7 Fe b 2 0 2 4 | T M F- 2 5 2 7 7 5 | 2. 0 
P P D 
P P D 
P P D 
P P D 
P P D 
P P D 